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ABSTRACT

RETROSPECTIVE COHORT STUDY OF PATIENTS WITH CHRONIC LOW
BACK PAIN IN AN OUTPATIENT PAIN SPECIALIST CLINIC

By
Gauri Desai
December 2020

Thesis supervised by Dr. Khalid Kamal
Background: Chronic low back pain (LBP) is a back pain that lasts for three or
more than three months in the lumbar region of the spinal cord. A nerve injury or damage
in the spinal cord region (neuropathic pain) requires multimodal treatment approach for
pain reduction. With various treatment options utilized in the pain management of these
patients, identifying demographical and clinical characteristics of patients with chronic
LBP utilizing interventional procedures and pharmacologic treatments is imperative.
Objective: (i) To describe the demographics (age, gender, race, ethnicity, smoking status,
alcohol consumption status, drug use status) and clinical characteristics (procedures,
medications) of patients with chronic LBP, (ii) to assess the prevalence of comorbid
conditions including hypertension, anxiety and depression in the chronic LBP cohort and
assess their demographic an clinical characteristics, (iii) to assess the demographic and
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clinical characteristics of patients with chronic LBP who are currently prescribed the
following medications: blood thinners (anticoagulants/antiplatelet), herbal medications,
benzodiazepines and opioids, (iv) to assess the mean pain level pre- and post-procedure
for patients with chronic LBP that have undergone a single interventional therapeutic
LBP procedure throughout the study period.
Methods: A retrospective cohort data analysis was conducted using electronic medical
record (EMR) data of newly enrolled patients with chronic LBP in 2018. Data extraction
was carried out for LBP patients, but all the analyses were conducted for adult patients
with chronic non-cancer LBP. The chronic LBP cohort was identified by filtering out
patients who suffered with LBP for less than 3 months (acute) within the study period.
Further, patients with any type of cancer as a comorbid condition and those with age
below 18 years were excluded from the chronic LBP cohort. Descriptive analyses were
conducted to assess demographical and clinical characteristics of chronic LBP patients
and cohorts identified within these patients based on the type of comorbidity or
medications they were on. Pain relief obtained from interventional therapeutic procedures
was also calculated using the mean pain scores before and after the procedure. All
statistical analyses were conducted using SAS (SAS Institute Inc., Cary, NC, USA).
Results: A total of 464 adult patients with chronic LBP were identified in the EMR from
January 2018 to February 2020. The mean age of the patient cohort was 61.96 years,
majority were females (52.8%), Whites (93.97%) and non-Hispanic Latino (96.77%).
Most patients never smoked (57.24%) or currently consumed alcohol (53.39%). The
mean duration of chronic LBP was 64.15 months and mean office follow-up visits were 3
visits. The most prevalent therapeutic procedure was lumbar epidural steroid injection
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(ESI) (36.85%) and diagnostic procedure was lumbar medial branch block (15.73%). For
patients that underwent lumbar ESI, a maximum of five repetitions and an average of
1.68 repetitions were required to obtain sustained pain relief over a 2-year follow-up
period. Also, on an average pain reduction of about 55% was obtained from this
procedure. The prevalence of pain medications by line of therapy was found as 24.78%
for first-line medications, 26.07% for second-line medications and 9.91% for third-line
medications. Patients with chronic LBP also had hypertension (n=188, 40.52%) and
anxiety and depression (n=120, 25.86%). Similar patient characteristics were further
analyzed based on the type of medications patients were on: (i) blood thinners (n=154,
33.18%), herbal medications (n=45, 9.69%), benzodiazepines (n=67, 14.43%) and
opioids (n=121, 26.07%).
Conclusion: Patients with chronic LBP suffer with the condition for a prolonged duration
and require multimodal treatment approach including interventional procedures and
pharmacologic treatments. Although these treatment options do not provide sustained
pain relief, they do provide temporary symptomatic pain relief.
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CHAPTER 1: BACKGROUND
INTRODUCTION
Chronic non-cancer pain
Chronic non-cancer pain (CNCP) is defined as moderate to severe pain typically
lasting three months or more and not associated with any malignancy. 1 A number of
conditions such as low back pain, neck pain, osteoarthritis, rheumatoid arthritis, bilateral
leg pain, and fibromyalgia are classified as CNCP.1 There is evidence to suggest that
CNCP is linked to restrictions in functional mobility and daily activities, poor quality of
life (QoL), and comorbid conditions such as anxiety and depression. 1,16

Types of CNCP
CNCP is mainly categorized into nociceptive pain and neuropathic pain. Both
nociceptive and neuropathic pain can coexist and can be chronic in nature. Nociceptive
pain is induced by nociceptors, which are primary afferent nerve endings present in skin,
muscle, joints or visceral forms.2 The nociceptors are activated in response to either
noxious stimuli such as mechanical injury, cold, and heat insults or polymodal stimuli
such as chemical, mechanical, and thermal insults.2 The peripheral inflammation of
nociceptors activates non-myelinated C-fibers and myelinated A-δ fibers which releases
substance P and calcitonin gene-related peptide (CGRP), thus amplifying the local
inflammation.2 This inflammation is generally considered transient in nature.
Neuropathic pain involves both peripheral and central nervous systems (CNS).
After an injury to the nervous system, the spinal cord receives the pain impulse from the
primary afferent C-fibers and A-δ nerves through its dorsal horn.2 These nerves
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terminating at lamina I-II further transmit the input to thalamus via the neurokinin-1receptors present in lamina I. The pain signals are processed in the CNS and if the signals
are persistent it contributes to its chronicity.2 Neuropathic pain is more severe and tends
to have higher than average pain scores along with poor QoL.

Pathogenesis of CNCP
After tissue injury, a host of inflammatory mediators including adenosine-5triphosphate (ATP), bradykinin, interleukin–1 ß (IL-1ß), prostaglandin E2, tumor necrosis
factor-α (TNF- α), sodium (Na+), proton (H+), potassium (K+), histamine, nerve growth
factor and serotonin are released from the mast cells, macrophages and epithelial cells of
the damage tissue.3 Activation of cyclo-oxygenase-2 (COX-2) enzyme produces
prostaglandins that results in the nociceptors activation. Nociceptors transmit the signals
via the voltage- or ligand-gated channels and protein kinases A and C pathways. C-fibers
activated by the peripheral inflammation releases substance P and calcitonin gene-related
peptide (CGRP). The process occurs in the periphery defined as peripheral sensitization
or primary hyperalgesia.2 Ongoing and intense sensitization of C-fiber in primary afferent
neurons and spinal cord causes N-methyl-D-aspartate (NMDA) activation and removal of
Mg2+ block on the NMDA receptor, thereby facilitating the co-release of substance P and
CGRP within the CNS. These substances activate the glial cells, which then upregulate
COX-2 and nitric oxide synthetase (NOS) resulting in release of prostaglandin E 2 and
inflammatory mediators including interleukin-1, interleukin-6 and TNF- α causing central
sensitization or secondary hyperalgesia.2 The increase of COX-2 in the spinal cord causes
the metabolism of 2-arachidonoylglycerol (2-AG) to prostaglandin E2, which increases
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the inflammation and pain intensity.2 Consequently, the persistent nociception transits to
chronic pain due to neural and glial remodeling (neuroplasticity) wherein the neuronal
synapses are remodeled and the neurons develop more connections with second-order
neurons within CNS. This process of neuroplasticity increases the pain sensitivity of
neurons in response to stimuli eventually leading to chronic pain.2 It is still not clear
whether persistent inflammation or the inflammatory mediators are responsible for
maintaining chronic neuropathic pain.

Low back pain
Depending on the duration of the pain, low back pain (LBP) can be classified into
acute, subacute, and chronic pain. Acute pain persists for less than six weeks, subacute
persists for six weeks to three months, and chronic pain for more than three months.4
Based on specific pathophysiological mechanism, LBP is further categorized into specific
or non-specific LBP. Specific LBP includes symptoms caused by infection, osteoporosis,
rheumatoid arthritis, fracture or tumor.4 Specific low back pain could be caused by a
herniated disc, degenerative disc disease and arthritis (i.e. facet joint arthritis). It could
also involve muscle pain. Non-specific LBP, on the other hand, incudes symptoms that
lack any identifiable cause.
Lower back is a complex structure that includes tendons and muscles, highly
sensitive nerves and nerve roots, small and complex joints and spinal discs. A problem or
an irritation with any of these structures can cause LBP. 5 Various conditions can cause
LBP such as lumbar spinal stenosis, lumbar radiculopathy, degenerative disc disease and
herniated disc.5 LBP radiates in the lumbar region of the spinal cord and can also cause
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leg pain (sciatica). If episodes of acute or subacute LBP are not detected in the early
stage, they can lead to chronic LBP.4 Chronic LBP has been shown to result in severe
exacerbations of pain leading to disability. 4 Early diagnosis and treatment of acute or
subacute LBP significantly reduces the pain intensity and persistence of the pain. Pain
medications and interventional procedures reduce the severity of chronic LBP but not its
persistence.4

EPIDEMIOLOGY
Among all the United States (US) adults with disability, LBP is the second most common
cause.6 Global prevalence estimates of LBP range from 1.4% to 20%.7 The prevalence of
LBP in high-income countries such as the US is about 30% compared to 18% in lowincome countries.7 The global incidence estimates of LBP range from as low as 0.024%
to a high of 7%.7 The global 1-year incidence of any episode of LBP ranges from 1.5% to
36%. The incidence of LBP is found to increase with age7, and the odds of reporting LBP
is 1.5 times in white individuals compared to individuals who are Black and/or
Hispanics.8

RISK FACTORS
Several risk factors are associated with occurrence and chronicity of LBP and can
be categorized into personal, psychosocial and occupational factors.4 Personal risk
factors include age, physical fitness, metabolism, weakness of back and abdominal
muscles and smoking and those for chronicity include obesity, low educational level and
high levels of pain and disability.4 Psychosocial risk factors for occurrence include stress,
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anxiety, negative mood, poor cognitive functioning and pain behavior and those for
chronicity include distress, depressive mood, somatization. 4 Occupational risk factors for
occurrence include working with heavy weights, job dissatisfaction, lengthy period of
standing and poor work relationships and for chronicity include unavailability of light
duty on return to work; job requirement of lifting for three quarters of the day. 4

PAIN ASSESSMENT
A comprehensive pain assessment is recommended prior to implementing a
treatment plan for LBP. Instruments such as Visual Analog Scale (VAS), Numerical
Rating Scale (NRS), Verbal Rating Scale/Descriptor Scale, Faces Pain Rating Scale, and
Short form McGill Pain Questionnaire have reportedly been utilized to assess the level of
LBP in patients.9,10 (Refer Figure 2)

1) Visual Analog Scale: It consists of a straight line anchored by two endpoints ‘no pain’
and ‘worst possible pain.’ The patients are required to mark their current pain intensity
level on the scale.9 Major drawbacks with this tool are the requirement for a physical
equipment (e.g. pen and paper) and the need for patients to possess motor skills, visual
acuity, and abstract thinking.10
2) Numerical Rating Scale: It is a numerical scale ranging from 0 to 10, where 0 = no
pain, 1-3 = mild pain, 4-6 = moderate pain and 7-10 = severe pain. The instrument can be
administered via telephone or in-person.9 NRS is a preferred tool to measure pain
intensity when the population of interest can use it reliably.10
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Figure 1: Pain Assessment Scales

A: Visual Analog Scale (VAS), B: Numerical Rating Scale (NRS), C: Verbal Rating
Scale (VRS)
Source: Karcioglu et al, 2018 9
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3) Verbal Rating Scale/Descriptor Scale: In this scale, patients are required to mark their
level of pain intensity based on descriptors, which range from none, mild, moderate, or
severe pain. The precision of the scale compared to VAS and NRS is limited due to its
inability to provide more choices.9
4) Short-Form McGill Pain Questionnaire: This pain questionnaire consists of a VDS
with 15 adjectives to describe sensory and affective qualities of pain and a VAS to
evaluate the patient’s current pain intensity. The questionnaire possesses the ability to
distinguish between different types of pain and is sensitive to the change in the pain
level.11,12

TREATMENT
Multimodal interventions are utilized for pain management of patients with chronic pain.
Single modality interventions are rarely used alone and are often combined into the
multimodal treatment strategy.13 Using more than one type of therapy provides better
pain control and reduces pain intensity for about 4 months to a year. Different
multimodal interventions include: (1) ablative techniques, (2) acupuncture, (3) blocks
(i.e., joint and nerve or nerve root), (4) botulinum toxin injections, (5) electrical nerve
stimulation, (6) epidural steroids with or without local anesthetics, (7) intrathecal drug
therapies, (8) minimally invasive spinal procedures, (9) pharmacologic management, (10)
physical or restorative therapy, (11) psychologic treatment, and (12) trigger point
injections.13 Out of the various multimodal interventions, this chapter focuses on
pharmacologic management and interventional procedures only.
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Pain medications
For the pharmacological treatment of neuropathic pain, Neuropathic Pain Special
Interest Group (NeuPSIG) evidence-based guidelines recommend following step-wise
treatment approach.14 After diagnosis, it is recommended that the pain specialist, if
applicable should initiate treatment for the disease-causing neuropathic pain.
For symptomatic treatment of neuropathic pain, first-line treatment options
including tricyclic antidepressants (nortriptyline, desipramine), dual reuptake inhibitors
of serotonin and norepinephrine (duloxetine, venlafaxine), calcium channel α2-δ ligands
(ie, gabapentin and pregabalin) should be utilized, and topical lidocaine for localized
peripheral neuropathic pain alone or in combination with other first-line therapies should
be utilized.14 While on the treatment, reassess the pain level and health-related quality of
life of the patients. If significant pain relief (eg, average pain reduced to ≤3/10) is
obtained using first-line therapy, continue with that treatment option. If partial pain relief
(eg, average pain remains ≥4/10) after an appropriate trial, add one of the other 4 firstline medications. If inadequate pain relief (eg, <30% reduction) is obtained at target
dosage after an appropriate trial, switch to an alternative first-line medication. If trials of
first-line medications alone and in combination fail, the guidelines recommend
consideration of second-line medications.14
Opioid analgesics and tramadol are recommended as second-line treatments and
can be considered for first-line use under certain clinical circumstances.14 Patients who
cannot tolerate or who do not respond adequately to first- and second-line medications,
are recommended with third-line medications including antidepressant medications (e.g.
bupropion, citalopram, and paroxetine), antiepileptic medications (e.g. carbamazepine,
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lamotrigine, oxcarbazepine, topiramate, and valproic acid), topical low concentration
capsaicin, dextromethorphan, memantine, and mexiletine. 14

Interventional Procedures
Practice Guidelines developed by the American Society of Anesthesiologists
(ASA) provides recommendations on chronic pain management using interventional
procedures.13 After a thorough patient history assessment, physical examination and
psychosocial evaluation, interventional diagnostic procedures can be conducted as a part
of patient’s evaluation based on patient’s clinical presentation. 13 The interventional
diagnostic procedures should be followed by appropriate therapeutic procedures. Some of
the procedures can be used for both purposes. Table 1 provides classification of
interventional diagnostic and therapeutic procedures for chronic pain.13
Chronic pain patients on anticoagulants/antiplatelets and on various concomitant
medications with antiplatelet effects including non-steroidal anti-inflammatory drugs
(NSAIDs), aspirin and serotonin reuptake inhibitors have demonstrated increased
bleeding complications when continued during interventional pain procedures. Therefore,
the American Society of Regional Anesthesia and Pain Medicine (ASRA) guidelines
have classified interventional spine and pain procedures based on potential risk of
bleeding in patients on anticoagulants/antiplatelets.15 (Refer Table 2)
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Table 1: Classification of interventional diagnostic and therapeutic procedures for
CNCP
Diagnostic procedures

Therapeutic procedures












Selective nerve root blocks
Medial branch blocks
Facet joint injections
Sacroiliac joint injections
Lateral branch blocks
Sympathetic blocks
Peripheral blocks
Provocative discography














Epidural steroid injection (Interlaminar,
Transforaminal)
Joint blocks (Intraarticular facet joint
injections, Sacroiliac joint injections)
Nerve and nerve root blocks (Lumbar
sympathetic blocks, Sympathetic nerve
blocks, Medial branch blocks)
Ablative techniques (Chemical
denervation, Cryoablation,
radiofrequency ablation)
Intrathecal drug injections (opioid, nonopioid)
Electrical nerve stimulation
(Subcutaneous peripheral nerve
stimulation, Spinal cord stimulation,
Permanent spinal cord stimulation
implantation
Transcutaneous electrical nerve
stimulation (TENS)
Minimally invasive spinal procedures
(Kyphoplasty, Vertebroplasty,
Percutaneous disc decompression)
Trigger point injections

Source: Practice guidelines for chronic pain management, ASA 13
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Table 2: Pain Procedures Classification According to the Potential Risk of Serious
Bleeding
High-risk procedures

Intermediate-risk procedures

Low-risk procedures







Spinal cord stimulation
trial and implant



Dorsal root ganglion

S)


stimulation


Intrathecal catheter and



pump implant


Percutaneous







Peripheral nerve
blocks

Transforaminal ESIs (C, T,



Peripheral joints and

L, S)

musculoskeletal

Cervical facet MBNB and

injections


RFA

decompression
laminotomy

Interlaminar ESIs (C, T, L,

Trigger point

Intradiscal procedures (C,

injections including

T, L)

piriformis injection

Sympathetic blocks



Sacroiliac joint

Epiduroscopy and

(stellate, T, splanchnic,

injection and sacral

epidural decompression

celiac, lumbar, hypogastric)

lateral branch blocks



Trigeminal and



sphenopalatine ganglia

facet MBNB and RFA


blocks

Thoracic and lumbar

Peripheral nerve
stimulation trial and
implant



Pocket revision and
implantable pulse
generator/intrathecal
pump replacement
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Abbreviations: C, cervical; L, lumbar; S, sacral; T, thoracic; ESI, epidural steroid
injection; MBNB, medial branch nerve block; RFA, radiofrequency ablation
Source: ASRA guidelines, Regional Anesthesia and Pain Medicine, 2018 15

COMORBID CONDITIONS
The predominant comorbidities in LBP population include anxiety and
depression since most studies 16 have reported the association between LBP and anxiety
and depression. Previous studies17, 18 have reported that hypertension did not have any
association with chronic LBP. There is a need to identify the prevalence of chronic LBP
patients with these comorbid conditions to better inform the clinical practice to treat the
underlying cause of chronic LBP for such patients.
Anxiety: The American Psychological Association (APA) defines anxiety as “an emotion
characterized by feelings of tension, worried thoughts and physical changes like
increased blood pressure.” Patients with anxiety disorders and chronic pain have lower
tolerance for pain compared to those without anxiety disorders. Being more fearful to the
side-effects of medications lead to exacerbations of pain in this cohort. 19
Depression: The APA defines depression as “a negative affective state, ranging from
unhappiness and discontent to an extreme feeling of sadness, pessimism, and
despondency, that interferes with daily life.” Chronic pain and depression are intertwined
due to the involvement of same nerves and neurotransmitters. Chronic pain can have
impact in different aspects of life such as sleep, social network, relationships or work
inducing stressful feelings. People with depression and chronic pain might be less
tolerant towards the pain and experience it considerably. 20
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Hypertension: Patients with chronic pain may have reduced heart rate variability and
baroreflex sensitivity and is related to impaired cardiovascular regulation. The elevated
blood pressure is associated with increased sensitivity to pain, thus aggravating the pain
and worsening the pain experience in patients with chronic pain and comorbid
hypertension.21,22 Therefore, heart rate and blood pressure are not reliable indicators of
pain intensity.

PROBLEM STATEMENT
LBP is a common chronic condition, especially in the older population, and is
typically treated with different pain medications and interventional procedures. Most
studies have assessed the utilization of pain treatments, however there is a lack of
description of patients at risk for chronic LBP and utilization data on pharmacologic
treatments and procedures with respect to disease duration and pain severity. Also,
studies16 have reported the association of comorbid conditions such as anxiety and
depression with chronic pain, but none have focused specifically on patients with LBP.
Since pain management requires multimodal interventions, the procedures need to
be monitored for certain drug interactions. The American Society of Regional Anesthesia
and Pain Medicine (ASRA) guidelines for patients on antiplatelet and anticoagulants
undergoing interventional spine and pain procedures, recommend the discontinuation of
blood thinners prior to conducting intermediate-risk or high-risk procedures to avoid
spinal hematoma.15 The ASRA guidelines also recommend the discontinuation of herbal
medicines prior to any interventional procedure, as the co-administration of herbal
medicines with blood thinners causes significant bleeding or interaction.15
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There’s a need to evaluate characteristics of patients on opioids and
benzodiazepines in order to identify the different types of procedures these patients
undergo in their multimodal treatment strategy. Finally, a few studies have assessed the
change in pain scores from baseline to after the use of a single interventional therapeutic
procedure. However, none of them have been conducted in patients with LBP.

CONCEPTUAL FRAMEWORK
This study will utilize the electronic medical record data from an outpatient pain
clinic based in southwestern Pennsylvania. The pain management clinic provides a
comprehensive treatment plan and uses diagnostics techniques to detect the origin of pain
with the ultimate goal of providing significant pain relief to the patients. This study will
include new patients with a diagnosis of chronic LBP enrolled in the practice from
January 2018 through February 2020.

STUDY OBJECTIVES AND RESEARCH QUESTIONS
Overall goal is to explore pain management in patients with LBP in an outpatient pain
clinic.
Specific research questions include:
1. To describe the demographics (age, gender, race, ethnicity, smoking status,
alcohol consumption status, drug use status) and clinical characteristics
(procedures, medications) of patients with chronic LBP
2. To assess the prevalence of comorbid conditions including hypertension, anxiety
and depression in the chronic LBP cohort and to compare the demographic and
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clinical characteristics of patients (i) with and without hypertension and (ii) with
and without anxiety and/or depression
3. To assess the demographic and clinical characteristics of patients with chronic
LBP who are currently prescribed the following medications: blood thinners
(anticoagulants/antiplatelet), herbal medications, benzodiazepines and opioids
4. To assess the mean pain level pre- and post-procedure for patients with chronic
LBP that have undergone a single interventional therapeutic LBP procedure
throughout the study period

STUDY SIGNIFICANCE
The evaluation of clinical characteristics including pain scores in patients with
chronic LBP will provide useful data on commonly prescribed pain medications and
interventional procedures and assist physicians in making informed decisions regarding
appropriate pain management. The study will help to identify and inform the practice
regarding the type of patient population at highest risk for chronic LBP, various treatment
options within pharmacologic and interventional procedure and the extent of pain relief
provided by these treatments.

STUDY LIMITATIONS
The study generalizability is limited as data is collected from one outpatient clinic
in southwestern Pennsylvania. Moreover, the study assesses the population that has been
treated by a single practictioner limiting the treatment options that could have been
considered after consensus from multiple practitioners. As the study includes newly
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enrolled patients in 2018 at the clinic, it does not differentiate between patients that were
first diagnosed in this practice or that were previously diagnosed in other practice. This
might lead to loss of important information and introduced a systematic bias.
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CHAPTER 2: SYSTEMATIC LITERATURE REVIEW
Chronic Non-Cancer Pain
Increase in prescription opioid use among patients with CNCP has been a public health
concern over the last decade. Existing protocol-driven studies have limitations in
assessing the effectiveness of therapies and thus, there is a need to identify real-world
studies from diverse population regarding the use and effectiveness of opioids and nonopioids in CNCP. A systematic literature review was conducted to report the findings of
existing real-world evidence studies of opioid and non-opioid use in patients with CNCP.

METHODS
Utilizing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines, a systematic literature review was conducted to identify real-world
evidence studies. A search strategy was developed for the following key words: chronic
non-cancer pain, opioid, non-opioid, prescription drug misuse and study designs. The
search was conducted in three databasesPubMed, PsycINFO and EMBASE (Refer
Appendix I) with a search limit set at the year 2018. Identified articles were imported in
Covidence systematic review software (Veritas Health Innovation, Melbourne,
Australia). Duplicates were eliminated and the remaining articles were subjected to title
abstract screening followed using inclusion and exclusion criteria. Finally, full text
reviews were conducted, and a qualitative synthesis was conducted to extract information
of interest from the articles.
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Inclusion and Exclusion Criteria
The studies included adult patients with CNCP undergoing pain management and
prescribed opioid and/or non-opioid drugs. Following real-world evidence study designs
were included retrospective studies, cohort studies, longitudinal studies, case-control
studies and cross-sectional studies. Studies involving illicit drugs, pregnant women,
patients below 18 years of age, economic evaluations or healthcare resource utilization
were excluded from the review. Additionally, qualitative studies, experimental design
studies, systematic reviews, case studies, editorials, commentaries, review articles, nonEnglish articles, erratum, conference abstracts and dissertations were excluded.

RESULTS
Upon executing the search strategy on the PubMed, PsycINFO and EMBASE, a
total of 421 articles were identified. After removing 52 duplicate articles, 369 articles
underwent title abstract screening and further, articles were excluded based on
inclusion/exclusion criteria. A full text review of 37 articles was then conducted
following which 23 articles were included in the final review. (Refer Figure 3)
All but two studies (n=21, 91.3%) were conducted in the
US.23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43.The other two were conducted in France44
and Switzerland45. Majority of the studies utilized administrative claims data (n=15,
65.21%) followed by electronic medical record (n=3, 13.04 %), institutional database
(n=3, 13.04 %) and survey (n=2, 8.7%). Out of 23 studies, 10 studies (43.47%) assessed
LBP along with other CNCP conditions.
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Figure 2: Schematic representation of systematic literature review using the
Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA)
Guidelines
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Amongst these 10 studies, only one study focused on chronic LBP alone. Following
types of studies were identified from the review: 1) Opioid use studies in patients with
CNCP and/or comorbidity/surgical procedure, 2) Opioid use studies based on prescribing
pattern, 3) Opioid overdose/misuse related studies.
1) Opioid use studies in patients with CNCP and/or comorbidity/surgical procedure:
Eight studies25, 31, 33,35,36,37,38,42 (34.8%) evaluated the use of opioids in patients with
CNCP who had a history of substance use or mental health disorder, or other conditions
like epilepsy and HIV/AIDS. These studies observed a high prevalence of long-term use
of opioids and higher-dose opioids. Studies assessing specifically migraine or headacherelated pain (n=5, 21.73%) reported more opioids being prescribed than triptans and that
the prevalence of chronic headache was high among those with analgesic overuse.
Brummett et al. (2017) reported no significant difference in incidence of new persistent
opioid use between patients that underwent minor surgery compared to those that
underwent major surgery. The results suggested that prolonged opioid use probably was
not entirely due to surgical pain, and could be associated with preoperative pain
disorders, anxiety and depression.25
2) Opioid use studies based on prescribing pattern:
Axeen et al. (2018) indicated that opioid users in the Medicare population between 2006
to 2010 were actually abusing opioids and interestingly, the largest quantity increases
were being prescribed by nurse practitioners and physician assistants.24 In a study
comparing residents of San Francisco, California to those nonlocal residents, Bauer et al.
(2016) observed higher opioid doses and lower rates of urine drug testing among patients
with a nonlocal home address. Patients treated by resident physicians were less likely to
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receive higher-dose chronic opioid compared with patients treated by faculty or nurse
practitioner.28
3) Opioid overdose/misuse related studies:
Several studies demonstrated a direct relationship between prescribed opioid dose and the
risk of opioid overdose death.26,29,31,39 Hoffman et al. (2017) reported that in patients with
polyneuropathy who received prolonged opioid treatment, there was no improvement in
the functional status markers. Instead adverse outcomes were seen in these patients
including depression, opioid dependence and opioid overdose. 27 West et al. (2016)
reported higher rates of prescription opioids misuse and serious medical outcomes in
older adults compared to younger adults.32 Several studies have reported a host of risk
factors including anxiety, depression, alcohol and substance use disorders, mood
disorders, concomitant use of benzodiazepine and sedative-hypnotics associated with
persistent opioid use and opioid overdose. 25,26,36,40 A summary of the systematic literature
review is included in Table 3.
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Table 3: Description of CNCP studies
Author,
Year,
Country

Study Aim

Data Source,
Study Design,
Sample Size,
Study Period

Setting of the
study

CNCP condition

Key findings

Limitations

Schwedt
et al,23

To estimate
rates of acute
medication
overuse
(AMO) and
determine
associations of
AMO with
individual and
headache
characteristics.

Survey

Members of
Research Now,
Plano, TX
(internet
research panel)

Migraine

Compared with those not
overusing medications,
respondents with AMO were
significantly more likely to
be taking triptans, opioids,
barbiturates, and ergot
alkaloids and significantly
less likely to be taking
NSAIDs.

The risk of AMO by
individual medication
class was not assessed,
information that might
have helped to guide
drug choices and
targeted educational
efforts in clinical
practice.

2018
USA

Longitudinal
cross-sectional
study
3,649 patients
October 2016
to January
2017
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Respondents with AMO had
significantly more monthly
headache days (MHDs);
higher migraine symptom
severity, higher pain
intensity scores; and higher
rates of cutaneous allodynia.

Axeen et
al,24
2018
USA
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De Rijk
et al,44
2018
France

To determine
characteristics
and trends in
opioid use,
questionable
use, and
prescribing in
Medicare
(extracted data
for chronic
non-cancer
pain only).

Administrative
claims data

To investigate
the headache
characteristics
and clinical
features of
elderly
migraine
patients at a
tertiary
headache
center.

French
National
Observatory of
Migraine and
Headache
database

Medicare
claims data

Retrospective
cohort study

Headache,
chronic pain,
myalgia, arthritis,
low back pain

21,120,682
patients

Prescribing quantity and
intensity varied by specialty.
The largest quantity
increases were among nurse
practitioners and physician
assistants.

2006 to 2012

Retrospective
cohort study
239 patients
2006 to 2015

Opioid users were
increasingly likely to abuse
opioids or display patterns of
questionable use from 2006
to 2010, with a slowdown in
later years.

16 tertiary-care
headache
clinics and one
specialized
headache
emergency
department

Migraine

Out of 30.1% patients that
reported medication overuse,
31.65% overused triptan and
70.9% overused combination
analgesics.
Higher frequencies of
migraine were observed for
patients whose age at onset
of migraine was younger
than 18 years, and low
frequency migraine was
observed in the later onset
group.

Because prescriptions
are not tied directly to a
medical encounter in
the claims data,
measures of diagnoses
reflect the
comorbidities of
patients receiving
opioids rather than the
direct diagnosis for
which the opioid was
prescribed.

Age onset of the
patients may not be
accurate since migraine
cannot be recognized
when younger.

Brumme
tt et al,25
2017
USA

To determine
the incidence
of new
persistent
opioid use after
minor and
major surgical
procedures.

Administrative
claims data
Retrospective
cohort study
36,177 patients
January 2012
to June 2015

National
managed care
company
affiliated with
OptumInsight

Minor and
Major surgical
procedure

No significant difference was
observed in incidence of new
persistent opioid use between
minor surgery and major
surgery group thereby
suggesting that prolonged
opioid use is not entirely due
to surgical pain.

Actual opioid
consumption was not
captured in the study.

Risk factors independently
associated with new
persistent postoperative
opioid use included
preoperative tobacco use,
alcohol and substance abuse
disorders, mood disorders,
anxiety and preoperative
pain disorders.

Claims data does not
allow for assessment of
degree of impairment
of painful conditions
and mood disorders
that might be driving
persistent opioid use.

Categorization of major
vs. minor surgical
conditions may be
subject to critique.
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Garg et
al,26
2017
USA

To determine
whether
patterns of
opioid use are
associated with
risk of opioidrelated
mortality
among opioid
users.

Administrative
claims data
Retrospective
cohort study
150,821
patients
April 2006 to
December 2010

Washington
Medicaid

NA

Compared with patients at 1–
19 mg/d, risk of opioid
overdose death significantly
increased at 50–89 mg/d, 90–
119 mg/d, 120–199 mg/d,
and >=200 mg/d.
Patients using long-acting
plus short-acting Schedule II
opioids had 4.7 times the risk
of opioid overdose death
than non- Schedule II
opioids alone.
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Risk of opioid overdose
death was particularly high
for opioids combined with
skeletal muscle relaxants,
benzodiazepines, sedativehypnotics.

Unable to distinguish
between incident and
chronic opioid users.
Data were only
available for
individuals with feefor-service (67%–75%
of Medicaid enrollees
during study years).

Hoffman
et al,27
2017
USA

To quantify the
prevalence of
long-term
opioid use
among patients
with
polyneuropath
y and to assess
the association
of long-term
opioid use with
functional
status, adverse
outcomes, and
mortality.

Rochester
Epidemiology
Project (REP)
database
Retrospective
case-control
cohort study

Prescription
database from
all ambulatory
practice
professionals
in Olmsted
County,
Minnesota

Polyneuropathy

No functional status markers
were improved by long-term
use of opioids in patients
with polyneuropathy.

Cases: 2892
patients with
Polyneuropathy
and Controls:
14435 patients

26
2016
USA

To describe the
population of
patients
prescribed
opioids
(CNCP) at 2
academic
primary care
clinics and
evaluate
patient and
provider
characteristics
associated with
higher-risk

Electronic
medical record
Retrospective
cohort study
842 patients
March 2012 to
March 2013

Prescription duration
was calculated in most
cases presuming
patients took each asneeded dosage.
Daily morphine
equivalents were not
estimated, which
prevented
determination of a dose
effect.

Adverse outcomes were
more common among
patients with polyneuropathy
receiving long-term opioids,
including depression, opioid
dependence and opioid
overdose.

January 2006
to December
2010

Bauer et
al,28

Among the 2892 patients
with polyneuropathy and the
14,435 controls, patients
with polyneuropathy
received long-term opioids
more often than did controls
(545 [18.8%] vs 780 [5.4%]).

Two academic
primary care
clinics

NA

Higher opioid doses and
lower rates of urine drug
testing were observed among
patients with a nonlocal
home address when
compared to San Francisco
address.
Patients treated by resident
physicians were less likely to
receive higher-dose chronic
opioid compared with
patients treated by faculty or
nurse practitioner.

Risk factors for
initiation of opioids or
opioid dose escalation
could not be assessed
since cohort was
already treated with
opioid and the opioid
dose was determined
based on most recent
prescriptions.
Patients could have
obtained additional
prescriptions or urine

opioid
prescriptions.

Bohnert
et al,29
2016
USA
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To examine the
association of
prescribed
opioid dosage
as a continuous
measure in
relation to risk
of
unintentional
opioid
overdose to
identify the
range of
dosages
associated with
risk of
overdose at a
detailed level.

Lower rates of urine drug
testing were observed among
patients with faculty or nurse
practitioner.

Administrative
claims data
Nested casecontrol study
Cases: 399 and
Controls: 221
patients
2004 to 2009

Veterans
Health
Administration
system
Veterans
Health
Administration'
s National
Patient Care
Database
VHA's
Pharmacy
Benefits

Headache,
peripheral
neuropathy,
central pain
syndrome,
chronic pain
syndrome,
migraine,
atypical face
pain,
osteomyelitis

Black patients were almost
twice as likely to complete a
urine drug test as compared
to non-Hispanic white
patients.
Average prescribed opioid
dosage was higher for cases,
with a mean of 98.1 MEM
than controls, whose
prescribed opioid dosage had
a mean of 47.7 MEM.
In a receiver operating
characteristic (ROC)
analysis, dosage was a
moderately good “predictor”
of opioid overdose death,
indicating that, on average,
overdose cases had a
prescribed opioid dosage
higher than 71% of controls.

drug testing outside
these 2 clinics.

Exclusion of deaths
that were undetected
unintentional opioid
overdoses (eg,
misclassified as
suicide, or opioids
involved but not
detected or recorded by
medical examiner)

Ray et
al,30
2016
USA

Liang et
al,31
2016
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USA

To compare
all-cause
mortality for
CNCP patients
prescribed
either longacting opioids
or alternative
medications for
moderate to
severe chronic
pain.

Administrative
claims data

To examine
risk factors for
drug overdose
by sex
reflecting
differing
patterns of
opioid and
other drug use.

Administrative
claims data

Retrospective
cohort study
22,912 patients

Tennessee
Medicaid
linked to death
certificates and
a standard
hospital
discharge
database

Back pain, other
musculoskeletal
pain, abdominal
pain, headache,
other neurologic
pain

Prescription of long-acting
opioids for CNCP, compared
with anticonvulsants or
cyclic antidepressants, was
associated with a
significantly increased risk
for all-cause mortality,
including deaths from causes
other than overdose.

Reliance on the death
certificate to classify
the cause of death,
raised the possibility
that the cardiovascular
death finding was due
to misclassification.

National
privately
insured
enrollees from
Aetna Health
Maintenance
Program
(HMO)

Back pain, large
joint
arthritis/other
musculoskeletal
disorders,
neuropathic pain,
chronic pain
unspecified,
chronic headache

For both sexes, substance use
was the strongest predictor
of drug overdose with an
adjusted odds ratio (AOR) of
5.95 for women vs. 4.69 for
men.

The study could not
distinguish prevalent
opioid users from new
users.

1999 to 2012

Retrospective
cohort study
206,869
patients
January 2009
to July 2012

AOR for benzodiazepine use
was higher in men than
women (2.75 vs 2.35
respectively).

Only predictors
measured within six
months after the first
filled opioid
prescription were
considered because it is
important to distinguish
risks early after starting
therapy.

West et
al,32
2016
USA
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Wilner
et al,33
2016
USA

To examine
recent trends in
misuse of
prescription
opioids and
associated
medical
outcomes
among olderaged adults
(60+ years)
and compared
the patterns
with trends
among
younger-aged
adults (20–59
years).

Electronic
medical record
and narrative
report (calls)

To compare
the prevalence
of analgesic
opioid use in
an insured
patient
population
with epilepsy
to a matched
control
population
without
epilepsy.

Administrative
claims data

Retrospective
cohort study
57,681 patients
2006 to 2014

Case-control
cohort study
Cases: 10,271
patients with
Polyneuropathy
and Controls:
20,542 patients
2012

Researched
Abuse,
Diversion and
AddictionRelated
Surveillance
(RADARS®)
System Poison
Centers
Program
database (40 to
49 centers)

NA

Nine health
plans
contracting
with Accordant
Health
Services
(AHS)

Joint pain or
stiffness,
abdominal pain,
headache, pain in
limb, chest pain,
sprain of
different parts,
sinusitis,
migraine,
lumbago,
backache,
cervicalgia,
fracture,
fibromyalgia,
sciatica, chronic
pain, jaw pain

Population rates of misuse of
prescription opioids were
higher for older adults than
for younger adults, and this
disparity increased over
time.
Rates of serious medical
outcomes among the older
ages followed an increasing
linear trend; in contrast, rates
among younger adults rose
and fell during the period,
with recent rates trending
downward.

The prevalence of pain
diagnosis was 51% in the
group with epilepsy and 39%
in the matched control group.
Analgesic opioids were used
by 26% of individuals in the
group with epilepsy vs. 18%
of matched controls.
The prevalence of
psychiatric diagnoses was
27% in the group with
epilepsy and 12% in the
matched controls.

Use of passive data
collection systems that
introduced a potential
selection bias by
reliance on information
that is voluntarily
reported to poison
centers.

Patients with
nonepileptic seizures
may have been
mistakenly included if
they were taking
antiepileptic
medication.
Conversely, people
with controlled
epilepsy on no
antiepileptic
medication may have
been missed by the
identification
algorithm.

Liang et
al,34
2015
USA
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Turner
et al,35
2015
USA

To address the
hypothesis that
daily opioid
dose and total
dose may offer
complementary
information for
clinicians to
distinguish
patients at
increased risk
of drug
overdose.

Administrative
claims data

To examine
interactions of
filled
prescriptions
for opioids,
benzodiazepine
s,
antidepressants
, and zolpidem
with mental
health
disorders in
regard to drug
overdose.

Administrative
claims data

Retrospective
cohort study
206,869
patients

National
privately
insured
enrollees from
Aetna Health
Maintenance
Program
(HMO)

Back pain,
musculoskeletal
disorders,
neuropathic pain,
chronic pain
unspecified,
chronic headache

January 2009
to July 2012

Retrospective
cohort study
206,869
patients
January 2009
to July 2012

Relative to no opioid
therapy, persons at highest
risk for overdose received a
daily MED of ≥100 mg
regardless of total dose or a
daily MED of 50 to 99 mg
with a high total MED
(>1,830 mg).

The study could not
evaluate the reason for
increased overdose risk
in patients with high
total dose of opioid
prescriptions.

The hazard ratio was
significantly lower (1.43) for
50 to 99 mg daily MED with
a lower total MED (≤1,830
mg), whereas hazard ratios
for lower daily MEDs did
not differ by total dose.
National
privately
insured
enrollees from
Aetna Health
Maintenance
Program
(HMO)

Back pain, large
joint arthritis,
musculoskeletal
disorders,
neuropathic pain,
chronic pain
unspecified,
chronic headache

The adjusted odds ratios
(AOR) for overdose was
highest (AOR=7.06) for
persons with depression and
a high opioid dose (≥100
mg) versus no depression or
opioid use.
Opioids and longer-duration
benzodiazepines
were associated with drug
overdose among all subjects,
but opioid risk was greatest
for persons with depression.

Drug overdoses in this
cohort may have been
due to illicit drug use
or suicide attempts.

Dobscha
et al,36
2013
USA

To describe
patterns of
prescription
opioid
initiation,
identify
correlates of
opioid
initiation, and
examine
correlates of
receipt of
chronic opioid
therapy (COT)
among
veterans with
persistent noncancer pain.

Administrative
claims data

To evaluate the
diagnostic
criteria of
MOH in a
mixed
population of
chronic pain
patients to gain
information
about the
prevalence and
possible
associations
with MOH.

Data of all
patients
referred to
interdisciplinar
y pain clinic

Retrospective
cohort study
5,961 patients
2008

Regional VA
healthcare
facilities and
two national
VA databases
Veterans
Integrated
Service
Network
[VISN]-20
Data
Warehouse

Fibromyalgia,
inflammatory
bowel disease,
low back pain,
migraine
headache, neck
or joint pain,
neuropathy,
arthritis

Veterans prescribed COT
were younger, had greater
pain intensity, and high rates
of psychiatric and substance
use disorders (SUDs)
compared to veterans in the
other two groups.

Headache,
neurological,
psychiatric,
rheumatologic,
other pain
disorder

Chronic headache was more
prevalent among patients
with analgesic overuse
(39.8%) than without
analgesic overuse (18%).

Reasons for
prescription of
adjunctive medications
(e.g., antidepressants)
could not be
determined.

Adjusting for age, sex, and
baseline pain intensity, major
depression and nicotine
dependence were associated
with receiving any opioid
prescription and with COT
respectively.
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Schmid
et al,45
2013
Switzerl
and

Retrospective
cohort study
178 patients
September
2005 to
December 2007

Interdisciplinar
y pain clinic at
the University
Hospital of
Zurich

History of headache (OR
2.5), history of migration
(OR 2.9) and comorbid
depression (OR 3.5) were
associated with overuse of
acute medication.

Bias of data collection
due to quality of
recorded information
and inadequacy of
patient’s reports could
be seen.

Silverber
g et al,37
2012
USA

To examine
changes in use
of prescription
opioids for the
management of
chronic noncancer pain in
HIV-infected
patients and to
identify patient
characteristics
associated with
long-term use.

Administrative
claims data
Retrospective
cohort study
6,939 patients
1997 to 2005

Health plans:
Kaiser
Permanente
Northern
California
(KPNC) and
Group Health
Cooperative
(GHC) in
Washington
State

NA

In 2005, 8% of HIV+
individuals had prevalent
long-term opioid use, more
than double the prevalence
among HIV-uninfected
individuals.
The strongest associations
with prevalent use among
HIV-infected individuals
were female gender,
Charlson comorbidity score
of 2 or more, injection drug
use history, substance use
disorders.
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CD4, HIV RNA, and AIDS
diagnoses were associated
with prevalent opioid use
early in the antiretroviral
therapy era (1997), but not in
2005.

Lack of information
regarding indications
for opioid prescribing,
including types of pain
experienced.

Kobus et
al,38
2012
USA
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Dunn et
al,39
2010
USA

To study the
prevalence of
high-dose
opioid use, as
well as
associated
demographic,
clinical, and
health service
utilization
correlates
among low
back pain
patients.
(health service
utilization
information
was not
extracted)
To estimate
rates of opioid
overdose and
their
association
with an
average
prescribed
daily opioid
dose among
patients
receiving
medically
prescribed,
long-term
opioid therapy.

Administrative
claims data
Retrospective
cohort study
15,471 patients
2003 to 2005

Electronic
medical record
Retrospective
cohort study
9,940 patients
1997 to 2005

Ambulatory
data of Kaiser
Permanente
Northwest
(KPNW)
region, a large,
not-for-profit,
integrated
health care
system. KPNW
serves the
Portland,
Oregon and
Vancouver,
Washington
metropolitan
area.

Low back pain

Group Health
Cooperative Health
Maintenance
Organization
(HMO)

Back or neck
pain,
osteoarthritis,
headache,
extremity pain,
abdominal pain
or hernia,
menstrual
pain;
temporomandibul
ar disorder pain;
fractures,
contusions,
injuries

Higher-dose opioid use
occurred in 2.9% of patients
who received any opioids
and in 8.6% of patients who
received opioids long-term.
Compared to lower-dose or
no opioid use comparison
group, patients in the higherdose group had higher rates
of mental health and
substance use disorders,
concurrent sedative-hypnotic
use.

Compared with patients
receiving 1 to 20 mg/d of
opioids, patients receiving 50
to 99 mg/d had a 3.7-fold
increase in overdose risk and
a 0.7% annual overdose rate.
Patients receiving 100 mg/d
or more had an 8.9-fold
increase in overdose risk and
a 1.8% annual overdose rate.

While the focus of the
study was on patients
with a known back pain
diagnosis, the reason
for being prescribed
higher dose opioid
therapy was unknown,
particularly given high
levels of co-morbidity.

Small number of
overdoses in the study
cohort was observed.

Edlund
et al,40
2010
USA

To analyze
trends between
2000 and 2005
in opioid
prescribing
among
individuals
with noncancer pain
conditions
(NCPC), with
and without
MH and SUDs.

Administrative
claims data
Retrospective
cohort study
Health Core:
485,794
patients; 2000
and 897,537
patients; 2005
Arkansas
Medicaid:
36,283
patients; 2000
and 43,520
patients; 2005

A national,
commerciallyinsured
population
(Health Core)
and Arkansas
Medicaid
enrollees.

Back pain, neck
pain,
arthritis/joint
pain,
headache/migrain
e, and HIV/AIDS

Between 2000 and 2005, in
commercially insured, rates
of chronic opioid use
increased by 34.9% among
individuals with an MH or
SUD, and 27.8% among
individuals without these
disorders whereas in
Arkansas Medicaid, chronic
opioid use increased by
55.4% among individuals
with an MH or SUD, and
39.8% among those without.

2000 and 2005
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Scher et
al,41
2010
USA

To describe
patterns of
medication use
among Chronic
Daily
Headache
(CDH) and
Episodic
Headache (EH)
sufferers in a
general
population
sample.

Survey, Nested
case-control
study; CDH
cases: 206
patients and
EH controls:
507 patients,
NA

In 2000, among individuals
with CNCP, chronic opioid
use was more common
among those with a MH or
SUD than those without in
commercially insured (8%
versus 3%) and Arkansas
Medicaid (20% versus 13%).

Computerassisted
telephone
survey in
Atlanta, GA;
Baltimore, MD
or
Philadelphia,
PA,
metropolitan
areas

Chronic daily
headache

CDH subjects were more
likely than EH controls to
use over-the-counter/caffeine
combination products,
triptans, opioid compounds.
After adjusting for
demographic factors,
primary headache type and
number of medications
taken, CDH sufferers are
more likely to use opioidcombination analgesics, and
less likely to use aspirin or
ibuprofen, than EH sufferers.

Researchers were not
able to separate
methadone used for
pain from methadone
used for methadone
maintenance.
Results represent
population trends and
not the trends of
individual enrollees.

CDH status was
unknown at baseline;
thus, some of the CDH
sufferers at follow-up
may have already had
CDH at the first
assessment.

Weisner
et al,42
2009
USA

To examine
trends and
characteristics
of long-term
opioid use in
persons with
non-cancer
pain and a
substance
abuse history.

Administrative
claims data
Retrospective
cohort study
1997 to 2005

Health plans:
Kaiser
Permanente
Northern
California
(KPNC) and
Group Health
Cooperative
(GHC) in
Washington
State

NA

At KPNC (1999–2005),
prevalence of long-term use
increased from 11.6% to
17.0% for those with
substance use disorder
histories and from 2.6% to
3.9% for those without
substance use disorder
histories. Respective GH
rates (1997–2005), increased
from 7.6% to 18.6% and
from 2.7% to 4.2%.
Among persons with an
opioid disorder, KPNC rates
increased from 44.1% to
51.1%, and GH rates
increased from 15.7% to
52.4%.
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Long-term opioid users with
a prior substance abuse
diagnosis received higher
dosage levels, were more
likely to use Schedule II and
long-acting opioids, and
were more often frequent
users of sedative-hypnotic
medications in addition to
their opioid use.

Opioid use disorders
may be over-diagnosed
for those who had
already been prescribed
opioids, given the
confusion between
substance use disorders
(addiction) and
physiological
dependence, which
often occurs with
regular opioid use.

Tepper
et. al,43
2006
USA

To describe the
prescription
drug claims for
acute headache
treatments of
persons in the
United States
with a
migraine or
nonmigraine
headache
diagnosis who
were enrolled
in a large
health care
plan with
pharmacy
benefits.

Administrative
claims data
Retrospective
cohort study
2003

Integrated
Healthcare
Information
Services
National
Managed Care
Benchmark
Database - data
from more than
30 US
healthcare
plans

Migraine
346.xx, 307.81,
784.0

Of the 6.2 million continuous
enrollees in 2003,
approximately 10% had at
least 1 medical claim for
migraine or nonmigraine
headache. Of these persons,
64% did not have a claim for
any prescription drug
commonly used for the acute
treatment of headache.
Among persons with any
headache diagnosis who had
a claim for a prescription
headache medication, 69%
received opioids.
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Opioids were prescribed for
migraine sufferers more
frequently than triptans (59%
vs 41 %).

Could not differentiate
between medications
prescribed for daily use
and those to be taken as
needed, without
detailed pharmacy data
such as number of pills
prescribed or
dispensed.

Limitations
The systematic literature review has few limitations. Full text was not available
for few articles, thus excluding studies that had captured relevant information. Major
limitations were observed with respect to the type of data source utilized. Few studies
evaluated opioid and non-opioid utilization irrespective of the CNCP condition,
excluding information related to the pain condition. The search strategy did not include
specific opioid and non-opioid drugs, instead drug classes for opioid and non-opioid
drugs were broadly included, thus leaving out some relevant articles.

Conclusions
The systematic review provided a detailed summary into the opioid and nonopioid utilization and different factors associated with increased risk of drug overdose in
various CNCP conditions. Very few studies focused on patients with chronic LBP, which
is the commonly reported chronic pain illness in the population. There is a need to
identify the prevalence of opioid and non-opioid use and utilization of interventional
procedures in patients with chronic LBP with different pain levels.

Chronic Low Back Pain
Upon conducting a systematic review for patients with CNCP, an overall view of
pain management in the CNCP was captured. To further understand existing studies
carried out in chronic LBP with a focus on the interventional procedures performed in
this cohort, a literature review was conducted. A search strategy was built utilizing key
words related to back pain, interventional procedures and study designs (Refer Appendix
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II). A total of 164 studies were identified after executing the search strategy on PubMed.
Articles irrelevant to study objectives were excluded. Finally, qualitative synthesis of 10
articles was conducted to extract information related to Chronic LBP (Refer Table 4).
Studies assessed various Chronic LBP conditions including Bertolotti syndrome,
lumbosacral radiculopathy, lumbar radiculopathy, radicular pain, sacroiliac joint pain,
lumbosacral radicular pain, lumbar spinal stenosis, lumbago, lumbosacral sprain,
herniated disk, radiculopathy and degenerative disease. Goluboysky et al. reported that
patients with Bertolotti syndrome had significantly more prior epidural steroid injections
(ESI) and worse QoL as compared to those with lumbosacral radiculopathy.46 Tagowski
et al. indicated that 4 weeks after ESI injection the probability of >=50% pain reduction
was lower in the dexamethasone group than that in the triamcinolone group.47 Wei et al.
reported that increased pre-injection opioid use has no impact on long-term QoL after
ESI for degenerative spine diseases.48 Reddy et al. estimated a significant reduction in
mean pain score and improvement in QoL of patients with sacroiliac joint post
radiofrequency neurotomy.49 Plastaras et al. reported immediate and delayed adverse
events associated with transforaminal ESI and indicated that the adverse events were
associated with various risk factors including gender, age, pre-procedure VAS, steroid
type, and fluoroscopy time.50 El-Yahchouchi et al. concluded that immediate pain score
response was weakly associated with 2-month outcomes of transforaminal ESI.51 Kang et
al. observed decreased bone mineral density in patients treated with ESI using
triamcinolone (>200 mg) for a period of one year in postmenopausal women treated for
LBP.52 Smith et al. reported a decrease in pain scores from pre-injection to post-injection
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in both interlaminar ESI and transforaminal ESI groups, but no significant difference in
pain scores between the two groups.53
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Table 4: Description of Chronic LBP studies
Author,
Year,
Country

Study Aim

Data Source,
Study
Design,
Sample Size,
Study Period

Setting of the
study

Chronic
LBP
condition

Key findings

Limitations

Golubovsky
et al,46

To examine the
quality of life and
prior treatments
in patients with
Bertolotti
syndrome at first
presentation to
the authors’
center in
comparison with
those with
radiculopathy.

Center for
Spine Health
database

Center for Spine
Health

Bertolotti
syndrome,
Lumbosac
ral
radiculopa
thy

Patients with Bertolotti syndrome
had significantly more prior
epidural steroid injections (ESI)
and have worse physical and
mental health scores than ageand sex-matched patients with
lumbosacral radiculopathy.

The lack of
availability of
postoperative patientreported outcome
limited the ability to
evaluate preoperative
to postoperative
changes.

2019
USA

Retrospective
cohort study
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Bertolotti
syndrome: 22
patients,
Radiculopath
y: 46 patients
2005 to 2018

Both groups of patients had mild
depression and clinically
meaningful reduction in their
quality of life.

Tagowski et
al,47
2019
Switzerland

To compare pain
relief after CTguided lumbar
epidural steroid
injections (ESI)
using particulate
(triamcinolone)
and
non-particulate
(dexamethasone)
steroids, and to
explore factors
affecting the
effectiveness of
both steroid
types.

Institute of
Medical
Radiology of
the Solothurn
Hospitals
database

To evaluate the
association
between preinjection opioid
use and patientreported
outcomes (PROs)
following spine
epidural steroid
injection.

Prospective
web-based
longitudinal
spine registry
database

Institute of Medical
Radiology of the
Solothurn
Hospitals

Lumbar
radiculopa
thy

Four weeks post-injection, the
overall chance of >= 50% pain
reduction was lower in the
dexamethasone group than that in
the triamcinolone group.
In the dexamethasone cohort, the
intensity of baseline pain and the
presence of a herniated
intervertebral disc in the
infiltrated segment were both
significant and independent
predictors of >= 50% pain relief.

Retrospective
cohort study
806 patients
March 2005
to December
2014

Lack of information
regarding the duration
of symptoms or
additional oral
analgesic medication
which could have
potential effects on
outcome.
Loss of telephone
follow-up of several
patients could have
affected the outcome.

No significant correlation was
observed between effectiveness of
triamcinolone and other
concomitant variables including
baseline pain level.

41
Wei et al,48
2017
USA

Retrospective
cohort study
276 patients
March 2011
to July 2016

Academic
Institution

Radicular
pain

Increased pre-injection opioid use
does not impact long-term
outcomes after epidural steroid
injections (ESI) for degenerative
spine diseases.
A pre-injection morphineequivalent amount around 50
mg/day may represent a threshold
above which the 3-month
effectiveness of ESI for back- and
neck-related disability decreases.

Researchers were
unable to directly
quantify the
preoperative duration
of opioid
consumption.
The differences in the
types of ESI and
number of injections
patients received may
affect the PROs.

Reddy et
al,49
2016
UK
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Plastaras et
al,50
2015
USA

To assess the
effectiveness of
Simplicity
Radiofrequency
(RF) neurotomy
in terms of pain
relief, quality of
health
improvement in
patients suffering
from sacroiliac
joint (SIJ) pain
and complications
associated with
the procedure.

Tertiary
hospital
database

To systematically
identify the types
and incidence of
adverse events
(AE) associated
with
transforaminal
epidural steroid
injection (TFESI).
Additionally, to
evaluate
demographic and
clinical factors
that may predict a
higher
risk of an AE.

Electronic
medical
record

Tertiary hospital

Sacroiliac
joint pain

Retrospective
cohort study
16 patients

A statistically significant
reduction in both mean pain score
and median pain score at
12 months was observed.

Change in medication
intake was not
recorded, which might
affect the outcomes.

An improvement in general health
and psychological components of
Short Form 12 scores was
reported.

Lost to follow-up of
10 patients out of 26
patients who
underwent RF.

Common immediate AEs were
vasovagal reaction and
interrupted procedure from
intravascular flow.

Follow-up period of
24 to 72 hours may
have been too short to
capture all delayed
AEs.

April 2012 to
June 2013

Retrospective
cohort study
1,295 patients
March 2004
and April
2007

Multi-physician
academic Physical
Medicine and
Rehabilitation
clinic

Lumbosac
ral
radicular
pain

Common delayed AEs included:
pain exacerbation, injection site,
soreness, headache, facial
flushing/sweating, and insomnia.
Significant associations were
identified between AEs and
gender, age, preprocedure VAS,
steroid type, and fluoroscopy
time.

ElYahchouchi
et al,51
2014
USA

Kang et al,52

43

2012
South Korea

To assess whether
the immediate
anesthetic
response of pain
relief (sensory
blockade) or
weakness (motor
blockade) after
lumbar
transforaminal
epidural steroid
injection (TFESI)
is associated
with longer term
effectiveness in
pain relief and
functional
recovery.

Quality
assurance
database

To explore the
relationship
between bone
mineral density
(BMD) and
Epidural steroid
injection (ESI) in
postmenopausal
women treated for
lower back pain.

Medical
record

Single academic
radiology practice

Radicular
pain

Retrospective
cohort study

January 2006
to February
2011

90 patients
July 2005 to
June 2011

Stratification by the
nature of compressive
lesion was not
performed.

NRS and Roland-Morris
disability questionnaire (R-M)
responses at 2 weeks were more
strongly associated with the 2month response.

2,634 patients

Retrospective
cohort study

Immediate numerical rating scale
(NRS) response was weakly
associated with 2-month
outcomes.

Kangwon National
University Hospital

LBP

Decreased BMD was observed in
patients treated with ESI.
No significant difference was
observed between or within the
group treated with ESI and group
treated without ESI in terms of
mean percentage change from
baseline BMD.

Study did not include
long-term assessments
of the effect of ESI on
BMD.

Smith et al,53
2010
USA

44

Friedly et
al,54
2008
USA

To compare
short-term
improvement
in pain and longterm surgical
rates and the need
for
repeat injections
between
interlaminar ESI
and
transforaminal
ESI for
symptomatic
lumbar spinal
stenosis.

Academic
spine center
database

To evaluate
whether the use
of epidural steroid
injections (ESIs)
is associated with
decreased
subsequent opioid
use in patients in
the Department of
Veteran’s Affairs
(VA) and to
determine
whether treatment
with multiple
injections are
associated with
decreased opioid
use and lumbar
surgery after
ESIs.

National VA
administrativ
e database

Academic spine
center

Lumbar
spinal
stenosis

Retrospective
case control
study

2007

13,741
patients
October 2001
to September
2003

Small sample size
might have affected
the results.

No statistically significant
difference between the two
groups in pre-injection to followup VAS scores was reported.

19 patients

Retrospective
case control
study

Decrease in visual analog scale
(VAS) scores from pre-injection
to post-injection was observed
within each group.

Neither transforaminal ESI
nor interlaminar ESI resulted
in superior short-term pain
improvement or fewer
long-term surgical interventions
or repeat injections when
compared with each other.

Department of VA

LBP,
lumbago,
lumbosacr
al sprain,
herniated
disk,
radiculopa
thy, spinal
stenosis,
degenerati
ve disease

Opioid use did not decrease in the
6 months after ESIs.
Patients who received more
than 3 injections were more likely
than patients receiving fewer
injections to start taking opioids
after ESIs (19% vs 13%) and to
undergo lumbar surgery after
ESIs (8.7% vs 6.3%).

Patients were tracked
for only 6 months
before and after
receiving ESIs, hence
information regarding
lumbar surgery
conducted either
before or after the
study period were not
captured.
Opioid dose was not
determined, excluding
the information about
reduction of opioid
dose after ESI.

Kapural et
al,55
2007
USA

To examine the
relationship
between the
magnetic
resonance
imaging (MRI)
findings, pain
scores, and
opiates use in
patients with
lumbar spinal
stenosis (LSS)
undergoing
lumbar epidural
steroid (LES)
injections.

Electronic
medical
record
Retrospective
case control
study
719 patients
1999

Pain management
department

Lumbar
spinal
stenosis

No association exists between the
pretreatment age, sex, or number
of vertebral levels affected on
MRI with pretreatment VAS pain
scores or opioid use.
The improvement in VAS pain
scores after LES injections
correlated with number of lumbar
levels affected and the severity of
stenosis.

The study lacks
control over cointerventions including
oral medications and
other interventional
pain procedures.
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Friedly et al. reported that opioid use did not decrease in the 6 months follow-up period
after ESI in the Veteran population. Moreover, patients receiving more than 3 ESIs were
more likely to start taking opioids and undergo lumbar surgery after ESI. 54 Kapural et al.
indicated a correlation between an improvement in pain scores after lumbar ESI and
number of lumbar levels affected and severity of stenosis. 55

Conclusion
Studies have reported mixed results pertaining to the outcomes observed after LBP
procedures. A few studies reported an improvement in pain reduction while others have
reported several adverse events after LBP procedures. There is a need to evaluate the
post-procedural outcomes. The opioid utilization did not decrease after the interventional
procedure, indicative of lower pain relief obtained from procedures. Also, a need to
assess the opioid utilization pattern among patients that have undergone procedures has
been identified through this review, which would enable an understanding of severity of
pain managed by the procedures using their pain scores.
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CHAPTER 3: METHODS
The overall aim of the study was to explore pain management such as pain
medications and interventional procedures in patients with chronic LBP. The data was
obtained from an outpatient pain specialist clinic based in southwestern Pennsylvania.
The study was approved by the pain clinic and Institutional Review Board (IRB) of
Duquesne University. Additionally, patient data was protected by complying with the
Health Insurance Portability and Accountability Act (HIPAA) standards of Duquesne
University and the pain clinic.

ELECTRONIC MEDICAL RECORD DATA OF OUTPATIENT PAIN
CLINIC
The clinic treats an array of pain conditions including LBP, neck pain, arthritis
pain, nerve pain, cancer pain and complex regional pain syndrome and offer various pain
treatment procedures in the multimodal treatment approach. The electronic medical
record (EMR) data of the clinic includes patient information pertaining to demographics,
medications, procedures, laboratory tests, x-rays, discontinuation instructions and
progress notes. The progress notes are recorded during each patient visit and include
current condition, history of present illness, past medical history, family history, social
history, review of symptoms, vitals, exams, care plan and medications (new or
discontinued). Information regarding social history, family history, history of present
illness, past medical history, prior medications are collected via a self-reported pain
assessment form by the clinic, and then recorded into the EMR system by the clinic staff.
For the study sample, patients who were new to the practice with chronic LBP in the year
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2018 were identified and data was extracted from January 1st, 2018 to February 29th,
2020. All patients were followed from their first office visit till the cut-off date. The
maximum follow-up duration for any patient in the study was 26 months. But not all
patients will have follow-up duration of 26 months. The follow-up duration for patients
will vary depending on their first visit date into the practice. Table 5 includes variables
and their values as listed in the EMR and operationalized values of each variables to
conduct analyses for the study.
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Table 5: Operationalized value of variables of interest for the study
Variable

Value of the variable in EMR

Patient Identification Unique IDs assigned to each
Number (ID)
patient
Date of birth
Mm/dd/yyyy format

Operationalized value of the
variable for the study
Randomly assigned dummy IDs
Mm/dd/yyyy format
Age calculated as of Feb, 2020
 White
 Black
 Asian
 Declined to
specify/unknown
 Other Races: Includes
mixed and all other
races

Race








White
Black
Asian
Mixed
All other races
Declined to
specify/unknown

Ethnicity





Hispanic/Latino
Non-Hispanic/Latino
Decline to specify





Hispanic/Latino
Non-Hispanic/Latino
Decline to specify

Gender




Male
Female




Male
Female

Current condition

Pain-related disease conditions
(name listed) for which the
patient was visiting the office
were recorded for first and
follow-up visits

Pain-related disease conditions
(name listed) for which the
patient was visiting the office
was recorded only from the first
visit

Medical problems

Comorbid conditions (name
listed) were recorded for first
and follow-up visits
Smoking history was recorded in
each office visit
 Smoking status: Light
tobacco smoker, Heavy
tobacco smoker, Current
smoker, Occasionally,
Former smoker, Never

Comorbid conditions (name
listed) were recorded only from
first visit
Smoking history was recorded
only from first office visit
 Smoking status:
o Current smoker:
Includes light
tobacco smoker,
heavy tobacco
smoker,

Social history:
 Smoking
 Alcohol
consumption
 Drug use
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Alcohol Consumption:
Number of drinks/day or
week or month,
Consumed in the past,
Occasionally, Rare,
Never, No





Alcohol consumption
status:
o Currently
consume
alcohol: Includes
number of
drinks/day or
week or month,
occasionally,
rare
o No: Includes
consumed in the
past, never and
no



Drug use status:
o Current user:
Includes
regularly uses
marijuana,
sporadically uses
marijuana,
medical
marijuana use
o Former user
o No: Includes
regularly uses
herbal
supplements, no
and never



Height (inches): was
recorded only from first

Drug Use status:
Regularly uses
marijuana, Sporadically
uses marijuana, Medical
marijuana use, Regularly
uses herbal supplements,
Former drug user, Never,
No
Drug use is inclusive of
use of illicit drugs such
as heroin, cocaine,
marijuana or others. It
also includes medical
marijuana use

Review of systems
(ROS):
 Height
 Weight

occasionally,
current smoker
o Former smoker
o Never

Height (inches): was
recorded for each visit
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Blood
pressure
Pain level







Drug Abuse
Screening Test
(DAST) Score
DAST score has a
scale of 1 to 10.
Score of 0 = no
problem related to
drug abuse and 10 =
severe level of
problem related to
drug abuse
International
Classification of
Diseases (ICD) code
Disease duration

visit and rounded up to
whole number

Weight (lbs): was
recorded for each visit
Blood pressure (mmHg):
was recorded for each
visit
Pain level: was recorded
for each visit using
numeric rating scale
(NRS) of 0 to 10



Weight (lbs): was
recorded for each visit



Blood pressure
(mmHg): was recorded
for each visit



Pain level: was recorded
for each visit using
numeric rating scale
(NRS) of 0 to 10

DAST score was recorded for
each visit for eligible patients.

DAST score was recorded for
each visit for eligible patients

ICD codes for chronic pain
conditions were recorded for
each office visit

ICD codes for chronic pain
conditions were recorded for
each office visit

Disease duration was recorded
from initial pain assessment
form filled by the patient during
first visit

If disease duration was reported
in days, weeks or year then it
was converted to months.
If patient reported duration as
several weeks or months or
years, then it was assumed that
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the pain was for more than 3
months (chronic)
Medications:
 Prior
medications
 Current
medications
 Newly
prescribed
medications
 Discontinued
medications









Procedures:
 Procedure
name
 Current
Procedural
Terminology
(CPT)
 Telephone
follow-up
Date with
Pain level





Prior medications:
Medication name,
strength, dose; was
recorded for each visit
Current medications:
Medication name,
strength, dose, quantity;
was up to date when the
data was collected
Newly prescribed
medications: Medication
name, strength, dose,
quantity, date of
prescribing; was up to
date when the data was
collected
Discontinued
medications: Medication
name, strength, dose,
quantity, date of
discontinuation; was up
to date when the data was
collected



Procedure name and CPT
code: Name of the
procedure with its unique
CPT code and date the
procedure was performed
was recorded
Telephone follow-up
Date with Pain level



52







Prior medications:
Medication name,
strength; was recorded
only from first visit
Current medication (as
of Feb 2020):
Medication name,
strength
Newly prescribed
medications: Medication
name, strength, date of
prescribing (cutoff date
Feb 2020)
Discontinued
medications: Medication
name, strength, date of
discontinuation (cutoff
date Feb 2020)

Duration of patients on
current and prior
medications was not
captured



Procedure name and
CPT code: Name of the
procedure with its CPT
code and date the
procedure was
performed was recorded
(cutoff date Feb 2020)
Telephone follow-up
Date with Pain level

DATA EXTRACTION
A list of patients with LBP who were newly enrolled in the practice in 2018, was
provided to the researchers by the clinic. The variables of interest were manually
extracted from the EMR into an Excel file and the patients’ identification numbers were
then de-identified. Data extraction was carried out for LBP patients, but all the analyses
were conducted for patients with chronic LBP. Patients with chronic LBP were identified
by using the following inclusion/exclusion criteria:
Inclusion criteria:
1) Patients suffering with LBP for three or more than three months (chronic) when they
come into the practice for the first time
2) Patients with or without concurrent other chronic pain conditions
3) Patients could be newly diagnosed with chronic LBP at this clinic or could be previously
diagnosed
4) Patients seeking treatment for pain and other disease conditions from other physicians

Exclusion criteria:
1) Patients who suffered with LBP for less than 3 months (acute) within the study period
2) Patients with any type of cancer as a comorbid condition and
3) those with age below 18 years

The Excel files were converted into Statistical Analysis System (SAS) file and all data
analyses were conducted using SAS (SAS Institute Inc., Cary, NC, USA). Appendix III
provides the SAS codes for data import and analyses.
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DATA ANALYSIS
Objective 1: To describe the demographics (age, gender, race, ethnicity, smoking status,
alcohol status, drug use status) and clinical characteristics (disease duration,
procedures, medications) of patients with chronic LBP.
Descriptive analyses (mean, median, standard deviation, frequency distribution)
were carried out to provide distribution of patient demographics and clinical
characteristics of the entire cohort. Patient demographics including age, gender, race,
ethnicity, smoking status, alcohol status and drug use status were described. Clinical
characteristics including disease duration, types of procedures, average number of office
visits were described. The types of procedures were categorized as those performed for
LBP and non-LBP related conditions. The procedures were further categorized as
diagnostic and therapeutic procedures. Average number of repetitions of each LBP
therapeutic procedure was determined. The prevalence of the line of therapy of current
medications for treating neuropathic chronic LBP patients, was also identified.

Objective 2: To assess the prevalence of comorbid conditions including hypertension,
anxiety and depression in the chronic LBP cohort and to compare the demographic and
clinical characteristics of patients (i) with and without hypertension and (ii) with and
without anxiety and/or depression
The study identified hypertension and anxiety and/or depression from the
comorbid conditions variable list, extracted for each patient from their first office visit.
Similarly, patients without hypertension and patients without anxiety and/or depression
were identified from comorbidities reported in their first office visit. Descriptive analyses
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(mean, median, standard deviation, frequency distribution) were conducted to provide
distribution of patient demographics and clinical characteristics of patients with and
without each of these comorbid conditions by creating separate cohorts for these
comorbid conditions.

Objective 3: To assess the demographic and clinical characteristics of patients with
chronic LBP who are currently prescribed the following medications: blood thinners
(anticoagulants/antiplatelet), herbal medicines, benzodiazepines and opioids
Four separate cohorts were developed of patients with chronic LBP currently
taking: 1) blood thinners (anticoagulants/antiplatelet), 2) herbal medicines, 3)
benzodiazepines and 4) opioids. These groups were not mutually exclusive, and patients
could be in multiple cohorts based on the medications they were taking. Appendix IV
provides the list of medications under each of these categories identified in this cohort.
The list was created by extracting current medications for all patients and classifying
them based on their therapeutic class in Microsoft Excel. NSAIDs, except for aspirin,
were not included in the anticoagulants/antiplatelets category. Herbal medicines with
only anticoagulant effect (potential for bleeding) were included. 15 Descriptive analyses
(mean, median, standard deviation, frequency distribution) were conducted within each
of these cohorts. Descriptive analyses of patient demographics including age, gender,
race, ethnicity, smoking status, alcohol status and drug use status were conducted.
Similarly, descriptive analyses of clinical characteristics including disease duration,
office visits and types of therapeutic LBP procedures were carried out. The therapeutic
LBP procedures identified in blood thinner and herbal medicines cohort were categorized
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based on the potential risk of serious bleeding. The four groups were not mutually
exclusive, and patients could be in multiple cohorts based on the medications they were
taking.

Objective 4: To assess the mean pain level pre- and post- procedure for patients with
chronic LBP that have undergone a single therapeutic LBP procedure throughout the
study period.
Patients with chronic LBP who have undergone single interventional procedure
throughout the study period were identified. Patients that have undergone diagnostic
procedures and non-LBP procedures were excluded from the analysis. The mean
difference between pain level of patients was calculated using the pain level at the first
visit and pain level reported after the procedure was performed. This calculation was
performed for each procedure type. Patients with missing value for pain level were
excluded from the analysis. Within the cohort of patients that have undergone single
procedure, a paired t-test was conducted by grouping patients based on procedure type.

Next chapter entails results of the research questions discussed in this chapter and
provides summary of results obtained from the analysis of the EMR data of patients with
chronic LBP.
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CHAPTER 4: RESULTS
A total of 586 newly enrolled patients with chronic LBP in the year 2018 were
identified from the EMR database of the clinic. After excluding patients with acute pain
(pain for less than three months, n=60), patients with cancer as a comorbid condition
(n=62) and patients below the age of 18 years (n=0), the final cohort included 464 adult
patients with chronic non-cancer LBP.

Objective 1
To describe the demographics (age, gender, race, ethnicity, smoking status, alcohol
status, drug use status) and clinical characteristics (disease duration, procedures,
medications) of patients with chronic LBP
Descriptive analyses were conducted on the final cohort of 464 patients with
chronic non-cancer LBP. Table 6 describes the demographic characteristics including
age, gender, race, ethnicity, smoking status, alcohol status, drug use status and clinical
characteristics such as disease duration, procedure types and office visits. The mean age
of the patient cohort was 60.87 years, majority were females (52.8%), Whites (93.97%)
and non-Hispanic Latino (96.77%). Most patients never smoked (57.24%) or currently
consumed alcohol (53.39%). The mean duration of chronic LBP was 64.15 months and
mean office follow-up visits were about 3 visits during the study period. Table 7
describes the LBP and non-LBP procedures performed in patients with chronic LBP. A
total of 289 (62.28%) of patients were identified that had undergone at least one
procedure throughout the follow-up period. The most prevalent procedures among LBP
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Table 6: Demographic and clinical characteristics of patients with chronic LBP
Variables

Overall (N=464)

Age in years
Mean ± SD
Median (IQR)

60.87 ± 15.74
62 (22)

Gender (n,%)
Female
Male

245, 52.80%
219, 47.20%

Race (n,%)
White
Black
Asian
Other races

436, 93.97%
23, 4.96%
2, 0.43%
3, 0.65%

Ethnicity (n,%)
Non-Hispanic Latino

449, 96.77%

Declined to specify/Unknown

13, 2.80%

Hispanic/Latino

2, 0.43%

Smoking Status (n,%)
Never
Former smoker
Current smoker

261, 57.24%
104, 22.81%
91, 19.96%

Alcohol consumption status (n,%)
Currently consume alcohol
No

244, 53.39%
213, 46.61%

Drug use status (n,%)
No

431, 94.52%

Current user

18, 3.95%

Former user

7, 1.54%

Disease duration in months
Mean ± SD
Median (IQR)

64.15 ± 93.79
22 (65)

Office visits
Mean ± SD
Median (IQR)

3.34 ± 3.12
2 (3)
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Table 7: Types of LBP and non-LBP interventional procedures performed in
patients with chronic LBP
LBP procedures
Diagnostic procedures
Lumbar medial branch block
Therapeutic procedures
Lumbar epidural steroid injection
Caudal epidural steroid injection
Transforaminal epidural steroid
injection
Lumbar/Sacral medial branch
radiofrequency
Trigger point injection
Spinal cord stimulation trial
Permanent spinal cord stimulation
implantation
Nerve root block
Sacroiliac joint radiofrequency
Both diagnostic and therapeutic
Intra-articular sacroiliac joint injection

Frequency (n)
N=464

Percent (%)

73

15.73%

171
34
32

36.85%
7.33%
6.90%

16

3.45%

11
6
3

2.37%
1.29%
0.65%

2
1

0.43%
0.22%

15

3.23%
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Non-LBP procedures

Frequency (n)
N=464

Percent (%)

1

0.22%

8

1.72%

Superior lateral genicular nerve block
Piriformis injection
Trochanteric bursa injection

3
3
3

0.65%
0.65%
0.65%

Intra-articular hip injection
Knee injection
Ilioinguinal/iliohypogastric nerve block

2
2
1

0.43%
0.43%
0.22%

Cervical epidural steroid
injection/Multiple trigger point
injection
Sacrococcygeal injection
Shoulder injection
Genicular neurotomy
Saphenous nerve block
Suprascapular nerve block

1

0.22%

1
1
1
1
1

0.22%
0.22%
0.22%
0.22%
0.22%

2
1
1
1

0.43%
0.22%
0.22%
0.22%

Diagnostic procedures
Genicular nerve block
Therapeutic procedures
Cervical epidural steroid injection

Both diagnostic and therapeutic
Lateral femoral cutaneous nerve block
Thoracic medial branch block
Cervical medial branch block
Thoracic/Lumbar medial branch block
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procedures were lumbar epidural steroid injection (36.85%), followed by lumbar medial
branch block (15.73%) and caudal epidural steroid injection (7.33%). The most prevalent
procedure among non-LBP procedures was cervical epidural steroid injection (1.72%).
Out of all the 11 LBP procedures conducted, the most prevalent diagnostic procedure was
lumbar medial branch block and therapeutic procedure was interlaminar (lumbar, caudal)
epidural steroid injection. Only one procedure was identified as being both diagnostic and
therapeutic in nature, intra-articular sacroiliac joint injection. Table 8 describes the
repetition for interventional therapeutic LBP procedures performed in the chronic LBP
cohort with maximum of five and four repetitions and an average of 1.68 and 1.41
repetitions for lumbar epidural steroid injection and transforaminal epidural steroid
injection during the study period. No procedures were performed in about 37.71%
(n=175) of patients in this cohort. Different line of therapy were identified from current
medications for patients with chronic LBP (Refer Table 9).
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Table 8: Number of repetitions for interventional therapeutic LBP procedures
performed in the chronic LBP patient cohort
Type of procedure
Repetitions across entire cohort
Lumbar epidural steroid injection
Mean ± SD: 1.68 ± 0.85
Median (IQR): 2 (1)
Maximum: 5
Caudal epidural steroid injection
Mean ± SD: 1.41 ± 0.65
Median (IQR): 1 (1)
Maximum: 3
Transforaminal epidural steroid injection
Mean ± SD: 1.41 ± 0.75
Median (IQR): 1 (1)
Maximum: 4
Lumbar/Sacral medial branch
Mean ± SD: 1.38 ± 0.71
radiofrequency
Median (IQR): 1 (0.5)
Maximum: 3
Intra-articular sacroiliac joint injection
Mean ± SD: 1.33 ± 0.61
Median (IQR): 1 (1)
Maximum: 3
Trigger point injection
Mean ± SD: 1.27 ± 0.64
Median (IQR): 1 (0)
Maximum: 3
Spinal cord stimulation trial
Mean ± SD: 1.17 ± 0.40
Median (IQR): 1 (0)
Maximum: 2
Permanent spinal cord stimulation
Mean ± SD: 1 ± 0
implantation
Median (IQR): 1 (0)
Maximum: 1
Sacroiliac joint radiofrequency
Mean ± SD: 1 ± 0
Median (IQR): 1 (0)
Maximum: 1
Nerve root block
Mean ± SD: 1 ± 0
Median (IQR): 1 (0)
Maximum: 1

Table 9: Different line of therapy identified from current medications for patients
with chronic LBP
Patients on pain medications

Frequency, percent (n,%)

First-line medications
Second-line medications
Third-line medications

115, 24.78%
121, 26.07%
46, 9.91%
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Objective 2
To assess the prevalence of comorbid conditions including hypertension, anxiety and
depression in the chronic LBP cohort and to compare the demographic and clinical
characteristics of patients (i) with and without hypertension and (ii) with and without
anxiety and/or depression
Patients with chronic LBP who had hypertension (n=188, 40.52%) were
compared to those without hypertension (n=276, 59.48%). Similarly, patients with
chronic LBP who had anxiety and/or depression (n=120, 25.86%) were compared to
those without anxiety and/or depression (n=344, 74.14%). Descriptive analyses were
conducted on the four cohorts. Table 10 describes the demographic characteristics
including age, gender, race, ethnicity, smoking status, alcohol status, drug use status and
clinical characteristics such as disease duration, procedure types and office visits. A
relatively older population was observed in the hypertension cohort (67 years) as
compared to the non-hypertension cohort (56 years). Males were predominant in the
hypertension cohort whereas females were predominant in the non-hypertension cohort.
A relatively younger population was observed in the anxiety and/or depression cohort (55
years) as compared to the non-anxiety and/or depression cohort (62 years). Females were
predominant in the anxiety and/or depression cohort whereas males were predominant in
non-anxiety and/or depression cohorts. In hypertension cohort most patients did not
consume alcohol compared to non-hypertension cohort. Similar proportion of alcohol
consumption was seen in anxiety and/or depression when compared with non- anxiety
and/or depression cohort. Mean duration of chronic LBP was more in hypertension
cohort (65 months) than in non-hypertension cohort (62 months). The mean duration of
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Table 10: Demographic and clinical characteristics of patients with chronic LBP
and hypertension and Anxiety/Depression compared to patients with chronic LBP
without hypertension and Anxiety/Depression
Variables

Age in years
Mean ± SD
Median (IQR)
Sex (n,%)
Female
Male
Race (n,%)
White
Black
Asian
Other races
Declined to specify/
Unknown
Ethnicity (n,%)
Non-Hispanic Latino
Declined to specify/
Unknown
Hispanic Latino
Smoking Status (n,%)
Never
Former smoker
Current smoker
Alcohol status (n,%)
Currently consume
alcohol
No
Drug Use status (n,%)
No
Current user
Former user
Disease duration in months
Mean ± SD
Median (IQR)
Office visits
Mean ± SD
Median (IQR)

Hypertension No
(N=188)
Hypertensio
n
(N=276)

Anxiety &/or
Depression
(N=120)

No Anxiety
&/or
Depression
(N=344)

67.07 ± 12.48
67 (18)

56.64 ± 16.34
57.5 (24)

55.5 ± 15.22
56 (19.5)

62.74 ± 15.51
65 (22.5)

88, 46.81%
100, 53.19%

157, 56.88%
119, 43.12%

77, 64.17%
43, 35.83%

168, 48.84%
176, 51.16%

171, 90.96%
15, 7.98%
1, 0.53%
1, 0.53%

265, 96%
8, 2.9%
1, 0.36%
1, 0.36%
1, 0.36%

109, 90.83%
8, 6.67%
1, 0.83%
2, 1.67%

327, 95.06%
5, 4.36%
2, 0.58%
-

186, 98.94%
2, 1.06%

263, 95.29%
11, 3.99%

114, 95%
5, 4.17%

335, 97.38%
8, 2.33%

-

2, 0.72%

1, 0.83%

1, 0.29%

103, 55.38%
44, 23.66%
39, 20.97%

158, 58.52%
60, 22.22%
52, 19.26%

62, 52.10%
27, 22.69%
30, 25.21%

199, 59.05%
77, 22.85%
61, 18.10%

88, 47.57%

156, 57.35%

58, 49.15%

186, 54.87%

97, 52.43%

116, 42.65%

60, 50.85%

153, 45.13%

177, 95.68%
5, 2.7%
3, 1.62%

254, 93.73%
13, 4.8%
4, 1.48%

108, 90.76%
9, 7.56%
2, 1.68%

323, 95.85%
9, 2.67%
5, 1.48%

65.98 ± 97.77
24 (64)

62.67 ± 90.75
18 (66)

76.2 ± 89.76
36 (108)

59.69 ± 95.08
16 (54)

3.57 ± 3.63
3 (3)

3.18 ± 2.72
2 (3)

3.45 ± 3.73
2 (3)

3.3 ± 2.89
2 (3)
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chronic LBP was more for patients suffering with anxiety and/or depression (76 months)
than those without (59 months). Majority of the population was White and non-Hispanic
Latino across all four cohorts. Most patients never smoked and did not use drugs in all
four cohorts. Mean office visits were highest for hypertension cohort (4 visits) and
similar for the other three cohorts (3 visits) during the study period.
The most prevalent therapeutic procedure was interlaminar (lumbar, caudal)
epidural steroid injection across all the four cohorts, followed by transforaminal epidural
steroid injection in hypertension cohort and intra-articular sacroiliac joint injection in
anxiety and/or depression cohorts (Refer Table 11).
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Table 11: Types of interventional therapeutic LBP procedures performed in
patients with chronic LBP and hypertension and Anxiety/Depression compared to
patients with chronic LBP without hypertension and Anxiety/Depression
Type of procedure

Hypertension
(n,%)
(N=188)
70, 37.23%

No Hypertension Anxiety
(n,%)
and/or
(N=276)
Depression
(n,%)
(N=120)
101, 36.59%
32, 26.67%

No Anxiety
and/or
Depression
(n,%)
(N=344)
139, 40.41%

Lumbar epidural
steroid injection
Caudal epidural
steroid injection
Transforaminal
epidural steroid
injection
Lumbar/Sacral medial
branch
radiofrequency
Intra-articular
sacroiliac joint
injection
Trigger point
injection
Spinal cord
stimulation trial
Permanent spinal cord
stimulation
implantation
Sacroiliac joint
radiofrequency
Nerve root block

14, 7.45%

20, 7.25%

11, 9.17%

23, 6.69%

8, 4.26%

24, 8.7%

6, 5%

26, 7.56%

6, 3.19%

10, 3.62%

4, 3.33%

12, 3.49%

4, 2.13%

11, 3.99%

7, 5.83%

8, 2.33%

4, 2.13%

7, 2.54%

5, 4.17%

6, 1.74%

2, 1.06%

4, 1.45%

2, 1.67%

4, 1.16%

1, 0.53%

2, 0.72%

2, 1.67%

1, 0.29%

1, 0.53%

-

1, 0.83%

-

1, 0.53%

1, 0.36%

1, 0.83%

1, 0.29%
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Objective 3:
To assess the demographic and clinical characteristics of patients with chronic LBP who
are currently prescribed the following medications: blood thinners
(anticoagulants/antiplatelet), herbal medicines, benzodiazepines and opioids
Patients with chronic LBP (n=464) were further categorized based on the type of
medications they were taking during the study period (Refer Table 12). A total of 154
(33.18%) patients were prescribed blood thinners (anticoagulants and antiplatelets). The
mean age across the patient cohort was 70.84 years with majority being Male (61.69%),
White (95.45%) and non-Hispanic Latino (99.35%). Most patients never smoked
(54.30%) and 52.98% did not consume alcohol. The mean duration of chronic LBP
across this patient cohort was 59.87 months with a mean of three office visits during the
study period. The most prevalent procedure performed across the cohort was interlaminar
(lumbar, caudal) epidural steroid injection (37.66%) which belongs to the category of
intermediate-risk for bleeding when performed with concurrent use of blood thinners. Of
all the 9 procedures conducted in the blood thinner cohort all 3 categories of procedures
based on potential risk for bleeding were identified. Other LBP therapeutic procedures
conducted within blood thinner cohort are classified based on their potential risk of
serious bleeding (Refer Table 13).
A total of 11 (2.37%) patients were prescribed herbal medicines that had
anticoagulant effects. The mean age of the patient cohort was 69.90 years with majority
being Female (54.55%), White (90.91%) and non-Hispanic Latino (100%). Most patients
never smoked (63.64%) and 63.64% currently consumed alcohol. The mean duration of
chronic LBP was 34.22 months with a mean of three office visits during the study period.
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Table 12: Demographic of patients with chronic LBP and currently on blood
thinners, herbal medicines, benzodiazepines, opioids
Variables

Blood
Thinners
(N=154)

Herbal
medications
(N=11)

Benzodiazep
ines
(N=67)

Opioids
(N=121)

70.84 ± 12.26

69.90 ± 9.56

71 (17)

72 (10)

59.43 ±
13.22
59 (19)

64.44 ±
14.98
65 (22)

59, 38.31%
95, 61.69%

6, 54.55%
5, 45.45%

47, 70.15%
20, 29.85%

74, 61.16%
47, 38.84%

147, 95.45%
7, 4.55%
-

10, 90.91%
1, 9.09%
-

65, 97.01%
1, 1.49%
1, 1.49%
-

116, 95.87%
3, 2.48%
1, 0.83%
1, 0.83%

153, 99.35%

11, 100%

64, 95.52%

119, 98.35%

1, 0.65%

-

3, 4.48%

2, 1.65%

82, 54.30%
44, 29.14%
25, 16.56%

7, 63.64%
4, 36.36%
-

32, 48.48%
21, 31.82%
13, 19.70%

69, 57.50%
25, 20.83%
26, 21.67%

71, 47.02%

7, 63.64%

32, 48.48%

49, 40.50%

80, 52.98%

4, 36.36%

34, 51.52%

72, 59.50%

Drug Use status
No
Current user
Former user

145, 95.39%
5, 3.29%
2, 1.32%

11, 100%
-

61, 92.42%
4, 6.06%
1, 1.52%

116, 96.67%
2, 1.67%
2, 1.67%

Disease duration in months
Mean ± SD

59.87 ± 96.99

34.22 ± 42.77

18 (53)

12 (16)

108.74 ±
117.72
54

75.70 ±
94.68
24

3 ± 2.99
3 (2)

3.4 ± 2.29
3 (2)

3.55 ± 3.87
2 (3)

3.24 ± 3.69
2 (3)

Age in years
Mean ± SD
Median (IQR)
Sex (n,%)
Female
Male
Race (n,%)
White
Black
Other races
Declined to specify/
Unknown
Ethnicity
Non-Hispanic Latino
Declined to specify/
Unknown
Smoking Status
Never
Former smoker
Current smoker
Alcohol status
Currently consume
alcohol
No

Median (IQR)
Office visits
Mean ± SD
Median (IQR)

68

Table 13: Types of interventional therapeutic LBP procedures within each cohort of
patients with LBP on blood thinners, herbal medicines, benzodiazepines, opioids
Type of procedure

Blood
Thinners
(n,%)
(N=154)

Herbal
medications
(n,%)
(N=11)

Benzodiazepines
(n,%)
(N=67)

Opioids
(n,%)
(N=121)

Lumbar/Sacral
medial branch
radiofrequency

6, 3.90%

-

2, 2.99%

3, 2.48%

Intra-articular
sacroiliac joint
injection

4, 2.60%

-

2, 2.99%

-

Trigger point
injection

2, 1.30%

-

3, 4.48%

1, 0.83%

Sacroiliac joint
radiofrequency

1, 0.65%

-

-

-

7, 63.64%

20, 29.85%

34, 28.10%

1, 9.09%

5, 7.46%

8, 6.61%

Transforaminal
5, 3.25%
epidural steroid
injection
High-risk procedures
Spinal cord
1, 0.65%
stimulation trial

-

3, 4.48%

7, 5.79%

-

2, 2.99%

1, 0.83%

Permanent spinal
cord stimulation
implantation

-

2, 2.99%

-

Low-risk procedures

Intermediate risk procedures
Lumbar epidural
58, 37.66%
steroid injection
Caudal epidural
steroid injection

12, 7.79%

1, 0.65%

Note: Procedures were categorized based on their potential risk of bleeding only for blood
thinners cohort and herbal medicines cohort
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The most prevalent procedure performed in this cohort was lumbar epidural
steroid injection (63.64%). In herbal medications cohort, predominantly intermediate-risk
procedures were conducted whereas none were identified in the low-risk and high-risk
procedure category.
A total of 67 (14.43%) patients were prescribed benzodiazepines. The mean age
of the cohort was 59.43 years with majority being Female (70.15%), White (97.01%) and
Non-Hispanic Latino (95.52%). Most patients never smoked (48.48%) and 51.52% did
not consume alcohol. The mean duration disease was 108.74 months with a mean of four
office visits during the study period. The most prevalent procedure performed in this
cohort was lumbar epidural steroid injection (29.85%).
A total of 121 (26.07%) patients were prescribed opioids. The mean age was
64.44 years with majority being Female (61.16%), White (95.87%) and Non-Hispanic
Latino (98.35%). Most patients never smoked (57.50%) and 59.5% did not consume
alcohol. The mean duration of chronic LBP was 75.70 months with a mean of three office
visits during the study period. The most prevalent procedure performed was lumbar
epidural steroid injection (28.10%).

Objective 4:
To assess the mean pain level pre- and post- procedure for patients with chronic LBP
that have undergone a single therapeutic LBP procedure throughout the study period
The difference in mean pain scores was calculated in patients that have undergone
single interventional therapeutic procedure utilizing pain levels recorded at first office
visit and after the procedure was performed. As different types of procedures were
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performed on patients, mean difference in pain scores were calculated separately for each
of these procedures. Paired t-test was conducted for the most performed procedure which
was lumbar epidural steroid injection. A total of 109 patients (23.49%) of the cohort with
chronic LBP had undergone only a single procedure. After excluding patients that had
undergone non-LBP and diagnostic procedures (both LBP and non-LBP) from this
cohort, a total of 84 patients were remaining that had undergone therapeutic LBP
procedure. Six different therapeutic LBP procedures were identified in these 84 patients
during the 26 months follow-up period. Further, eight patients that had missing value for
pain level were excluded and finally 76 patients were analyzed (Refer Table 14). Based
on the level of mean difference in pain levels before and after the procedure, lumbar
epidural steroid injection demonstrated statistically significant pain reduction (p < 0.05)
with a mean difference of 2.86. Refer figure 4 for graphical depiction of the mean
differences results of the procedure type lumbar epidural steroid injection.
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Table 14: Mean difference between pain levels at first office visit and after
therapeutic LBP procedure
Procedure Name

Number of

At first

After

patients

office visit

procedure between pain levels at

(n)

(Mean)

(Mean)

N= 76
Lumbar epidural

Mean difference

first office visit and
after procedure

46

5.28

2.41

2.87*

13

5.62

2.62

3

10

6

3.4

2.6

4

7.25

5

2.25

2

5

3

2

1

8

1

7

steroid injection
Caudal epidural
steroid injection
Transforaminal
epidural steroid
injection
Trigger point
injection
Intra-articular
sacroiliac joint
injection
Nerve root block

* Paired t-test, p<0.05
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Figure 3: Mean difference between pain levels at first office visit and after
procedure type - lumbar epidural steroid injection
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CHAPTER 5: DISCUSSION
This chapter discusses the study findings, draws conclusions, presents study
implications, lists limitations of the study and provides recommendations for future
research.
LBP is the second most common cause of disability in the US and it is important
to understand the demographic and clinical characteristics of patients who suffer with this
condition. The majority of the patients with chronic LBP in the study were females and
over 60 years of age. A national study that surveyed patients with chronic LBP reported
similar patient demographics in terms of gender and age.8 Also, chronic LBP was
predominantly seen in White and non-Hispanic Latino population in the study. Similarly,
a study by Freburger et al. reported the prevalence of chronic LBP higher in White nonHispanic individuals in relation to Hispanic individuals.56 However, there are some
differences seen in our population compared to those reported in the literature. A majority
of the patients with chronic LBP in our study never smoked which is contrary to the
results of a systematic review that reported that chronic LBP was more prevalent in
smokers than in non-smokers.57 Another finding of our study that majority of patients did
not use illicit drugs was contradictory to the findings from the National Health and
Nutrition Examination Survey (NHANES) which reported illicit drug use in chronic LBP
population in the US.58 In the NHANES survey, the drug use information was collected
via private computer-based questionnaire, which is less susceptible to self-reporting bias
as compared to the pain clinic, that collects the information directly from patients through
a form during their first office visit. The other reason for this contradiction could be the
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small sample size of our study in comparison to NHANES survey which includes a large
population representative of the US population.
One of the ways to alleviate pain in patients with chronic LBP is through the use
of interventional procedures. The clinic routinely performs a number of these procedures
depending on the demographic and clinical characteristics of the patients. The procedure
that was performed in majority of the patients was epidural steroid injections (lumbar,
caudal, transforaminal). Epidural steroid injection is reported to be an effective treatment
option, and has shown to provide moderate to short-term effect in the management of
chronic LBP.59 In addition to LBP procedures, other non-LBP procedures were also seen
to be prevalent in this cohort, that might be because of presence of concomitant chronic
pain conditions including neck pain, shoulder pain, knee pain, leg pain, hand pain, foot
pain, cervical pain, coccygeal pain, hip pain, buttocks pain, thigh pain, thoracic pain, mid
back pain, ankle pain, groin pain, abdominal pain, arm pain and whole body pain in the
study cohort.
The study investigated the prevalence of comorbid conditions commonly seen in
patients with chronic LBP. Almost half of the study population had hypertension, and this
was consistent with the findings of by Jacob et al, which reported that hypertension is one
of the predictors for chronic LBP.60 The elevated blood pressure is associated with
increased sensitivity to pain, thus aggravating the pain and worsening the pain experience
in patients with chronic LBP and comorbid hypertension, 21,22 thus indicating that the pain
level could be overestimated. Hypertension was observed in older persons in our study
which was similar to findings from Riguad et al that reported higher prevalence of
hypertension was observed in older population (60 years and older). 66 Our study also
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found that more females suffered with anxiety and/or depression compared to males, this
was finding was similar to Albert et al that estimated higher prevalence of depression in
females than males.67
Patients with chronic pain usually take a number of pain medications including
tricyclic depressants, dual reuptake inhibitors of serotonin and norepinephrine, calcium
channel α2-δ ligands, opioid analgesics, tramadol and NSAIDs. However, aspirin,
NSAIDs and serotonin reuptake inhibitors (SRIs) demonstrate antiplatelet activity and
thus, need to be monitored during interventional procedures due to increased risk of
bleeding.15 A number of patients with chronic LBP take anticoagulant/antiplatelet therapy
and one of the reasons for that could be due to comorbidities such as atrial fibrillation
(AF), deep vein thrombosis (DVT), pulmonary embolism and coronary artery disease
(CAD) that require acute or chronic anticoagulation or chronic antiplatelet
treatment.15,61,62 The prevalence of patients on blood thinners and with AF, DVT, CAD
and pulmonary embolism within our cohort was about 18% (result calculated but now
shown in the results section, SAS code attached). Further, if patients are on both blood
thinners and pain medications with antiplatelet effects, the risk is even higher. Thus, it is
important to make sure these medications are used with caution. The study reported the
most prevalent procedure performed in patients on blood thinners was interlaminar
(lumbar, caudal) epidural steroid injection, which is a procedure with potential for
intermediate risk of bleeding. 15 Patients on herbal medications such as garlic extract,
ginkgo biloba, green tea, ginseng among many others, cause significant bleeding due to
their antiplatelet effect or interact with other anticoagulants.15 Although, prevalence of
patients on herbal medications was only about 9% in this study, lumbar epidural steroid
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injection (intermediate-risk procedure) was most performed in about 46% of patients
within this cohort. Thus, physician might require discontinuation of
anticoagulants/antiplatelet and herbal medications a few days prior to conducting the
procedure to avoid bleeding. We also explored the prevalence of patients on
benzodiazepines (14%) which is used to treat anxiety. Majority of the population in the
benzodiazepine cohort was female (70.15%) and a similar prevalence of female
population was observed in the anxiety cohort (67%) of this study as well. Although we
did not study the use of benzodiazepines in the anxiety population, the greater use of
benzodiazepines in females could be due to them suffering from anxiety disorders. About
48% of patients on benzodiazepines consumed alcohol, these patients could be heavy
drinkers or occasional or rare drinkers. Because all such patients were categorized as
current alcohol drinkers, the extent of their alcohol consumption was not distinguished
among patients on benzodiazepines and is a limitation of the study. Opioids are secondline treatment option for chronic neuropathic pain and about 26% of patients are on
opioids. In addition to pharmacological treatments, patients in this cohort have undergone
interlaminar and transforaminal epidural steroid injection, lumbar/sacral medial branch
radiofrequency, trigger point injections and spinal cord stimulation trial, this indicates
that a multimodal treatment approach was required for management of chronic LBP as
mentioned in the guideline.13
Upon calculation of mean change in pain scores before and after the single
therapeutic LBP procedure, most procedures reported pain reduction to some extent. The
study revealed that an immediate and significant pain relief was provided by the
interlaminar epidural steroid injections, trigger point injections for patients with chronic
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LBP. However, the effect is not long-lasting. For example, the most commonly
performed procedure across the entire cohort was lumbar epidural steroid injection
(36.85%) and provides significant pain relief. But lumbar epidural steroid injection is also
the most repeated procedure with maximum five repetitions (median = 2) in the study
period of about two years. This indicates that the procedure does not provide a sustained
and prolonged pain relief. Supporting evidence for the effect of epidural corticosteroid
injections was found in Chou et al where the injection was associated with immediate
alleviations in pain and function, but advantages were small and not sustained.63

STUDY IMPLICATIONS
The present study was one of the first to assess the demographical and clinical
characteristics of patients with chronic LBP specifically focusing on their pain level,
interventional procedures and pharmacologic management, using EMR data.

Implications to the patients and caregivers
The study provides real-world data on procedures and pain level, which can assist
patients and their caregivers during shared decision making about the procedures they
intend to undergo and for understanding the extent of pain relief they can potentially
obtain from these procedures. The data also highlights the repetition of certain procedures
in a clinical setting required for desired pain relief. This can help the patients and their
caregivers to set up a concrete treatment plan and establish realistic expectations from the
procedures and treatment plan with their specialist.64,65
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Implications to the pain specialists
The study findings indicate that epidural steroid injections were performed the
most in treating chronic LBP. The injections provided significant pain relief when
compared to other procedures and repeated injections provided sustained effect.
Moreover, the study will help to identify and inform the practice regarding the type of
patient population at highest risk for chronic LBP via their demographics, comorbid
conditions and medication related information. Thus, enabling the specialists to identify
relevant important factors that can relieve or exacerbate the pain and if dose adjustments
or monitoring would be required.

LIMITATIONS OF THE STUDY
The study has some limitations, and these should be considered before drawing
inferences from the reported results.
The limitations associated with any retrospective and cross-sectional database are
applicable to this study. These include systematic or recorder bias, data coding-recoding
errors, incomplete data and lack of temporality.
First, the study duration is limited to about two years January 2018 to February 2020,
hence any changes in patient’s treatment plan after this period were not captured in our
database. Second, patient’s history of prior procedures performed or prior visits to other
pain specialists before visiting the study pain clinic were not included in the database.
Third, visits to other physicians and inpatient procedures conducted during the study
period were not captured in our database. Fourth, since it was impossible to determine
pain duration for patients who reported as several weeks/months instead of a definite
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length, they were assumed to have chronic pain for more than three months. There’s a
possibility that some of these patients could have had pain for less than three months.
Fifth, the study has a small sample size, is confined to a particular region and has only
one physician treating all patients in the clinic; therefore, the generalizability of this study
is limited to patients visiting similar practices, with similar demographics and geographic
region. Sixth, the patients were classified into cohorts based on the specific class of
medications the patients were currently taking during the study period. However, there’s
a possibility that these patients could be concomitantly taking one or more medications
(for instance, both blood thinners and opioids) and our study did not capture such
patients. Therefore, these patients could be overlapping in other medication specific
cohorts as well. Because the comorbid conditions were identified from first visit’s
progress notes, patients that were diagnosed with hypertension, anxiety and depression
conditions in the follow-up visits were not captured. Seventh, patients could be on other
multimodal treatments such as pharmacologic treatment, physical therapy, psychologic
treatment, acupuncture or chiropractic care that could impact pain relief, such variables
were not captured in the database. Also, it is possible that these variables could have
impacted the pain reduction as observed before and after the lumbar epidural steroid
injection was performed. The classification of medications by line of therapy was not
conducted by type of pain such neuropathic pain, nociceptive pain or mixed pain. We did
a cohort analyses and the follow-ups were different for different patients and the data
could possibly be skewed by patients who could have had longer follow-ups than those
who did not have. Moreover, we also attempted to capture the change in mean pain
scores for patients that had undergone multiple procedures, but the variability in follow-
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up period after the first procedure was a major limitation while conducting analysis. For
instance, second procedure could be performed after the 3 rd follow-up visit and third
procedure could be performed after the 6th follow-up visit. Thus, making it difficult to
track pain scores and quantify the change in pain score for all patients across all their
follow-up visits either when grouped by number of procedures or by type of procedure.

RECOMMENDATIONS FOR FUTURE RESEARCH
This study described the demographical and clinical characteristics of patients
with chronic LBP in an outpatient clinic in Pittsburgh region utilizing a cross-sectional
study design (study period of 2 years). However, further studies should aim at conducting
a longitudinal study with broader patient sample (i.e. not limited to single center as this
study is) to trace the change in pain level and sustainability of interventional procedures
over a longer duration. Moreover, future research should compare interventional
procedures and pain relief obtained from them and their safety in other outpatient clinics
with similar population. This will help in providing scientific evidence in association
with treatment strategies opted at this study clinic. Additionally, a study tracking the
patient journey from various other pain clinics, evaluating their change in pharmacologic
treatment, procedures and pain relief obtained would be useful in a robust comparison of
treatment plans and their benefits across pain clinics. Various patient characteristics
identified from the study can be used to explore risk factors for chronic LBP and to
determine their association with chronic LBP.
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Appendix I
Search strategy for CNCP systematic review
Search strategy for PubMed
("Analgesics, Opioid"[Mesh] OR "Analgesics, Opioid"[tiab] OR "Opioid
Analgesics"[tiab] OR "Opioids"[tiab] OR "Partial Opioid Agonists"[tiab] OR "Opioid
Partial Agonists"[tiab] OR "Full Opioid Agonists"[tiab] OR "Opioid Full Agonists"[tiab]
OR "Opioid Mixed Agonist-Antagonists"[tiab] OR "Opioid Mixed Agonist
Antagonists"[tiab] OR "Narcotics"[MeSH] OR "Narcotics"[tiab] OR "Narcotic"[tiab] OR
"Narcotic Analgesics"[tiab] OR "Narcotic Effect"[tiab] OR "Narcotic Effects"[tiab] OR
"Analgesics, Short Acting"[MeSH] OR "Short-Acting Analgesics"[tiab] OR "Calcitonin
Gene-Related Peptide Receptor Antagonists"[Mesh] OR "Calcitonin Gene-Related
Peptide Receptor Antagonists"[tiab] OR "Calcitonin Gene Related Peptide Receptor
Antagonists"[tiab] OR "CGRP Receptor Antagonists"[tiab] OR "GEPANTS"[tiab] OR
"Opiate Alkaloids"[Mesh] OR "Opiate Alkaloids"[tiab] OR "Opiates"[tiab] OR "Alkaloid
Opiates"[tiab] OR "Analgesics, Non-Narcotic"[Mesh] OR "Non-Narcotic
Analgesics"[tiab] OR "Nonopioid Analgesics"[tiab] OR "Non-Opioid Analgesics"[tiab]
OR "Non Opioid Analgesics"[tiab] OR "Nonnarcotic Analgesics"[tiab] OR "Muscle
Relaxants, Central"[Mesh] OR "Central Muscle Relaxants"[tiab] OR "Centrally Acting
Muscle Relaxants"[tiab] OR "Antipsychotic Agents"[Mesh] OR "Antipsychotic
Agents"[tiab] OR "Antipsychotics"[tiab] OR "Major Tranquilizers"[tiab] OR "Major
Tranquilizing Agents"[tiab] OR "Neuroleptic Drugs"[tiab] OR "Neuroleptics"[tiab] OR
"Antipsychotic Drugs"[tiab] OR "Neuroleptic Agents"[tiab] OR "Antipsychotic Effect"
OR "Antipsychotic Effects" OR "Antidepressive Agents"[Mesh] OR "Antidepressive
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Agents"[tiab] OR "Antidepressant Drugs"[tiab] OR "Antidepressants"[tiab] OR
"Thymoanaleptics"[tiab] OR "Thymoleptics"[tiab] OR "Anticonvulsants"[Mesh] OR
"Anticonvulsants"[tiab] OR "Anticonvulsive Agents"[tiab] OR "Anticonvulsive
Drugs"[tiab] OR "Anticonvulsant Drugs"[tiab] OR "Antiepileptic Drugs"[tiab] OR
"Antiepileptic Agents”[tiab] OR "Antiepileptics"[tiab] OR "Pain Management"[Mesh]
OR "Pain Management"[tiab] OR "Pain Managements"[tiab]) AND ("Prescription Drug
Misuse"[Mesh] OR "Prescription Drug Misuse"[tiab] OR "NMUPD"[tiab] OR "NonMedical Use of Prescription Drugs"[tiab] OR "Non Medical Use of Prescription
Drugs"[tiab] OR "Prescription Drug Abuse"[tiab] OR "Medication Overuse"[tiab] OR
"Prescription Drug Overuse"[tiab]) AND ("Chronic non-cancer pain"[tiab] OR "noncancer pain"[tiab] OR "non-malignant pain"[tiab] OR "Abdominal Pain"[Mesh] OR
"Abdominal Pain"[tiab] OR "Abdominal Pains"[tiab] OR "Colicky Pain"[tiab] OR
"Colicky Pains"[tiab] OR "Arthralgia"[Mesh] OR "Arthralgia"[tiab] OR
"Arthralgias"[tiab] OR "Joint pain"[tiab] OR "Joint pains"[tiab] OR "Polyarthralgia"[tiab]
OR "Polyarthralgias"[tiab] OR "Back Pain"[Mesh] OR "Back Pain"[tiab] OR "Back
Pains"[tiab] OR "Backache"[tiab] OR "Backaches"[tiab] OR "Back Ache"[tiab] OR
"Back Aches"[tiab] OR "Back Pain without Radiation"[tiab] OR "Vertebrogenic Pain
Syndrome"[tiab] OR "Vertebrogenic Pain Syndromes"[tiab] OR "Back Pain with
Radiation"[tiab] OR "Chest Pain"[Mesh] OR "Chest Pain"[tiab] OR "Chest Pains"[tiab]
OR "Precordial Catch Syndrome"[tiab] OR "Precordial Catch"[tiab] OR "Texidor’s
Twinge"[tiab] OR "Chronic Pain"[Mesh] OR "Chronic Pain"[tiab] OR "Chronic
Pains"[tiab] OR "Widespread Chronic Pain"[tiab] OR "Widespread Chronic Pains"[tiab]
OR "Headache"[Mesh] OR "Headache"[tiab] OR "Head Pain"[tiab] OR "Head
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Pains"[tiab] OR "Cephalodynia"[tiab] OR "Cranial Pain"[tiab] OR "Cranial Pains"[tiab]
OR "Cephalgia"[tiab] OR "Cephalgias"[tiab] OR "Cephalalgia"[tiab] OR
"Cephalalgias"[tiab] OR "Generalized Headache"[tiab] OR "Generalized
Headaches"[tiab] OR "Ocular Headache"[tiab] OR "Ocular Headaches"[tiab] OR
"Orthostatic Headache"[tiab] OR "Orthostatic Headaches"[tiab] OR "Vertex
Headaches"[tiab] OR "Retro-Ocular Headache"[tiab] OR "Sharp Headache"[tiab] OR
"Sharp Headaches"[tiab] OR "Throbbing Headache"[tiab] OR "Throbbing
Headaches"[tiab] OR "Unilateral Headache"[tiab] OR "Unilateral Headaches"[tiab] OR
"Hemicrania"[tiab] OR "Bilateral Headache"[tiab] OR "Bilateral Headaches"[tiab] OR
"Periorbital Headache"[tiab] OR "Periorbital Headaches"[tiab] OR
"Metatarsalgia"[Mesh] OR "Metatarsalgia"[tiab] OR "Musculoskeletal Pain"[Mesh] OR
"Musculoskeletal Pain"[tiab] OR "Musculoskeletal Pains"[tiab] OR "Neck Pain"[Mesh]
OR "Neck Pain"[tiab] OR "Neck Pains"[tiab] OR "Neck Ache"[tiab] OR "Neck
Aches"[tiab] OR "Cervicalgia"[tiab] OR "Cervicalgias"[tiab] OR "Cervicodynia"[tiab]
OR "Cervicodynias"[tiab] OR "Neckache"[tiab] OR "Neckaches"[tiab] OR "Cervical
Pain"[tiab] OR "Cervical Pains"[tiab] OR "Posterior Cervical Pain"[tiab] OR
"Posterior Neck Pain"[tiab] OR "Anterior Cervical Pain"[tiab] OR "Anterior Neck
Pain"[tiab] OR "Neuralgia"[Mesh] OR "Neuralgia"[tiab] OR "Neuralgias"[tiab] OR
"Neuropathic pain"[tiab] OR "Neuropathic pains"[tiab] OR "Neurodynia"[tiab] OR
"Atypical Neuralgia"[tiab] OR "Atypical Neuralgias"[tiab] OR "Paroxysmal Nerve
Pain"[tiab] OR "Perineal Neuralgia"[tiab] OR "Perineal Neuralgias"[tiab] OR
"Supraorbital Neuralgia"[tiab] OR "Nerve Pain"[tiab] OR "Nerve Pains"[tiab] OR
"Ilioinguinal Neuralgia"[tiab] OR "Ilioinguinal Neuralgias"[tiab] OR "Nociceptive
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Pain"[Mesh] OR "Nociceptive Pain"[tiab] OR "Nociceptive Pains"[tiab] OR "Tissue
Pain"[tiab] OR "Tissue Pains"[tiab] OR "Somatic Pain"[tiab] OR "Somatic Pains"[tiab]
OR "Pain, Intractable"[Mesh] OR "Intractable Pain"[tiab] OR "Intractable Pains"[tiab]
OR "Refractory Pain"[tiab] OR "Refractory Pains"[tiab] OR "Pain, Postoperative"[Mesh]
OR "Pain, Postoperative"[tiab] OR "Postoperative Pain"[tiab] OR "Postoperative
Pains”[tiab] OR "Facial Neuralgia"[Mesh] OR "Facial Neuralgia"[tiab] OR "Facial
Neuralgias"[tiab] OR "Craniofacial Pain Syndrome"[tiab] OR "Craniofacial Pain
Syndromes"[tiab] OR "Facial Pain Syndrome"[tiab] OR "Facial Pain Syndromes"[tiab]
OR "Myofacial Pain Syndrome"[tiab] OR "Myofacial Pain Syndromes"[tiab] OR
"Sphenopalatine Neuralgia"[tiab] OR "Patellofemoral Pain Syndrome"[Mesh] OR
"Patellofemoral Pain Syndrome"[tiab] OR "Anterior Knee Pain Syndrome"[tiab] OR
"Patellofemoral Syndrome"[tiab] OR "Complex Regional Pain Syndromes"[Mesh] OR
"Complex Regional Pain Syndromes"[tiab] OR “CRPS (Complex Regional Pain
Syndromes)”[tiab] OR "Reflex Sympathetic Dystrophy"[Mesh] OR "Reflex Sympathetic
Dystrophy"[tiab] OR "Reflex Sympathetic Dystrophies"[tiab] OR "Shoulder-Hand
Syndrome"[tiab] OR "Shoulder-Hand Syndromes"[tiab] OR "Shoulder Hand
Syndrome"[tiab] OR "RSD (Reflex Sympathetic Dystrophy"[tiab] OR "RSDs”[tiab] OR
“Reflex Sympathetic Dystrophy"[tiab] OR "CRPS Type I"[tiab] OR "Sympathetic Reflex
Dystrophia"[tiab] OR "Type I Complex Regional Pain Syndrome"[tiab] OR "Reflex
Sympathetic Dystrophy Syndrome"[tiab] OR "Algodystrophic Syndrome"[tiab] OR
"Algodystrophy"[tiab] OR "Algodystrophies"[tiab] OR "Hyperalgesia"[Mesh] OR
"Hyperalgesia"[tiab] OR "Hyperalgesias"[tiab] OR "Mechanical Allodynia"[tiab] OR
"Mechanical Hyperalgesia"[tiab] OR "Tactile Allodynia"[tiab] OR "Allodynia"[tiab] OR
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"Thermal Hyperalgesia"[tiab] OR "Thermal Allodynia"[tiab]) AND ("Retrospective
Studies"[Mesh] OR "Retrospective Studies"[tiab] OR "Retrospective Study"[tiab] OR
"Retrospective Analysis"[tiab] OR "Electronic Health Records"[Mesh] OR "Electronic
Health Records"[tiab] OR "Electronic Health Record"[tiab] OR "EHR"[tiab] OR
"Electronic Medical Record"[tiab] OR "Electronic Medical Records"[tiab] OR
"EMR"[tiab] OR "Computerized Medical Record"[tiab] OR "Computerized Medical
Records"[tiab] OR "Cohort Studies"[tiab] OR "Cohort Study"[tiab] OR "Cohort
Analysis"[tiab] OR "Cohort"[tiab] OR "Longitudinal Studies"[Mesh] OR "Longitudinal
Studies"[tiab] OR "Longitudinal Study"[tiab] OR "Longitudinal Analysis"[tiab]
OR "Longitudinal"[tiab] OR "Case-Control Studies"[Mesh] OR "Case-Control
Studies"[tiab] OR "Cross-Sectional Studies"[Mesh] OR "Cross-Sectional Studies"[tiab]
OR "Cross-Sectional Study"[tiab] OR "Cross-Sectional Analyses"[tiab] OR "CrossSectional Analysis"[tiab] OR "Cross Sectional Analyses"[tiab] OR "Cross
Sectional Analysis"[tiab] OR "Cross-sectional"[tiab] OR "Prevalence"[mesh:noexp] OR
"Prevalence"[tiab] OR (Case[tiab] AND Control[tiab]) OR (Cases[tiab] AND
Controls[tiab]) OR (Cases[tiab] AND Controlled[tiab]) OR (Case[tiab] AND
Comparison*[ tiab]) OR (Cases[tiab] AND Comparison*[ tiab]) OR "Cohort
studies"[mesh:noexp] OR "Control group"[tiab] OR "Control groups"[tiab])

Search Strategy for PsycINFO
(DE "Analgesic Drugs" OR DE "Opiates" OR DE "Buprenorphine" OR DE "Fentanyl"
OR DE "Heroin" OR DE "Morphine" OR DE "Oxycodone" OR DE "Anti Inflammatory
Drugs" OR DE "Aspirin" OR DE "Glucocorticoids" OR DE "Dexamethasone" OR DE
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"Muscle Relaxing Drugs" OR DE "Baclofen" OR DE "Diazepam" OR DE
"Theophylline" OR DE "Succinylcholine" OR DE "Anticonvulsive Drugs" OR DE
"Carbamazepine" OR DE "Gabapentin" OR DE "Pregabalin" OR DE "Clonazepam OR
DE "Diphenylhydantoin" OR DE "Phenobarbital" OR DE "Valproic Acid" OR DE
"Antidepressant Drugs" OR DE "Bupropion" OR DE "Citalopram" OR DE "Fluoxetine"
OR DE "Fluvoxamine" OR DE "Lithium Carbonate" OR DE "Methylphenidate" OR DE
"Mianserin" OR DE "Moclobemide" OR DE "Nefazodone" OR DE "Nomifensine" OR
DE "Paroxetine" OR DE "Phenelzine" OR DE "Serotonin Norepinephrine Reuptake
Inhibitors" OR DE "Sertraline" OR DE "Sulpiride" OR DE "Trazodone" OR DE
"Tricyclic Antidepressant Drugs" OR DE "Venlafaxine" OR DE "Zimeldine" OR DE
"Neuroleptic Drugs" OR DE "Olanzapine" OR DE "Aripiprazole" OR DE "Clozapine"
OR DE "Quetiapine" OR DE "Reserpine" OR DE "Risperidone" OR DE "Sulpiride" OR
DE "Pain Management") AND (DE "Back Pain" OR DE "Chronic Pain" OR DE
"Headache" OR DE "Migraine Headache" OR DE "Muscle Contraction Headache" OR
DE "Myofascial Pain" OR DE "Neuralgia" OR DE "Trigeminal Neuralgia" OR DE
"Neuropathic Pain" OR DE "Somatoform Pain Disorder" OR DE "Complex Regional
Pain Syndrome (Type I)" OR DE "Fibromyalgia" OR "Non-cancer pain") AND
(("Prescription Drug*" AND (misuse* OR overuse* OR abuse*)) OR "Medication
Overuse") AND (DE "Longitudinal Studies" OR DE "Retrospective Studies" OR DE
"Cohort Analysis" OR DE "Hypothesis Testing" OR "Longitudinal Stud*" OR
"Retrospective Stud*" OR "Cohort Analys*" OR "Cohort stud*" OR "Hypothesis
Testing" OR "Cross-section* stud*" OR "Cross-section* analys*" OR "Prevalence
stud*")
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Search strategy for EMBASE
('opiate' OR 'opiate'/exp OR 'narcotic analgesic agent' OR 'narcotic analgesic agent'/exp
OR 'analgesic agent' OR 'analgesic agent'/exp OR 'antirheumatic agent' OR 'antirheumatic
agent'/exp OR 'nonsteroid antiinflammatory agent' OR 'nonsteroid antiinflammatory
agent'/exp OR 'muscle relaxant agent' OR 'muscle relaxant agent'/exp OR 'neuroleptic
agent' OR 'neuroleptic agent'/exp OR 'antidepressant agent' OR 'antidepressant agent'/exp
OR 'anticonvulsive agent' OR 'anticonvulsive agent'/exp OR 'pain management' OR 'pain
management'/exp OR 'pain control' OR 'pain control'/exp) AND ('prescription drug
misuse' OR 'prescription drug misuse'/exp OR 'prescription drug abuse' OR 'medication
overuse') AND ('chronic noncancer pain' OR 'nonmalignant pain' OR 'abdominal pain'
OR 'abdominal pain'/exp OR 'allodynia' OR 'allodynia'/exp OR 'bone pain' OR 'bone
pain'/exp OR 'burning sensation' OR 'burning sensation'/exp OR 'chronic pain' OR
'chronic pain'/exp OR 'migraine' OR 'migraine'/exp OR 'chronic daily headache' OR
'chronic daily headache'/exp OR 'face pain' OR 'face pain'/exp OR 'hyperalgesia' OR
'hyperalgesia'/exp OR 'chronic inflammatory pain' OR 'chronic inflammatory pain'/exp
OR 'intractable pain' OR 'intractable pain'/exp OR 'musculoskeletal pain' OR
'musculoskeletal pain'/exp OR 'myalgia' OR 'myalgia'/exp OR 'neuralgia' OR
'neuralgia'/exp OR 'nociceptive pain' OR 'nociceptive pain'/exp OR 'noncardiac chest
pain' OR 'noncardiac chest pain'/exp OR 'postoperative pain' OR 'postoperative pain'/exp
OR 'spinal pain' OR 'spinal pain'/exp OR 'psychogenic pain' OR 'psychogenic pain'/exp)
AND ('retrospective study' OR 'retrospective study'/exp OR 'cross-sectional study' OR
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'cross-sectional study'/exp OR 'longitudinal study' OR 'longitudinal study'/exp OR 'case
control study' OR 'case control study'/exp OR ‘cohort analysis’ OR ‘cohort analysis’/exp)
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Appendix II
Search strategy for LBP literature review
Search Strategy for PubMed
("Low Back Pain"[tiab] OR "Back Pain"[Mesh] OR "Back Pain"[tiab] OR "Back
Pains"[tiab] OR "Backache"[tiab] OR "Backaches"[tiab] OR "Back Ache"[tiab] OR
"Back Aches"[tiab] OR "Back Pain without Radiation"[tiab] OR "Vertebrogenic Pain
Syndrome"[tiab] OR "Vertebrogenic Pain Syndromes"[tiab] OR "Back Pain with
Radiation"[tiab]) AND ("Epidural steroid injections"[tiab] OR "Lumbar medial branch
block"[tiab] OR "Pain procedures"[tiab] OR "Interventional
procedures"[tiab]) AND ("Retrospective Studies"[Mesh] OR "Retrospective
Studies"[tiab] OR "Retrospective Study"[tiab] OR "Retrospective Analysis"[tiab] OR
"Electronic Health Records"[Mesh] OR "Electronic Health Records"[tiab] OR
"Electronic Health Record"[tiab] OR "EHR"[tiab] OR "Electronic Medical Record"[tiab]
OR "Electronic Medical Records"[tiab] OR "EMR"[tiab] OR "Computerized Medical
Record"[tiab] OR "Computerized Medical Records"[tiab] OR "Cohort Studies"[tiab] OR
"Cohort Study"[tiab] OR "Cohort Analysis"[tiab] OR "Cohort"[tiab] OR "Longitudinal
Studies"[Mesh] OR "Longitudinal Studies"[tiab] OR "Longitudinal Study"[tiab] OR
"Longitudinal Analysis"[tiab] OR "Longitudinal"[tiab] OR "Case-Control
Studies"[Mesh] OR "Case-Control Studies"[tiab] OR "Cross-Sectional Studies"[Mesh]
OR "Cross-Sectional Studies"[tiab] OR "Cross-Sectional Study"[tiab] OR "CrossSectional Analyses"[tiab] OR "Cross-Sectional Analysis"[tiab] OR "Cross Sectional
Analyses"[tiab] OR "Cross Sectional Analysis"[tiab] OR "Cross-sectional"[tiab] OR
"Prevalence"[mesh:noexp] OR "Prevalence"[tiab] OR (Case[tiab] AND Control[tiab])
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OR (Cases[tiab] AND Controls[tiab]) OR (Cases[tiab] AND Controlled[tiab]) OR
(Case[tiab] AND Comparison*[ tiab]) OR (Cases[tiab] AND Comparison*[tiab]) OR
"Cohort studies"[mesh:noexp] OR "Control group"[tiab] OR "Control groups"[tiab])
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APPENDIX III:
SAS Code
/*Data import*/
proc import datafile= "C:\Users\gauri\Desktop\Data_XYZ_10_10_2020.xlsx"
dbms=xlsx out=Totalcohort replace;
getnames=yes ;
sheet=Original_data;
run;
/*Removed blank 2 observations*/
Data Totalcohort_1;/*586 patients*/
set Totalcohort;
if Patient_ID ne .;
run;
/*Creating final cohort of pts with > 3 months non-cancer pain*/
data Finalcohort Cancer_comorb_pts;
set Totalcohort_1;
if Patient_ID ne .;
if Disease_Duration__months_ >=3 or Disease_Duration__months_ = . ;
/*526*/
Age=year('29feb2020'd- DOB)- 1960;
If Age>=18;/*526*/
Comorb_1=Upcase(Comorb_1); Comorb_2=Upcase(Comorb_2);
Comorb_3=Upcase(Comorb_3); Comorb_4=Upcase(Comorb_4);
Comorb_5=Upcase(Comorb_5);Comorb_6=Upcase(Comorb_6);Comorb_7=Upcase(Com
orb_7);Comorb_8=Upcase(Comorb_8);Comorb_9=Upcase(Comorb_9);Comorb_10=Up
case(Comorb_10);Comorb_11=Upcase(Comorb_11);Comorb_12=Upcase(Comorb_12)
;Comorb_13=Upcase(Comorb_13);Comorb_14=Upcase(Comorb_14);
Comorb_15=Upcase(Comorb_15);Comorb_16=Upcase(Comorb_16);Comorb_17=Upcas
e(Comorb_17);
Comorb_18=Upcase(Comorb_18);Comorb_19=Upcase(Comorb_19);Comorb_20=Upcas
e(Comorb_20);Comorb_21=Upcase(Comorb_21);Comorb_22=Upcase(Comorb_22);Co
morb_23=Upcase(Comorb_23);Comorb_24=Upcase(Comorb_24);Comorb_25=Upcase(
Comorb_25);Comorb_26=Upcase(Comorb_26);Comorb_27=Upcase(Comorb_27);Como
rb_28=Upcase(Comorb_28);Comorb_29=Upcase(Comorb_29);
Disease_Duration__months_1= input(Disease_Duration__months_, 5.);
%let Cancer_Type="BREAST CANCER" "COLON CANCER" "KIDNEY CANCER"
"PROSTATE CANCER" "THROAT CANCER" "OVARIAN CANCER" "LUNG CANCER"
"BLADDER CANCER" "CERVICAL CANCER" "SKIN CANCER" "BASAL CELL CANCER"
"LIVER CANCER" "CANCER" "ORAL CANCER" "THYROID CANCER" "UTERINE CANCER"
"MELANOMA";
if Comorb_1 in (&Cancer_Type) or Comorb_2 in (&Cancer_Type) or Comorb_3
in (&Cancer_Type) or Comorb_4 in (&Cancer_Type) or Comorb_5 in
(&Cancer_Type) or Comorb_6 in (&Cancer_Type) or Comorb_7 in
(&Cancer_Type) or Comorb_8 in (&Cancer_Type) or Comorb_9 in
(&Cancer_Type) or Comorb_10 in (&Cancer_Type) or
Comorb_11 in (&Cancer_Type) or Comorb_12 in (&Cancer_Type) or Comorb_13
in (&Cancer_Type) or Comorb_14 in (&Cancer_Type) or Comorb_15 in
(&Cancer_Type) or Comorb_16 in (&Cancer_Type) or Comorb_17 in
(&Cancer_Type) or Comorb_18 in (&Cancer_Type) or Comorb_19 in
(&Cancer_Type) or Comorb_20 in (&Cancer_Type) or

92

Comorb_21 in (&Cancer_Type) or Comorb_22 in (&Cancer_Type) or Comorb_23
in (&Cancer_Type) or Comorb_24 in (&Cancer_Type) or Comorb_25 in
(&Cancer_Type) or Comorb_26 in (&Cancer_Type) or Comorb_27 in
(&Cancer_Type) or Comorb_28 in (&Cancer_Type) or Comorb_29 in
(&Cancer_Type) then output Cancer_comorb_pts; /*62 pts*/
else output Finalcohort;/*464 pts- pain for more than 3 months and noncancer adult pts */
run;
/*Descriptive stats of demographics and clinical*/
proc freq data=Finalcohort order=freq;
tables race ethnicity sex smoking alcohol drug_use ;
run;
proc univariate data=Finalcohort ;
var Disease_Duration__months_1 Age;
run;
/*Total number of office visits for each patient*/
proc sort data=Finalcohort out=sorted_Finalcohort;
by Patient_ID;
run;
data Num_officevisits;
set sorted_Finalcohort;
by Patient_ID;
if first.Patient_ID;
Num_Officevisits=0;
if First_OfficeVisit ne . then do;
Num_Officevisits=1;
if Second_OfficeVisit ne . then Num_Officevisits+1;
if Third_OfficeVisit ne . then Num_Officevisits+1;
if Fourth_OfficeVisit ne . then Num_Officevisits+1;
if Fifth_OfficeVisit ne . then Num_Officevisits+1;
if sixth_OfficeVisit ne . then Num_Officevisits+1;
if seventh_OfficeVisit ne . then Num_Officevisits+1;
if eighth_OfficeVisit ne . then Num_Officevisits+1;
if ninth_OfficeVisit ne . then Num_Officevisits+1;
if tenth_OfficeVisit ne . then Num_Officevisits+1;
if eleventh_OfficeVisit ne . then Num_Officevisits+1;
if twelve_OfficeVisit ne . then Num_Officevisits+1;
if thirteen_OfficeVisit ne . then Num_Officevisits+1;
if fourteen_OfficeVisit ne . then Num_Officevisits+1;
if fifteen_OfficeVisit ne . then Num_Officevisits+1;
if sixteen_OfficeVisit ne . then Num_Officevisits+1;
if seventeen_OfficeVisit ne . then Num_Officevisits+1;
if eighteen_OfficeVisit ne . then Num_Officevisits+1;
if nineteen_OfficeVisit ne . then Num_Officevisits+1;
if twenty_OfficeVisit ne . then Num_Officevisits+1;
if twentyone_OfficeVisit ne . then Num_Officevisits+1;
if twentytwo_OfficeVisit ne . then Num_Officevisits+1;
if twentythree_OfficeVisit ne . then Num_Officevisits+1;
if twentyfour_OfficeVisit ne . then Num_Officevisits+1;
if twentyfive_OfficeVisit ne . then Num_Officevisits+1;
end;
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else do;
Num_Officevisits=0;
end;
run;
/*Mean median max office visits across entire cohort*/
proc univariate data=Num_officevisits;
var Num_Officevisits;
run;
/*Prevalence of comorbid conditions including hypertension, anxiety and
depression */
data comorbs_htn_anx_dep;
set Finalcohort ;
if Comorb_1 = "HTN" or Comorb_2= "HTN" or Comorb_3= "HTN" or Comorb_4=
"HTN" or Comorb_5= "HTN" or Comorb_6= "HTN" or Comorb_7= "HTN" or
Comorb_8= "HTN" or Comorb_9= "HTN" or Comorb_10= "HTN" or Comorb_11=
"HTN" or Comorb_12= "HTN" or Comorb_13= "HTN" or
Comorb_14= "HTN" or Comorb_15= "HTN" or Comorb_16= "HTN" or Comorb_17=
"HTN" or Comorb_18= "HTN" or Comorb_19= "HTN" or Comorb_20 = "HTN" then
HTN= 1; else HTN=0;
if Comorb_1 in ("ANXIETY" "DEPRESSION") or Comorb_2 in ("ANXIETY"
"DEPRESSION") or Comorb_3 in ("ANXIETY" "DEPRESSION") or Comorb_4 in
("ANXIETY" "DEPRESSION") or Comorb_5 in ("ANXIETY" "DEPRESSION") or
Comorb_6 in ("ANXIETY" "DEPRESSION") or Comorb_7 in ("ANXIETY"
"DEPRESSION") or Comorb_8 in ("ANXIETY" "DEPRESSION") or Comorb_9 in
("ANXIETY" "DEPRESSION") or Comorb_10 in ("ANXIETY" "DEPRESSION") or
Comorb_11 in ("ANXIETY" "DEPRESSION") or Comorb_12 in ("ANXIETY"
"DEPRESSION") or Comorb_13 in ("ANXIETY" "DEPRESSION") or
Comorb_14 in ("ANXIETY" "DEPRESSION") or Comorb_15 in ("ANXIETY"
"DEPRESSION") or Comorb_16 in ("ANXIETY" "DEPRESSION") or Comorb_17 in
("ANXIETY" "DEPRESSION") or Comorb_18 in ("ANXIETY" "DEPRESSION") or
Comorb_19 in ("ANXIETY" "DEPRESSION") or Comorb_20 in ("ANXIETY"
"DEPRESSION") or Comorb_21 in ("ANXIETY" "DEPRESSION") or Comorb_22 in
("ANXIETY" "DEPRESSION") or Comorb_23 in ("ANXIETY" "DEPRESSION") or
Comorb_24 in ("ANXIETY" "DEPRESSION") or Comorb_25 in ("ANXIETY"
"DEPRESSION") or Comorb_26 in ("ANXIETY" "DEPRESSION") or Comorb_27 in
("ANXIETY" "DEPRESSION") or Comorb_28 in ("ANXIETY" "DEPRESSION") or
Comorb_29 in ("ANXIETY" "DEPRESSION") then Anx_Dep= 1; else Anx_Dep=0;
run;
proc freq data=comorbs_htn_anx_dep order=freq;
tables HTN Anx_Dep;
run;
/*Descriptive stats of demographics and clinical - htn*/
data htn;
set comorbs_htn_anx_dep;
if htn=1;
run;
proc freq data=htn order=freq;
tables race ethnicity sex smoking alcohol drug_use ;
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run;
proc univariate data=htn ;
var Disease_Duration__months_1 Age;
run;
/*Descriptive stats of demographics and clinical - without htn*/
data No_htn;
set comorbs_htn_anx_dep;
if htn=0;
run;
proc freq data=No_htn order=freq;
tables race ethnicity sex smoking alcohol drug_use ;
run;
proc univariate data=No_htn ;
var Disease_Duration__months_1 Age;
run;
/*Descriptive stats of demographics and clinical - with anxiety and/or
depression*/
data Anx_Dep;
set comorbs_htn_anx_dep;
if Anx_Dep=1;
run;
proc freq data=Anx_Dep order=freq;
tables race ethnicity sex smoking alcohol drug_use ;
run;
proc univariate data=Anx_Dep ;
var Disease_Duration__months_1 Age;
run;
/*Descriptive stats of demographics and clinical - without anxiety
and/or depression*/
data No_Anx_Dep;
set comorbs_htn_anx_dep;
if Anx_Dep=0;
run;
proc freq data=No_Anx_Dep order=freq;
tables race ethnicity sex smoking alcohol drug_use ;
run;
proc univariate data=No_Anx_Dep ;
var Disease_Duration__months_1 Age;
run;
/*Total number of office visits for each patient-htn*/
proc sort data=htn out=sorted_htn;
by Patient_ID;
run;
data Num_officevisits_htn;
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set sorted_htn;
by Patient_ID;
if first.Patient_ID;
Num_Officevisits=0;
if First_OfficeVisit ne . then do;
Num_Officevisits=1;
if Second_OfficeVisit ne . then Num_Officevisits+1;
if Third_OfficeVisit ne . then Num_Officevisits+1;
if Fourth_OfficeVisit ne . then Num_Officevisits+1;
if Fifth_OfficeVisit ne . then Num_Officevisits+1;
if sixth_OfficeVisit ne . then Num_Officevisits+1;
if seventh_OfficeVisit ne . then Num_Officevisits+1;
if eighth_OfficeVisit ne . then Num_Officevisits+1;
if ninth_OfficeVisit ne . then Num_Officevisits+1;
if tenth_OfficeVisit ne . then Num_Officevisits+1;
if eleventh_OfficeVisit ne . then Num_Officevisits+1;
if twelve_OfficeVisit ne . then Num_Officevisits+1;
if thirteen_OfficeVisit ne . then Num_Officevisits+1;
if fourteen_OfficeVisit ne . then Num_Officevisits+1;
if fifteen_OfficeVisit ne . then Num_Officevisits+1;
if sixteen_OfficeVisit ne . then Num_Officevisits+1;
if seventeen_OfficeVisit ne . then Num_Officevisits+1;
if eighteen_OfficeVisit ne . then Num_Officevisits+1;
if nineteen_OfficeVisit ne . then Num_Officevisits+1;
if twenty_OfficeVisit ne . then Num_Officevisits+1;
if twentyone_OfficeVisit ne . then Num_Officevisits+1;
if twentytwo_OfficeVisit ne . then Num_Officevisits+1;
if twentythree_OfficeVisit ne . then Num_Officevisits+1;
if twentyfour_OfficeVisit ne . then Num_Officevisits+1;
if twentyfive_OfficeVisit ne . then Num_Officevisits+1;
end;
else do;
Num_Officevisits=0;
end;
run;
/*Mean median max office visits across entire cohort*/
proc univariate data=Num_officevisits_htn ;
var Num_Officevisits;
run;
/*Total number of office visits for each patient- without htn*/
proc sort data=No_htn out=sorted_No_htn;
by Patient_ID;
run;
data Num_officevisits_No_htn;
set sorted_No_htn;
by Patient_ID;
if first.Patient_ID;
Num_Officevisits=0;
if First_OfficeVisit ne . then do;
Num_Officevisits=1;
if Second_OfficeVisit ne . then Num_Officevisits+1;
if Third_OfficeVisit ne . then Num_Officevisits+1;
if Fourth_OfficeVisit ne . then Num_Officevisits+1;
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if Fifth_OfficeVisit ne . then Num_Officevisits+1;
if sixth_OfficeVisit ne . then Num_Officevisits+1;
if seventh_OfficeVisit ne . then Num_Officevisits+1;
if eighth_OfficeVisit ne . then Num_Officevisits+1;
if ninth_OfficeVisit ne . then Num_Officevisits+1;
if tenth_OfficeVisit ne . then Num_Officevisits+1;
if eleventh_OfficeVisit ne . then Num_Officevisits+1;
if twelve_OfficeVisit ne . then Num_Officevisits+1;
if thirteen_OfficeVisit ne . then Num_Officevisits+1;
if fourteen_OfficeVisit ne . then Num_Officevisits+1;
if fifteen_OfficeVisit ne . then Num_Officevisits+1;
if sixteen_OfficeVisit ne . then Num_Officevisits+1;
if seventeen_OfficeVisit ne . then Num_Officevisits+1;
if eighteen_OfficeVisit ne . then Num_Officevisits+1;
if nineteen_OfficeVisit ne . then Num_Officevisits+1;
if twenty_OfficeVisit ne . then Num_Officevisits+1;
if twentyone_OfficeVisit ne . then Num_Officevisits+1;
if twentytwo_OfficeVisit ne . then Num_Officevisits+1;
if twentythree_OfficeVisit ne . then Num_Officevisits+1;
if twentyfour_OfficeVisit ne . then Num_Officevisits+1;
if twentyfive_OfficeVisit ne . then Num_Officevisits+1;
end;
else do;
Num_Officevisits=0;
end;
run;
/*Mean median max office visits across entire cohort*/
proc univariate data=Num_officevisits_No_htn ;
var Num_Officevisits;
run;
/*Total number of office visits for each patient-anxiety and/or
depressson*/
proc sort data=Anx_Dep out=sorted_Anx_Dep;
by Patient_ID;
run;
data Num_officevisits_Anx_Dep;
set sorted_Anx_Dep;
by Patient_ID;
if first.Patient_ID;
Num_Officevisits=0;
if First_OfficeVisit ne . then do;
Num_Officevisits=1;
if Second_OfficeVisit ne . then Num_Officevisits+1;
if Third_OfficeVisit ne . then Num_Officevisits+1;
if Fourth_OfficeVisit ne . then Num_Officevisits+1;
if Fifth_OfficeVisit ne . then Num_Officevisits+1;
if sixth_OfficeVisit ne . then Num_Officevisits+1;
if seventh_OfficeVisit ne . then Num_Officevisits+1;
if eighth_OfficeVisit ne . then Num_Officevisits+1;
if ninth_OfficeVisit ne . then Num_Officevisits+1;
if tenth_OfficeVisit ne . then Num_Officevisits+1;
if eleventh_OfficeVisit ne . then Num_Officevisits+1;
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if twelve_OfficeVisit ne . then Num_Officevisits+1;
if thirteen_OfficeVisit ne . then Num_Officevisits+1;
if fourteen_OfficeVisit ne . then Num_Officevisits+1;
if fifteen_OfficeVisit ne . then Num_Officevisits+1;
if sixteen_OfficeVisit ne . then Num_Officevisits+1;
if seventeen_OfficeVisit ne . then Num_Officevisits+1;
if eighteen_OfficeVisit ne . then Num_Officevisits+1;
if nineteen_OfficeVisit ne . then Num_Officevisits+1;
if twenty_OfficeVisit ne . then Num_Officevisits+1;
if twentyone_OfficeVisit ne . then Num_Officevisits+1;
if twentytwo_OfficeVisit ne . then Num_Officevisits+1;
if twentythree_OfficeVisit ne . then Num_Officevisits+1;
if twentyfour_OfficeVisit ne . then Num_Officevisits+1;
if twentyfive_OfficeVisit ne . then Num_Officevisits+1;
end;
else do;
Num_Officevisits=0;
end;
run;
/*Mean median max office visits across entire cohort*/
proc univariate data=Num_officevisits_Anx_Dep;
var Num_Officevisits;
run;
/*Total number of office visits for each patient-without anxiety and/or
depressson*/
proc sort data=No_Anx_Dep out=sorted_No_Anx_Dep;
by Patient_ID;
run;
data Num_officevisits_No_Anx_Dep;
set sorted_No_Anx_Dep;
by Patient_ID;
if first.Patient_ID;
Num_Officevisits=0;
if First_OfficeVisit ne . then do;
Num_Officevisits=1;
if Second_OfficeVisit ne . then Num_Officevisits+1;
if Third_OfficeVisit ne . then Num_Officevisits+1;
if Fourth_OfficeVisit ne . then Num_Officevisits+1;
if Fifth_OfficeVisit ne . then Num_Officevisits+1;
if sixth_OfficeVisit ne . then Num_Officevisits+1;
if seventh_OfficeVisit ne . then Num_Officevisits+1;
if eighth_OfficeVisit ne . then Num_Officevisits+1;
if ninth_OfficeVisit ne . then Num_Officevisits+1;
if tenth_OfficeVisit ne . then Num_Officevisits+1;
if eleventh_OfficeVisit ne . then Num_Officevisits+1;
if twelve_OfficeVisit ne . then Num_Officevisits+1;
if thirteen_OfficeVisit ne . then Num_Officevisits+1;
if fourteen_OfficeVisit ne . then Num_Officevisits+1;
if fifteen_OfficeVisit ne . then Num_Officevisits+1;
if sixteen_OfficeVisit ne . then Num_Officevisits+1;
if seventeen_OfficeVisit ne . then Num_Officevisits+1;
if eighteen_OfficeVisit ne . then Num_Officevisits+1;
if nineteen_OfficeVisit ne . then Num_Officevisits+1;
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if twenty_OfficeVisit ne . then Num_Officevisits+1;
if twentyone_OfficeVisit ne . then Num_Officevisits+1;
if twentytwo_OfficeVisit ne . then Num_Officevisits+1;
if twentythree_OfficeVisit ne . then Num_Officevisits+1;
if twentyfour_OfficeVisit ne . then Num_Officevisits+1;
if twentyfive_OfficeVisit ne . then Num_Officevisits+1;
end;
else do;
Num_Officevisits=0;
end;
run;
/*Mean median max office visits across entire cohort*/
proc univariate data=Num_officevisits_No_Anx_Dep;
var Num_Officevisits;
run;
/*Therapeutic LBP Procedures prevalence in htn cohort*/
data proc_htn;
set htn;
CPT_Name_1=upcase(CPT_Name_1); CPT_Name_2=upcase(CPT_Name_2);
CPT_Name_3=upcase(CPT_Name_3);
CPT_Name_4=upcase(CPT_Name_4);CPT_Name_5=upcase(CPT_Name_5);CPT_Name_6=
upcase(CPT_Name_6);
If CPT_Name_1= "LESI" or CPT_Name_2= "LESI" or CPT_Name_3= "LESI" or
CPT_Name_4= "LESI" or CPT_Name_5= "LESI" or CPT_Name_6= "LESI" then
LESI=1; else LESI=0;
If CPT_Name_1= "CAUDAL ESI" or CPT_Name_2= "CAUDAL ESI" or CPT_Name_3=
"CAUDAL ESI" or CPT_Name_4= "CAUDAL ESI" or CPT_Name_5= "CAUDAL ESI" or
CPT_Name_6= "CAUDAL ESI" then Caudal_ESI=1; else Caudal_ESI=0;
If CPT_Name_1= "TFESI" or CPT_Name_2= "TFESI" or CPT_Name_3= "TFESI" or
CPT_Name_4= "TFESI" or CPT_Name_5= "TFESI" or CPT_Name_6= "TFESI" then
TFESI=1; else TFESI=0;
If CPT_Name_1= "LUMBAR/SACRAL MB RF" or CPT_Name_2= "LUMBAR/SACRAL MB
RF" or CPT_Name_3= "LUMBAR/SACRAL MB RF" or CPT_Name_4= "LUMBAR/SACRAL
MB RF" or CPT_Name_5= "LUMBAR/SACRAL MB RF" or CPT_Name_6=
"LUMBAR/SACRAL MB RF" then Lumb_Sac_MBRF=1; else Lumb_Sac_MBRF=0;
If CPT_Name_1= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_2= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_3= "INTRA ARTICULAR SIJ INJECTION"
or CPT_Name_4= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_5= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_6= "INTRA ARTICULAR SIJ INJECTION"
then Intrarticular_sij_Inj=1; else Intrarticular_sij_Inj=0;
If CPT_Name_1= "TPI" or CPT_Name_2= "TPI" or CPT_Name_3= "TPI" or
CPT_Name_4= "TPI" or CPT_Name_5= "TPI" or CPT_Name_6= "TPI" then TPI=1;
else TPI=0;
If CPT_Name_1= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_2= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_3= "SPINAL CORD STIMULATION TRIAL"
or CPT_Name_4= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_5= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_6= "SPINAL CORD STIMULATION TRIAL"
then Stim_trial=1; else Stim_trial=0;
If CPT_Name_1= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_2= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_3= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_4= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
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CPT_Name_5= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_6= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" then
Stim_implant=1; else Stim_implant=0;
If CPT_Name_1= "SIJ RF" or CPT_Name_2= "SIJ RF" or CPT_Name_3= "SIJ RF"
or CPT_Name_4= "SIJ RF" or CPT_Name_5= "SIJ RF" or CPT_Name_6= "SIJ RF"
then SIJ_RF=1; else SIJ_RF=0;
If CPT_Name_1= "NERVE ROOT BLOCK" or CPT_Name_2= "NERVE ROOT BLOCK" or
CPT_Name_3= "NERVE ROOT BLOCK" or CPT_Name_4= "NERVE ROOT BLOCK" or
CPT_Name_5= "NERVE ROOT BLOCK" or CPT_Name_6= "NERVE ROOT BLOCK" then
Nrvrootblk=1; else Nrvrootblk=0;
run;
proc freq data=proc_htn;
tables Caudal_ESI Intrarticular_sij_Inj LESI Lumb_Sac_MBRF Stim_trial
Stim_implant TPI TFESI SIJ_RF Nrvrootblk;
run;
/*Therapeutic LBP Procedures prevalence in non-htn cohort*/
data proc_no_htn;
set No_htn;
CPT_Name_1=upcase(CPT_Name_1); CPT_Name_2=upcase(CPT_Name_2);
CPT_Name_3=upcase(CPT_Name_3);
CPT_Name_4=upcase(CPT_Name_4);CPT_Name_5=upcase(CPT_Name_5);CPT_Name_6=
upcase(CPT_Name_6);
If CPT_Name_1= "LESI" or CPT_Name_2= "LESI" or CPT_Name_3= "LESI" or
CPT_Name_4= "LESI" or CPT_Name_5= "LESI" or CPT_Name_6= "LESI" then
LESI=1; else LESI=0;
If CPT_Name_1= "CAUDAL ESI" or CPT_Name_2= "CAUDAL ESI" or CPT_Name_3=
"CAUDAL ESI" or CPT_Name_4= "CAUDAL ESI" or CPT_Name_5= "CAUDAL ESI" or
CPT_Name_6= "CAUDAL ESI" then Caudal_ESI=1; else Caudal_ESI=0;
If CPT_Name_1= "TFESI" or CPT_Name_2= "TFESI" or CPT_Name_3= "TFESI" or
CPT_Name_4= "TFESI" or CPT_Name_5= "TFESI" or CPT_Name_6= "TFESI" then
TFESI=1; else TFESI=0;
If CPT_Name_1= "LUMBAR/SACRAL MB RF" or CPT_Name_2= "LUMBAR/SACRAL MB
RF" or CPT_Name_3= "LUMBAR/SACRAL MB RF" or CPT_Name_4= "LUMBAR/SACRAL
MB RF" or CPT_Name_5= "LUMBAR/SACRAL MB RF" or CPT_Name_6=
"LUMBAR/SACRAL MB RF" then Lumb_Sac_MBRF=1; else Lumb_Sac_MBRF=0;
If CPT_Name_1= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_2= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_3= "INTRA ARTICULAR SIJ INJECTION"
or CPT_Name_4= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_5= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_6= "INTRA ARTICULAR SIJ INJECTION"
then Intrarticular_sij_Inj=1; else Intrarticular_sij_Inj=0;
If CPT_Name_1= "TPI" or CPT_Name_2= "TPI" or CPT_Name_3= "TPI" or
CPT_Name_4= "TPI" or CPT_Name_5= "TPI" or CPT_Name_6= "TPI" then TPI=1;
else TPI=0;
If CPT_Name_1= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_2= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_3= "SPINAL CORD STIMULATION TRIAL"
or CPT_Name_4= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_5= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_6= "SPINAL CORD STIMULATION TRIAL"
then Stim_trial=1; else Stim_trial=0;
If CPT_Name_1= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_2= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_3= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_4= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_5= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
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CPT_Name_6= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" then
Stim_implant=1; else Stim_implant=0;
If CPT_Name_1= "SIJ RF" or CPT_Name_2= "SIJ RF" or CPT_Name_3= "SIJ RF"
or CPT_Name_4= "SIJ RF" or CPT_Name_5= "SIJ RF" or CPT_Name_6= "SIJ RF"
then SIJ_RF=1; else SIJ_RF=0;
If CPT_Name_1= "NERVE ROOT BLOCK" or CPT_Name_2= "NERVE ROOT BLOCK" or
CPT_Name_3= "NERVE ROOT BLOCK" or CPT_Name_4= "NERVE ROOT BLOCK" or
CPT_Name_5= "NERVE ROOT BLOCK" or CPT_Name_6= "NERVE ROOT BLOCK" then
Nrvrootblk=1; else Nrvrootblk=0;
run;
proc freq data=proc_no_htn;
tables Caudal_ESI Intrarticular_sij_Inj LESI Lumb_Sac_MBRF Stim_trial
Stim_implant TPI TFESI SIJ_RF Nrvrootblk;
run;
/*Therapeutic LBP Procedures prevalence in anxiety and/or depression
cohort*/
data proc_Anx_Dep;
set Anx_Dep;
CPT_Name_1=upcase(CPT_Name_1); CPT_Name_2=upcase(CPT_Name_2);
CPT_Name_3=upcase(CPT_Name_3);
CPT_Name_4=upcase(CPT_Name_4);CPT_Name_5=upcase(CPT_Name_5);CPT_Name_6=
upcase(CPT_Name_6);
If CPT_Name_1= "LESI" or CPT_Name_2= "LESI" or CPT_Name_3= "LESI" or
CPT_Name_4= "LESI" or CPT_Name_5= "LESI" or CPT_Name_6= "LESI" then
LESI=1; else LESI=0;
If CPT_Name_1= "CAUDAL ESI" or CPT_Name_2= "CAUDAL ESI" or CPT_Name_3=
"CAUDAL ESI" or CPT_Name_4= "CAUDAL ESI" or CPT_Name_5= "CAUDAL ESI" or
CPT_Name_6= "CAUDAL ESI" then Caudal_ESI=1; else Caudal_ESI=0;
If CPT_Name_1= "TFESI" or CPT_Name_2= "TFESI" or CPT_Name_3= "TFESI" or
CPT_Name_4= "TFESI" or CPT_Name_5= "TFESI" or CPT_Name_6= "TFESI" then
TFESI=1; else TFESI=0;
If CPT_Name_1= "LUMBAR/SACRAL MB RF" or CPT_Name_2= "LUMBAR/SACRAL MB
RF" or CPT_Name_3= "LUMBAR/SACRAL MB RF" or CPT_Name_4= "LUMBAR/SACRAL
MB RF" or CPT_Name_5= "LUMBAR/SACRAL MB RF" or CPT_Name_6=
"LUMBAR/SACRAL MB RF" then Lumb_Sac_MBRF=1; else Lumb_Sac_MBRF=0;
If CPT_Name_1= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_2= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_3= "INTRA ARTICULAR SIJ INJECTION"
or CPT_Name_4= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_5= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_6= "INTRA ARTICULAR SIJ INJECTION"
then Intrarticular_sij_Inj=1; else Intrarticular_sij_Inj=0;
If CPT_Name_1= "TPI" or CPT_Name_2= "TPI" or CPT_Name_3= "TPI" or
CPT_Name_4= "TPI" or CPT_Name_5= "TPI" or CPT_Name_6= "TPI" then TPI=1;
else TPI=0;
If CPT_Name_1= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_2= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_3= "SPINAL CORD STIMULATION TRIAL"
or CPT_Name_4= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_5= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_6= "SPINAL CORD STIMULATION TRIAL"
then Stim_trial=1; else Stim_trial=0;
If CPT_Name_1= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_2= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_3= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_4= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
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CPT_Name_5= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_6= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" then
Stim_implant=1; else Stim_implant=0;
If CPT_Name_1= "SIJ RF" or CPT_Name_2= "SIJ RF" or CPT_Name_3= "SIJ RF"
or CPT_Name_4= "SIJ RF" or CPT_Name_5= "SIJ RF" or CPT_Name_6= "SIJ RF"
then SIJ_RF=1; else SIJ_RF=0;
If CPT_Name_1= "NERVE ROOT BLOCK" or CPT_Name_2= "NERVE ROOT BLOCK" or
CPT_Name_3= "NERVE ROOT BLOCK" or CPT_Name_4= "NERVE ROOT BLOCK" or
CPT_Name_5= "NERVE ROOT BLOCK" or CPT_Name_6= "NERVE ROOT BLOCK" then
Nrvrootblk=1; else Nrvrootblk=0;
run;
proc freq data=proc_Anx_Dep;
tables Caudal_ESI Intrarticular_sij_Inj LESI Lumb_Sac_MBRF Stim_trial
Stim_implant TPI TFESI SIJ_RF Nrvrootblk;
run;

/*Therapeutic LBP Procedures prevalence in without anxiety and/or
depression cohort*/
data proc_No_Anx_Dep;
set No_Anx_Dep;
CPT_Name_1=upcase(CPT_Name_1); CPT_Name_2=upcase(CPT_Name_2);
CPT_Name_3=upcase(CPT_Name_3);
CPT_Name_4=upcase(CPT_Name_4);CPT_Name_5=upcase(CPT_Name_5);CPT_Name_6=
upcase(CPT_Name_6);
If CPT_Name_1= "LESI" or CPT_Name_2= "LESI" or CPT_Name_3= "LESI" or
CPT_Name_4= "LESI" or CPT_Name_5= "LESI" or CPT_Name_6= "LESI" then
LESI=1; else LESI=0;
If CPT_Name_1= "CAUDAL ESI" or CPT_Name_2= "CAUDAL ESI" or CPT_Name_3=
"CAUDAL ESI" or CPT_Name_4= "CAUDAL ESI" or CPT_Name_5= "CAUDAL ESI" or
CPT_Name_6= "CAUDAL ESI" then Caudal_ESI=1; else Caudal_ESI=0;
If CPT_Name_1= "TFESI" or CPT_Name_2= "TFESI" or CPT_Name_3= "TFESI" or
CPT_Name_4= "TFESI" or CPT_Name_5= "TFESI" or CPT_Name_6= "TFESI" then
TFESI=1; else TFESI=0;
If CPT_Name_1= "LUMBAR/SACRAL MB RF" or CPT_Name_2= "LUMBAR/SACRAL MB
RF" or CPT_Name_3= "LUMBAR/SACRAL MB RF" or CPT_Name_4= "LUMBAR/SACRAL
MB RF" or CPT_Name_5= "LUMBAR/SACRAL MB RF" or CPT_Name_6=
"LUMBAR/SACRAL MB RF" then Lumb_Sac_MBRF=1; else Lumb_Sac_MBRF=0;
If CPT_Name_1= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_2= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_3= "INTRA ARTICULAR SIJ INJECTION"
or CPT_Name_4= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_5= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_6= "INTRA ARTICULAR SIJ INJECTION"
then Intrarticular_sij_Inj=1; else Intrarticular_sij_Inj=0;
If CPT_Name_1= "TPI" or CPT_Name_2= "TPI" or CPT_Name_3= "TPI" or
CPT_Name_4= "TPI" or CPT_Name_5= "TPI" or CPT_Name_6= "TPI" then TPI=1;
else TPI=0;
If CPT_Name_1= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_2= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_3= "SPINAL CORD STIMULATION TRIAL"
or CPT_Name_4= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_5= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_6= "SPINAL CORD STIMULATION TRIAL"
then Stim_trial=1; else Stim_trial=0;
If CPT_Name_1= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_2= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
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CPT_Name_3= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_4= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_5= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_6= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" then
Stim_implant=1; else Stim_implant=0;
If CPT_Name_1= "SIJ RF" or CPT_Name_2= "SIJ RF" or CPT_Name_3= "SIJ RF"
or CPT_Name_4= "SIJ RF" or CPT_Name_5= "SIJ RF" or CPT_Name_6= "SIJ RF"
then SIJ_RF=1; else SIJ_RF=0;
If CPT_Name_1= "NERVE ROOT BLOCK" or CPT_Name_2= "NERVE ROOT BLOCK" or
CPT_Name_3= "NERVE ROOT BLOCK" or CPT_Name_4= "NERVE ROOT BLOCK" or
CPT_Name_5= "NERVE ROOT BLOCK" or CPT_Name_6= "NERVE ROOT BLOCK" then
Nrvrootblk=1; else Nrvrootblk=0;
run;
proc freq data=proc_No_Anx_Dep;
tables Caudal_ESI Intrarticular_sij_Inj LESI Lumb_Sac_MBRF Stim_trial
Stim_implant TPI TFESI SIJ_RF Nrvrootblk;
run;

/*Procedures performed across all patients*/
data Procedures;/*464 pts*/
set Finalcohort;
CPT_Name_1=upcase(CPT_Name_1); CPT_Name_2=upcase(CPT_Name_2);
CPT_Name_3=upcase(CPT_Name_3);
CPT_Name_4=upcase(CPT_Name_4);CPT_Name_5=upcase(CPT_Name_5);CPT_Name_6=
upcase(CPT_Name_6);
If CPT_Name_1= "CAUDAL ESI" or CPT_Name_2= "CAUDAL ESI" or CPT_Name_3=
"CAUDAL ESI" or CPT_Name_4= "CAUDAL ESI" or CPT_Name_5= "CAUDAL ESI" or
CPT_Name_6= "CAUDAL ESI" then Caudal_ESI=1; else Caudal_ESI=0;
If CPT_Name_1= "CERVICAL ESI" or CPT_Name_2= "CERVICAL ESI" or
CPT_Name_3= "CERVICAL ESI" or CPT_Name_4= "CERVICAL ESI" or CPT_Name_5=
"CERVICAL ESI" or CPT_Name_6= "CERVICAL ESI" then CERVICAL_ESI=1; else
CERVICAL_ESI=0;
If CPT_Name_1= "CERVICAL ESI/MULTIPLE TPI" or CPT_Name_2= "CERVICAL
ESI/MULTIPLE TPI" or CPT_Name_3= "CERVICAL ESI/MULTIPLE TPI" or
CPT_Name_4= "CERVICAL ESI/MULTIPLE TPI" or CPT_Name_5= "CERVICAL
ESI/MULTIPLE TPI" or CPT_Name_6= "CERVICAL ESI/MULTIPLE TPI" then
CERVICAL_ESI_MultTPI=1; else CERVICAL_ESI_MultTPI=0;
If CPT_Name_1= "GENICULAR NERVE BLOCK" or CPT_Name_2= "GENICULAR NERVE
BLOCK" or CPT_Name_3= "GENICULAR NERVE BLOCK" or CPT_Name_4= "GENICULAR
NERVE BLOCK" or CPT_Name_5= "GENICULAR NERVE BLOCK" or CPT_Name_6=
"GENICULAR NERVE BLOCK" then GENICULAR_NERVE_BLOCK=1; else
GENICULAR_NERVE_BLOCK=0;
If CPT_Name_1= "INTRA ARTICULAR HIP INJECTION" or CPT_Name_2= "INTRA
ARTICULAR HIP INJECTION" or CPT_Name_3= "INTRA ARTICULAR HIP INJECTION"
or CPT_Name_4= "INTRA ARTICULAR HIP INJECTION" or CPT_Name_5= "INTRA
ARTICULAR HIP INJECTION" or CPT_Name_6= "INTRA ARTICULAR HIP INJECTION"
then Intrarticular_Hip_Inj=1; else Intrarticular_Hip_Inj=0;
If CPT_Name_1= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_2= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_3= "INTRA ARTICULAR SIJ INJECTION"
or CPT_Name_4= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_5= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_6= "INTRA ARTICULAR SIJ INJECTION"
then Intrarticular_sij_Inj=1; else Intrarticular_sij_Inj=0;
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If CPT_Name_1= "KNEE INJECTION" or CPT_Name_2= "KNEE INJECTION" or
CPT_Name_3= "KNEE INJECTION" or CPT_Name_4= "KNEE INJECTION" or
CPT_Name_5= "KNEE INJECTION" or CPT_Name_6= "KNEE INJECTION" then
knee_inj=1; else knee_inj=0;
If CPT_Name_1= "LATERAL FEMORAL CUTANEOUS NERVE BLOCK" or CPT_Name_2=
"LATERAL FEMORAL CUTANEOUS NERVE BLOCK" or CPT_Name_3= "LATERAL FEMORAL
CUTANEOUS NERVE BLOCK" or CPT_Name_4= "LATERAL FEMORAL CUTANEOUS NERVE
BLOCK" or CPT_Name_5= "LATERAL FEMORAL CUTANEOUS NERVE BLOCK" or
CPT_Name_6= "LATERAL FEMORAL CUTANEOUS NERVE BLOCK" then
lat_femoral_CNB=1; else lat_femoral_CNB=0;
If CPT_Name_1= "LESI" or CPT_Name_2= "LESI" or CPT_Name_3= "LESI" or
CPT_Name_4= "LESI" or CPT_Name_5= "LESI" or CPT_Name_6= "LESI" then
LESI=1; else LESI=0;
If CPT_Name_1= "LUMBAR/SACRAL MB RF" or CPT_Name_2= "LUMBAR/SACRAL MB
RF" or CPT_Name_3= "LUMBAR/SACRAL MB RF" or CPT_Name_4= "LUMBAR/SACRAL
MB RF" or CPT_Name_5= "LUMBAR/SACRAL MB RF" or CPT_Name_6=
"LUMBAR/SACRAL MB RF" then Lumb_Sac_MBRF=1; else Lumb_Sac_MBRF=0;
If CPT_Name_1= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_2= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_3= "SPINAL CORD STIMULATION TRIAL"
or CPT_Name_4= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_5= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_6= "SPINAL CORD STIMULATION TRIAL"
then Stim_trial=1; else Stim_trial=0;
If CPT_Name_1= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_2= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_3= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_4= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_5= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_6= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" then
Stim_implant=1; else Stim_implant=0;
If CPT_Name_1= "PIRIFORMIS MUSCLE INJECTION" or CPT_Name_2= "PIRIFORMIS
MUSCLE INJECTION" or CPT_Name_3= "PIRIFORMIS MUSCLE INJECTION" or
CPT_Name_4= "PIRIFORMIS MUSCLE INJECTION" or CPT_Name_5= "PIRIFORMIS
MUSCLE INJECTION" or CPT_Name_6= "PIRIFORMIS MUSCLE INJECTION" then
piriformis_inj=1; else piriformis_inj=0;
If CPT_Name_1= "RIGHT ILIOINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_2= "RIGHT ILIOINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_3= "RIGHT ILIOINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_4= "RIGHT ILIOINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_5= "RIGHT ILIOINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_6= "RIGHT ILIOINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" then
Ilio_nerv_blk=1; else Ilio_nerv_blk=0;
If CPT_Name_1= "SACROCOCCYGEAL JOINT INJECTION" or CPT_Name_2=
"SACROCOCCYGEAL JOINT INJECTION" or CPT_Name_3= "SACROCOCCYGEAL JOINT
INJECTION" or CPT_Name_4= "SACROCOCCYGEAL JOINT INJECTION" or
CPT_Name_5= "SACROCOCCYGEAL JOINT INJECTION" or CPT_Name_6=
"SACROCOCCYGEAL JOINT INJECTION" then Sacrococc_Inj=1; else
Sacrococc_Inj=0;
If CPT_Name_1= "TPI" or CPT_Name_2= "TPI" or CPT_Name_3= "TPI" or
CPT_Name_4= "TPI" or CPT_Name_5= "TPI" or CPT_Name_6= "TPI" then TPI=1;
else TPI=0;
If CPT_Name_1= "TROCHANTERIC BURSA INJECTION" or CPT_Name_2=
"TROCHANTERIC BURSA INJECTION" or CPT_Name_3= "TROCHANTERIC BURSA
INJECTION" or CPT_Name_4= "TROCHANTERIC BURSA INJECTION" or CPT_Name_5=
"TROCHANTERIC BURSA INJECTION" or CPT_Name_6= "TROCHANTERIC BURSA
INJECTION" then Troch_Bursa_inj=1; else Troch_Bursa_inj=0;
If CPT_Name_1= "RIGHT SHOULDER INJECTION" or CPT_Name_2= "RIGHT
SHOULDER INJECTION" or CPT_Name_3= "RIGHT SHOULDER INJECTION" or
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CPT_Name_4= "RIGHT SHOULDER INJECTION" or CPT_Name_5= "RIGHT SHOULDER
INJECTION" or CPT_Name_6= "RIGHT SHOULDER INJECTION" then
Shoulder_inj=1; else Shoulder_inj=0;
If CPT_Name_1= "TFESI" or CPT_Name_2= "TFESI" or CPT_Name_3= "TFESI" or
CPT_Name_4= "TFESI" or CPT_Name_5= "TFESI" or CPT_Name_6= "TFESI" then
TFESI=1; else TFESI=0;
If CPT_Name_1= "SUPEROLATERAL GENICULAR NEUROTOMY" or CPT_Name_2=
"SUPEROLATERAL GENICULAR NEUROTOMY" or CPT_Name_3= "SUPEROLATERAL
GENICULAR NEUROTOMY" or CPT_Name_4= "SUPEROLATERAL GENICULAR NEUROTOMY"
or CPT_Name_5= "SUPEROLATERAL GENICULAR NEUROTOMY" or CPT_Name_6=
"SUPEROLATERAL GENICULAR NEUROTOMY" then Genicular_neurotomy=1; else
Genicular_neurotomy=0;
If CPT_Name_1= "RIGHT SAPHENOUS NERVE BLOCK" or CPT_Name_2= "RIGHT
SAPHENOUS NERVE BLOCK" or CPT_Name_3= "RIGHT SAPHENOUS NERVE BLOCK" or
CPT_Name_4= "RIGHT SAPHENOUS NERVE BLOCK" or CPT_Name_5= "RIGHT
SAPHENOUS NERVE BLOCK" or CPT_Name_6= "RIGHT SAPHENOUS NERVE BLOCK"
then Saphenous_Nerv_blk=1; else Saphenous_Nerv_blk=0;
If CPT_Name_1= "RIGHT SUPRASCAPULAR NERVE BLOCK" or CPT_Name_2= "RIGHT
SUPRASCAPULAR NERVE BLOCK" or CPT_Name_3= "RIGHT SUPRASCAPULAR NERVE
BLOCK" or CPT_Name_4= "RIGHT SUPRASCAPULAR NERVE BLOCK" or CPT_Name_5=
"RIGHT SUPRASCAPULAR NERVE BLOCK" or CPT_Name_6= "RIGHT SUPRASCAPULAR
NERVE BLOCK" then Suprascapular_nerv_blk=1; else
Suprascapular_nerv_blk=0;
If CPT_Name_1= "SIJ RF" or CPT_Name_2= "SIJ RF" or CPT_Name_3= "SIJ RF"
or CPT_Name_4= "SIJ RF" or CPT_Name_5= "SIJ RF" or CPT_Name_6= "SIJ RF"
then SIJ_RF=1; else SIJ_RF=0;
If CPT_Name_1= "THORACIC MBB" or CPT_Name_2= "THORACIC MBB" or
CPT_Name_3= "THORACIC MBB" or CPT_Name_4= "THORACIC MBB" or CPT_Name_5=
"THORACIC MBB" or CPT_Name_6= "THORACIC MBB" then THORACIC_MBB=1; else
THORACIC_MBB=0;
If CPT_Name_1= "LMBB" or CPT_Name_2= "LMBB" or CPT_Name_3= "LMBB" or
CPT_Name_4= "LMBB" or CPT_Name_5= "LMBB" or CPT_Name_6= "LMBB" then
LMBB=1; else LMBB=0;
If CPT_Name_1= "NERVE ROOT BLOCK" or CPT_Name_2= "NERVE ROOT BLOCK" or
CPT_Name_3= "NERVE ROOT BLOCK" or CPT_Name_4= "NERVE ROOT BLOCK" or
CPT_Name_5= "NERVE ROOT BLOCK" or CPT_Name_6= "NERVE ROOT BLOCK" then
Nrvrootblk=1; else Nrvrootblk=0;
If CPT_Name_1= "RIGHT CERVICAL MBB" or CPT_Name_2= "RIGHT CERVICAL MBB"
or CPT_Name_3= "RIGHT CERVICAL MBB" or CPT_Name_4= "RIGHT CERVICAL MBB"
or CPT_Name_5= "RIGHT CERVICAL MBB" or CPT_Name_6= "RIGHT CERVICAL MBB"
then cervical_mbb=1; else cervical_mbb=0;
If CPT_Name_1= "THORACIC AND LUMBAR MBB" or CPT_Name_2= "THORACIC AND
LUMBAR MBB" or CPT_Name_3= "THORACIC AND LUMBAR MBB" or CPT_Name_4=
"THORACIC AND LUMBAR MBB" or CPT_Name_5= "THORACIC AND LUMBAR MBB" or
CPT_Name_6= "THORACIC AND LUMBAR MBB" then thoralumbmbb=1; else
thoralumbmbb=0;
If CPT_Name_1= "SUPERIOR LATERAL GENICULAR NERVE BLOCK" or CPT_Name_2=
"SUPERIOR LATERAL GENICULAR NERVE BLOCK" or CPT_Name_3= "SUPERIOR
LATERAL GENICULAR NERVE BLOCK" or CPT_Name_4= "SUPERIOR LATERAL
GENICULAR NERVE BLOCK" or CPT_Name_5= "SUPERIOR LATERAL GENICULAR NERVE
BLOCK" or CPT_Name_6= "SUPERIOR LATERAL GENICULAR NERVE BLOCK" then
suplatgenblk=1; else suplatgenblk=0;
run;
/*Frequency of each of the above procedures*/
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proc freq data=Procedures;
tables Caudal_ESI CERVICAL_ESI CERVICAL_ESI_MultTPI
GENICULAR_NERVE_BLOCK Intrarticular_Hip_Inj Intrarticular_sij_Inj
knee_inj lat_femoral_CNB LESI Lumb_Sac_MBRF Stim_trial Stim_implant
piriformis_inj Ilio_nerv_blk Sacrococc_Inj TPI Troch_Bursa_inj TFESI
Shoulder_inj Genicular_neurotomy Saphenous_Nerv_blk
Suprascapular_nerv_blk SIJ_RF THORACIC_MBB LMBB Nrvrootblk cervical_mbb
thoralumbmbb suplatgenblk Ilio_nerv_blk;
run;
/*Most prevalent procedures repeated for a chronic LBP patient during
follow ups by
recording the max value of repetitions for each procedure and lowest
repetition (by min value)*/
Data Remainder_Procedures Procedures_Rep_LESI Procedures_Rep_CaudalESI
Procedures_Rep_TPI Procedures_Rep_SIJinj Proc_Rep_Stim_trial
Proc_Rep_Stim_implant Procedures_Rep_TFESI Proc_rep_lum_sac_mbrf
Proc_rep_SIJRF Proc_rep_nrvrootblk;
set Procedures;
If CPT_Name_1 ne " ";/*289 pts have had at least one procedure*/
If LESI= 1 then output Procedures_Rep_LESI;
if Caudal_ESI=1 then output Procedures_Rep_CaudalESI;
if TPI=1 then output Procedures_Rep_TPI;
if Intrarticular_sij_Inj=1 then output Procedures_Rep_SIJinj;
if Stim_Trial=1 then output Proc_Rep_Stim_trial;
if Stim_implant=1 then output Proc_Rep_Stim_implant;
if TFESI=1 then output Procedures_Rep_TFESI;
if Lumb_Sac_MBRF=1 then output Proc_rep_lum_sac_mbrf;
if SIJ_RF=1 then output Proc_rep_SIJRF;
if Nrvrootblk=1 then output Proc_rep_nrvrootblk;
else output Remainder_Procedures;
run;
data Procedures_Rep_LESI_1;
set Procedures_Rep_LESI;
If CPT_Name_1= "LESI" then CPT_name1_dummy=1;
If CPT_Name_2= "LESI" then CPT_name2_dummy=1;
If CPT_Name_3= "LESI" then CPT_name3_dummy=1;
If CPT_Name_4= "LESI" then CPT_name4_dummy=1;
If CPT_Name_5= "LESI" then CPT_name5_dummy=1;
If CPT_Name_6= "LESI" then CPT_name6_dummy=1;

else
else
else
else
else
else

CPT_name1_dummy=0;
CPT_name2_dummy=0;
CPT_name3_dummy=0;
CPT_name4_dummy=0;
CPT_name5_dummy=0;
CPT_name6_dummy=0;

CPT_LESI_Rep_Count =
CPT_name1_dummy+CPT_name2_dummy+CPT_name3_dummy+CPT_name4_dummy+CPT_nam
e5_dummy+CPT_name6_dummy;
run;
proc univariate data=Procedures_Rep_LESI_1;
var CPT_LESI_Rep_Count;
run;
data Procedures_Rep_CaudalESI_1;
set Procedures_Rep_CaudalESI;
If CPT_Name_1= "CAUDAL ESI" then CPT_name1_dummy=1; else
CPT_name1_dummy=0;
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If CPT_Name_2= "CAUDAL
CPT_name2_dummy=0;
If CPT_Name_3= "CAUDAL
CPT_name3_dummy=0;
If CPT_Name_4= "CAUDAL
CPT_name4_dummy=0;
If CPT_Name_5= "CAUDAL
CPT_name5_dummy=0;
If CPT_Name_6= "CAUDAL
CPT_name6_dummy=0;

ESI" then CPT_name2_dummy=1; else
ESI" then CPT_name3_dummy=1; else
ESI" then CPT_name4_dummy=1; else
ESI" then CPT_name5_dummy=1; else
ESI" then CPT_name6_dummy=1; else

CPT_CaudalESI_Rep_Count =
CPT_name1_dummy+CPT_name2_dummy+CPT_name3_dummy+CPT_name4_dummy+CPT_nam
e5_dummy+CPT_name6_dummy;
run;
proc univariate data= Procedures_Rep_CaudalESI_1;
var CPT_CaudalESI_Rep_Count;
run;
data Procedures_Rep_TPI_1;
Set Procedures_Rep_TPI;
If CPT_Name_1= "TPI" then CPT_name1_dummy=1;
If CPT_Name_2= "TPI" then CPT_name2_dummy=1;
If CPT_Name_3= "TPI" then CPT_name3_dummy=1;
If CPT_Name_4= "TPI" then CPT_name4_dummy=1;
If CPT_Name_5= "TPI" then CPT_name5_dummy=1;
If CPT_Name_6= "TPI" then CPT_name6_dummy=1;

else
else
else
else
else
else

CPT_name1_dummy=0;
CPT_name2_dummy=0;
CPT_name3_dummy=0;
CPT_name4_dummy=0;
CPT_name5_dummy=0;
CPT_name6_dummy=0;

CPT_TPI_Rep_Count =
CPT_name1_dummy+CPT_name2_dummy+CPT_name3_dummy+CPT_name4_dummy+CPT_nam
e5_dummy+CPT_name6_dummy;
run;
proc univariate data= Procedures_Rep_TPI_1 ;
var CPT_TPI_Rep_Count;
run;

data Procedures_Rep_SIJinj_1;
set Procedures_Rep_SIJinj;
If CPT_Name_1= "INTRA ARTICULAR
else CPT_name1_dummy=0;
If CPT_Name_2= "INTRA ARTICULAR
else CPT_name2_dummy=0;
If CPT_Name_3= "INTRA ARTICULAR
else CPT_name3_dummy=0;
If CPT_Name_4= "INTRA ARTICULAR
else CPT_name4_dummy=0;
If CPT_Name_5= "INTRA ARTICULAR
else CPT_name5_dummy=0;
If CPT_Name_6= "INTRA ARTICULAR
else CPT_name6_dummy=0;

SIJ INJECTION" then CPT_name1_dummy=1;
SIJ INJECTION" then CPT_name2_dummy=1;
SIJ INJECTION" then CPT_name3_dummy=1;
SIJ INJECTION" then CPT_name4_dummy=1;
SIJ INJECTION" then CPT_name5_dummy=1;
SIJ INJECTION" then CPT_name6_dummy=1;
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CPT_SIJinj_Rep_Count =
CPT_name1_dummy+CPT_name2_dummy+CPT_name3_dummy+CPT_name4_dummy+CPT_nam
e5_dummy+CPT_name6_dummy;
run;
proc univariate data= Procedures_Rep_SIJinj_1 ;
var CPT_SIJinj_Rep_Count;
run;
data Proc_rep_nrvrootblk_1;
set Proc_rep_nrvrootblk;
If CPT_Name_1= "NERVE ROOT BLOCK"
CPT_name1_dummy=0;
If CPT_Name_2= "NERVE ROOT BLOCK"
CPT_name2_dummy=0;
If CPT_Name_3= "NERVE ROOT BLOCK"
CPT_name3_dummy=0;
If CPT_Name_4= "NERVE ROOT BLOCK"
CPT_name4_dummy=0;
If CPT_Name_5= "NERVE ROOT BLOCK"
CPT_name5_dummy=0;
If CPT_Name_6= "NERVE ROOT BLOCK"
CPT_name6_dummy=0;

then CPT_name1_dummy=1; else
then CPT_name2_dummy=1; else
then CPT_name3_dummy=1; else
then CPT_name4_dummy=1; else
then CPT_name5_dummy=1; else
then CPT_name6_dummy=1; else

CPT_Nrvrootblk_Rep_Count =
CPT_name1_dummy+CPT_name2_dummy+CPT_name3_dummy+CPT_name4_dummy+CPT_nam
e5_dummy+CPT_name6_dummy;
run;
proc univariate data= Proc_rep_nrvrootblk_1 ;
var CPT_Nrvrootblk_Rep_Count;
run;
data Proc_Rep_Stim_trial_1;
set Proc_Rep_Stim_trial;
If CPT_Name_1= "SPINAL CORD
else CPT_name1_dummy=0;
If CPT_Name_2= "SPINAL CORD
else CPT_name2_dummy=0;
If CPT_Name_3= "SPINAL CORD
else CPT_name3_dummy=0;
If CPT_Name_4= "SPINAL CORD
else CPT_name4_dummy=0;
If CPT_Name_5= "SPINAL CORD
else CPT_name5_dummy=0;
If CPT_Name_6= "SPINAL CORD
else CPT_name6_dummy=0;

STIMULATION TRIAL" then CPT_name1_dummy=1;
STIMULATION TRIAL" then CPT_name2_dummy=1;
STIMULATION TRIAL" then CPT_name3_dummy=1;
STIMULATION TRIAL" then CPT_name4_dummy=1;
STIMULATION TRIAL" then CPT_name5_dummy=1;
STIMULATION TRIAL" then CPT_name6_dummy=1;

CPT_StimTrial_Rep_Count =
CPT_name1_dummy+CPT_name2_dummy+CPT_name3_dummy+CPT_name4_dummy+CPT_nam
e5_dummy+CPT_name6_dummy;
run;
proc univariate data= Proc_Rep_Stim_trial_1 ;
var CPT_StimTrial_Rep_Count;
run;
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data Proc_Rep_Stim_implant_1;
set Proc_Rep_Stim_implant;
If CPT_Name_1= "PERMANENT SPINAL CORD STIMULATION
CPT_name1_dummy=1; else CPT_name1_dummy=0;
If CPT_Name_2= "PERMANENT SPINAL CORD STIMULATION
CPT_name2_dummy=1; else CPT_name2_dummy=0;
If CPT_Name_3= "PERMANENT SPINAL CORD STIMULATION
CPT_name3_dummy=1; else CPT_name3_dummy=0;
If CPT_Name_4= "PERMANENT SPINAL CORD STIMULATION
CPT_name4_dummy=1; else CPT_name4_dummy=0;
If CPT_Name_5= "PERMANENT SPINAL CORD STIMULATION
CPT_name5_dummy=1; else CPT_name5_dummy=0;
If CPT_Name_6= "PERMANENT SPINAL CORD STIMULATION
CPT_name6_dummy=1; else CPT_name6_dummy=0;

IMPLANTATION" then
IMPLANTATION" then
IMPLANTATION" then
IMPLANTATION" then
IMPLANTATION" then
IMPLANTATION" then

CPT_StimImplant_Rep_Count =
CPT_name1_dummy+CPT_name2_dummy+CPT_name3_dummy+CPT_name4_dummy+CPT_nam
e5_dummy+CPT_name6_dummy;
run;
proc univariate data= Proc_Rep_Stim_implant_1 ;
var CPT_StimImplant_Rep_Count;
run;
data Procedures_Rep_TFESI_1;
Set Procedures_Rep_TFESI;
If CPT_Name_1= "TFESI" then CPT_name1_dummy=1;
If CPT_Name_2= "TFESI" then CPT_name2_dummy=1;
If CPT_Name_3= "TFESI" then CPT_name3_dummy=1;
If CPT_Name_4= "TFESI" then CPT_name4_dummy=1;
If CPT_Name_5= "TFESI" then CPT_name5_dummy=1;
If CPT_Name_6= "TFESI" then CPT_name6_dummy=1;

else
else
else
else
else
else

CPT_name1_dummy=0;
CPT_name2_dummy=0;
CPT_name3_dummy=0;
CPT_name4_dummy=0;
CPT_name5_dummy=0;
CPT_name6_dummy=0;

CPT_TFESI_Rep_Count =
CPT_name1_dummy+CPT_name2_dummy+CPT_name3_dummy+CPT_name4_dummy+CPT_nam
e5_dummy+CPT_name6_dummy;
run;
proc univariate data= Procedures_Rep_TFESI_1 ;
var CPT_TFESI_Rep_Count;
run;
data Proc_rep_lum_sac_mbrf_1;
Set Proc_rep_lum_sac_mbrf;
If CPT_Name_1= "LUMBAR/SACRAL
CPT_name1_dummy=0;
If CPT_Name_2= "LUMBAR/SACRAL
CPT_name2_dummy=0;
If CPT_Name_3= "LUMBAR/SACRAL
CPT_name3_dummy=0;
If CPT_Name_4= "LUMBAR/SACRAL
CPT_name4_dummy=0;

MB RF" then CPT_name1_dummy=1; else
MB RF" then CPT_name2_dummy=1; else
MB RF" then CPT_name3_dummy=1; else
MB RF" then CPT_name4_dummy=1; else

109

If CPT_Name_5= "LUMBAR/SACRAL MB RF" then CPT_name5_dummy=1; else
CPT_name5_dummy=0;
If CPT_Name_6= "LUMBAR/SACRAL MB RF" then CPT_name6_dummy=1; else
CPT_name6_dummy=0;
CPT_Lumsac_mbrf_Rep_Count =
CPT_name1_dummy+CPT_name2_dummy+CPT_name3_dummy+CPT_name4_dummy+CPT_nam
e5_dummy+CPT_name6_dummy;
run;
proc univariate data= Proc_rep_lum_sac_mbrf_1 ;
var CPT_Lumsac_mbrf_Rep_Count;
run;
data Proc_rep_SIJRF_1;
Set Proc_rep_SIJRF;
If CPT_Name_1= "SIJ RF"
If CPT_Name_2= "SIJ RF"
If CPT_Name_3= "SIJ RF"
If CPT_Name_4= "SIJ RF"
If CPT_Name_5= "SIJ RF"
If CPT_Name_6= "SIJ RF"

then
then
then
then
then
then

CPT_name1_dummy=1;
CPT_name2_dummy=1;
CPT_name3_dummy=1;
CPT_name4_dummy=1;
CPT_name5_dummy=1;
CPT_name6_dummy=1;

else
else
else
else
else
else

CPT_name1_dummy=0;
CPT_name2_dummy=0;
CPT_name3_dummy=0;
CPT_name4_dummy=0;
CPT_name5_dummy=0;
CPT_name6_dummy=0;

CPT_SIJRF_Rep_Count =
CPT_name1_dummy+CPT_name2_dummy+CPT_name3_dummy+CPT_name4_dummy+CPT_nam
e5_dummy+CPT_name6_dummy;
run;
proc univariate data= Proc_rep_SIJRF_1 ;
var CPT_SIJRF_Rep_Count;
run;

/*Mean pain score difference using pre-procedure and post-procedure
pain scores*/
data single_procedures;
set Finalcohort;
CPT_Name_1=upcase(CPT_Name_1); CPT_Name_2=upcase(CPT_Name_2);
CPT_Name_3=upcase(CPT_Name_3);
CPT_Name_4=upcase(CPT_Name_4);CPT_Name_5=upcase(CPT_Name_5);CPT_Name_6=
upcase(CPT_Name_6);
if (CPT_Name_1 ne " ") and (CPT_Name_2 eq " "); /*109 pts*/
if CPT_Name_1 in ("TFESI" "LESI" "TPI" "CAUDAL ESI" "INTRA ARTICULAR
SIJ INJECTION" "NERVE ROOT BLOCK"); /*84 pts*/
run;
proc freq data=single_procedures nlevels;
tables CPT_Name_1;
run;
proc means data=single_procedures n;
var patient_ID;
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run;
data single_procedures_1 ;
set single_procedures;
Pain_level_1stOfficevisit = input (Pain_level_O1, 1.);
Pain_level_telephoneFU = input (Pain_level_TFU_1, 1.);
if Pain_level_O1=. or Pain_level_TFU_1=. then delete;
run;
data SP_TFESI SP_LESI SP_TPI SP_CaudalESI SP_SIJinj SP_NRB;
set single_procedures_1;
If CPT_Name_1 = "TFESI" then output SP_TFESI;
If CPT_Name_1 = "LESI" then output SP_LESI;
If CPT_Name_1 = "TPI" then output SP_TPI;
If CPT_Name_1 = "CAUDAL ESI" then output SP_CaudalESI;
If CPT_Name_1 = "INTRA ARTICULAR SIJ INJECTION" then output SP_SIJinj;
If CPT_Name_1= "NERVE ROOT BLOCK" then output SP_NRB;
run;
proc sort data =single_procedures_1;
by CPT_Name_1;
run;
PROC TTEST DATA=single_procedures_1 ALPHA=.05; /*76 pts*/
PAIRED Pain_level_1stOfficevisit*Pain_level_telephoneFU;
by CPT_Name_1;
RUN;

/*Mean pain scores for TFESI*/
title1 "Mean/Median pain scores pre-proc and post-proc for TFESI";
proc means data=SP_TFESI mean median maxdec=2;
var Pain_level_1stOfficevisit;
run;
proc means data=SP_TFESI mean median maxdec=2;
var Pain_level_telephoneFU;
run;
title1;
/*Mean pain scores for LESI*/
title2 "Mean/Median pain scores pre-proc and post-proc for LESI";
proc means data=SP_LESI mean ;
var Pain_level_1stOfficevisit;
run;
proc means data=SP_LESI mean;
var Pain_level_telephoneFU;
run;
title2;
/*Mean pain scores for TPI*/
title3 "Mean/Median pain scores pre-proc and post-proc for TPI";
proc means data=SP_TPI mean median maxdec=2;
var Pain_level_1stOfficevisit;
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run;
proc means data=SP_TPI mean median maxdec=2;
var Pain_level_telephoneFU;
run;
title3;
/*Mean pain scores for Caudal ESI*/
title4 "Mean/Median pain scores pre-proc and post-proc for Caudal ESI";
proc means data=SP_CaudalESI mean median maxdec=2;
var Pain_level_1stOfficevisit;
run;
proc means data=SP_CaudalESI mean median maxdec=2;
var Pain_level_telephoneFU;
run;
title4;
/*Mean pain scores for SIJ injection*/
title5 "Mean/Median pain scores pre-proc and post-proc for SIJ
injection";
proc means data=SP_SIJinj mean median maxdec=2;
var Pain_level_1stOfficevisit;
run;
proc means data=SP_SIJinj mean median maxdec=2;
var Pain_level_telephoneFU;
run;
title5;
/*Mean pain scores for Nerve root block injection*/
proc means data=SP_NRB mean median maxdec=2;
var Pain_level_1stOfficevisit;
run;
proc means data=SP_NRB mean median maxdec=2;
var Pain_level_telephoneFU;
run;
/*Mean pain score difference code ends here*/

/*Descriptive characteristics -blood thinners meds under current meds*/
data blood_thinner;/*154 PATIENTS*/
set Finalcohort;
Current_meds_1=upcase(Current_meds_1);
Current_meds_2=upcase(Current_meds_2);
Current_meds_3=upcase(Current_meds_3);
Current_meds_4=upcase(Current_meds_4);
Current_meds_5=upcase(Current_meds_5);
Current_meds_6=upcase(Current_meds_6);Current_meds_7=upcase(Current_med
s_7);Current_meds_8=upcase(Current_meds_8);Current_meds_9=upcase(Curren
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t_meds_9);Current_meds_10=upcase(Current_meds_10);Current_meds_11=upcas
e(Current_meds_11);
Current_meds_12=upcase(Current_meds_12);Current_meds_13=upcase(Current_
meds_13);Current_meds_14=upcase(Current_meds_14);Current_meds_15=upcase
(Current_meds_15);Current_meds_16=upcase(Current_meds_16);Current_meds_
17=upcase(Current_meds_17);Current_meds_18=upcase(Current_meds_18);Curr
ent_meds_19=upcase(Current_meds_19);Current_meds_20=upcase(Current_meds
_20);Current_meds_21=upcase(Current_meds_21);Current_meds_22=upcase(Cur
rent_meds_22);
Current_meds_23=upcase(Current_meds_23);
Current_meds_24=upcase(Current_meds_24);
Current_meds_25=upcase(Current_meds_25);
Current_meds_26=upcase(Current_meds_26);
Current_meds_27=upcase(Current_meds_27);
Current_meds_28=upcase(Current_meds_28);
Current_meds_29=upcase(Current_meds_29);
Current_meds_30=upcase(Current_meds_30);
Current_meds_31=upcase(Current_meds_31);
Current_meds_32=upcase(Current_meds_32);
%let Blood_thinner="ELIQUIS" "JANTOVEN" "PLAVIX" "ECOTRIN" "BAYER LOW
DOSE" "CLOPIDOGREL" "ASPIRIN" "BRILINTA" "ELMIRON" "WARFARIN" "XARELTO"
"PRASUGREL";
if Current_meds_1 in (&blood_thinner) or Current_meds_2 in
(&blood_thinner)or Current_meds_3 in (&blood_thinner) or Current_meds_4
in (&blood_thinner) or Current_meds_5 in (&blood_thinner) or
Current_meds_6 in (&blood_thinner)or Current_meds_7 in (&blood_thinner)
or Current_meds_8 in (&blood_thinner) or Current_meds_9 in
(&blood_thinner) or Current_meds_10 in (&blood_thinner)or
Current_meds_11 in (&blood_thinner) or Current_meds_12 in
(&blood_thinner) or Current_meds_13 in (&blood_thinner) or
Current_meds_14 in (&blood_thinner) or Current_meds_15 in
(&blood_thinner)
or Current_meds_16 in (&blood_thinner) or Current_meds_17 in
(&blood_thinner) or Current_meds_18 in (&blood_thinner) or
Current_meds_19 in (&blood_thinner) or Current_meds_20 in
(&blood_thinner) or Current_meds_21 in (&blood_thinner) or
Current_meds_22 in (&blood_thinner) or Current_meds_23 in
(&blood_thinner)or Current_meds_24 in (&blood_thinner)or
Current_meds_25 in (&blood_thinner) or Current_meds_26 in
(&blood_thinner) or Current_meds_27 in (&blood_thinner) or
Current_meds_28 in (&blood_thinner) or Current_meds_29 in
(&blood_thinner)
or Current_meds_30 in (&blood_thinner) or Current_meds_31 in
(&blood_thinner) or Current_meds_32 in (&blood_thinner) then
blood_thinner=1; else blood_thinner=0;
if blood_thinner=1;
run;
/*Demographics for blood thinners*/
proc freq data=blood_thinner order=freq;
tables race ethnicity sex smoking alcohol drug_use ;
run;
proc univariate data=blood_thinner;
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var Disease_Duration__months_1 Age;
run;
/*Types of procedures performed - blood thinner cohort*/
data Bloodthinner_proc;
set blood_thinner;
CPT_Name_1=upcase(CPT_Name_1); CPT_Name_2=upcase(CPT_Name_2);
CPT_Name_3=upcase(CPT_Name_3);
CPT_Name_4=upcase(CPT_Name_4);CPT_Name_5=upcase(CPT_Name_5);CPT_Name_6=
upcase(CPT_Name_6);
If CPT_Name_1= "CAUDAL ESI" or CPT_Name_2= "CAUDAL ESI" or CPT_Name_3=
"CAUDAL ESI" or CPT_Name_4= "CAUDAL ESI" or CPT_Name_5= "CAUDAL ESI" or
CPT_Name_6= "CAUDAL ESI" then Caudal_ESI=1; else Caudal_ESI=0;
If CPT_Name_1= "CERVICAL ESI" or CPT_Name_2= "CERVICAL ESI" or
CPT_Name_3= "CERVICAL ESI" or CPT_Name_4= "CERVICAL ESI" or CPT_Name_5=
"CERVICAL ESI" or CPT_Name_6= "CERVICAL ESI" then CERVICAL_ESI=1; else
CERVICAL_ESI=0;
If CPT_Name_1= "CERVICAL ESI/MULTIPLE TPI" or CPT_Name_2= "CERVICAL
ESI/MULTIPLE TPI" or CPT_Name_3= "CERVICAL ESI/MULTIPLE TPI" or
CPT_Name_4= "CERVICAL ESI/MULTIPLE TPI" or CPT_Name_5= "CERVICAL
ESI/MULTIPLE TPI" or CPT_Name_6= "CERVICAL ESI/MULTIPLE TPI" then
CERVICAL_ESI_MultTPI=1; else CERVICAL_ESI_MultTPI=0;
If CPT_Name_1= "GENICULAR NERVE BLOCK" or CPT_Name_2= "GENICULAR NERVE
BLOCK" or CPT_Name_3= "GENICULAR NERVE BLOCK" or CPT_Name_4= "GENICULAR
NERVE BLOCK" or CPT_Name_5= "GENICULAR NERVE BLOCK" or CPT_Name_6=
"GENICULAR NERVE BLOCK" then GENICULAR_NERVE_BLOCK=1; else
GENICULAR_NERVE_BLOCK=0;
If CPT_Name_1= "INTRA ARTICULAR HIP INJECTION" or CPT_Name_2= "INTRA
ARTICULAR HIP INJECTION" or CPT_Name_3= "INTRA ARTICULAR HIP INJECTION"
or CPT_Name_4= "INTRA ARTICULAR HIP INJECTION" or CPT_Name_5= "INTRA
ARTICULAR HIP INJECTION" or CPT_Name_6= "INTRA ARTICULAR HIP INJECTION"
then Intrarticular_Hip_Inj=1; else Intrarticular_Hip_Inj=0;
If CPT_Name_1= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_2= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_3= "INTRA ARTICULAR SIJ INJECTION"
or CPT_Name_4= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_5= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_6= "INTRA ARTICULAR SIJ INJECTION"
then Intrarticular_sij_Inj=1; else Intrarticular_sij_Inj=0;
If CPT_Name_1= "KNEE INJECTION" or CPT_Name_2= "KNEE INJECTION" or
CPT_Name_3= "KNEE INJECTION" or CPT_Name_4= "KNEE INJECTION" or
CPT_Name_5= "KNEE INJECTION" or CPT_Name_6= "KNEE INJECTION" then
knee_inj=1; else knee_inj=0;
If CPT_Name_1= "LATERAL FEMORAL CUTANEOUS NERVE BLOCK" or CPT_Name_2=
"LATERAL FEMORAL CUTANEOUS NERVE BLOCK" or CPT_Name_3= "LATERAL FEMORAL
CUTANEOUS NERVE BLOCK" or CPT_Name_4= "LATERAL FEMORAL CUTANEOUS NERVE
BLOCK" or CPT_Name_5= "LATERAL FEMORAL CUTANEOUS NERVE BLOCK" or
CPT_Name_6= "LATERAL FEMORAL CUTANEOUS NERVE BLOCK" then
lat_femoral_CNB=1; else lat_femoral_CNB=0;
If CPT_Name_1= "LESI" or CPT_Name_2= "LESI" or CPT_Name_3= "LESI" or
CPT_Name_4= "LESI" or CPT_Name_5= "LESI" or CPT_Name_6= "LESI" then
LESI=1; else LESI=0;
If CPT_Name_1= "LUMBAR/SACRAL MB RF" or CPT_Name_2= "LUMBAR/SACRAL MB
RF" or CPT_Name_3= "LUMBAR/SACRAL MB RF" or CPT_Name_4= "LUMBAR/SACRAL
MB RF" or CPT_Name_5= "LUMBAR/SACRAL MB RF" or CPT_Name_6=
"LUMBAR/SACRAL MB RF" then Lumb_Sac_MBRF=1; else Lumb_Sac_MBRF=0;
If CPT_Name_1= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_2= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_3= "SPINAL CORD STIMULATION TRIAL"
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or CPT_Name_4= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_5= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_6= "SPINAL CORD STIMULATION TRIAL"
then Stim_trial=1; else Stim_trial=0;
If CPT_Name_1= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_2= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_3= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_4= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_5= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_6= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" then
Stim_implant=1; else Stim_implant=0;
If CPT_Name_1= "PIRIFORMIS MUSCLE INJECTION" or CPT_Name_2= "PIRIFORMIS
MUSCLE INJECTION" or CPT_Name_3= "PIRIFORMIS MUSCLE INJECTION" or
CPT_Name_4= "PIRIFORMIS MUSCLE INJECTION" or CPT_Name_5= "PIRIFORMIS
MUSCLE INJECTION" or CPT_Name_6= "PIRIFORMIS MUSCLE INJECTION" then
piriformis_inj=1; else piriformis_inj=0;
If CPT_Name_1= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_2= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_3= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_4= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_5= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_6= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" then
Ilio_nerv_blk=1; else Ilio_nerv_blk=0;
If CPT_Name_1= "SACROCOCCYGEAL JOINT INJECTION" or CPT_Name_2=
"SACROCOCCYGEAL JOINT INJECTION" or CPT_Name_3= "SACROCOCCYGEAL JOINT
INJECTION" or CPT_Name_4= "SACROCOCCYGEAL JOINT INJECTION" or
CPT_Name_5= "SACROCOCCYGEAL JOINT INJECTION" or CPT_Name_6=
"SACROCOCCYGEAL JOINT INJECTION" then Sacrococc_Inj=1; else
Sacrococc_Inj=0;
If CPT_Name_1= "TPI" or CPT_Name_2= "TPI" or CPT_Name_3= "TPI" or
CPT_Name_4= "TPI" or CPT_Name_5= "TPI" or CPT_Name_6= "TPI" then TPI=1;
else TPI=0;
If CPT_Name_1= "TROCHANTERIC BURSA INJECTION" or CPT_Name_2=
"TROCHANTERIC BURSA INJECTION" or CPT_Name_3= "TROCHANTERIC BURSA
INJECTION" or CPT_Name_4= "TROCHANTERIC BURSA INJECTION" or CPT_Name_5=
"TROCHANTERIC BURSA INJECTION" or CPT_Name_6= "TROCHANTERIC BURSA
INJECTION" then Troch_Bursa_inj=1; else Troch_Bursa_inj=0;
If CPT_Name_1= "RIGHT SHOULDER INJECTION" or CPT_Name_2= "RIGHT
SHOULDER INJECTION" or CPT_Name_3= "RIGHT SHOULDER INJECTION" or
CPT_Name_4= "RIGHT SHOULDER INJECTION" or CPT_Name_5= "RIGHT SHOULDER
INJECTION" or CPT_Name_6= "RIGHT SHOULDER INJECTION" then
Shoulder_inj=1; else Shoulder_inj=0;
If CPT_Name_1= "TFESI" or CPT_Name_2= "TFESI" or CPT_Name_3= "TFESI" or
CPT_Name_4= "TFESI" or CPT_Name_5= "TFESI" or CPT_Name_6= "TFESI" then
TFESI=1; else TFESI=0;
If CPT_Name_1= "SUPEROLATERAL GENICULAR NEUROTOMY" or CPT_Name_2=
"SUPEROLATERAL GENICULAR NEUROTOMY" or CPT_Name_3= "SUPEROLATERAL
GENICULAR NEUROTOMY" or CPT_Name_4= "SUPEROLATERAL GENICULAR NEUROTOMY"
or CPT_Name_5= "SUPEROLATERAL GENICULAR NEUROTOMY" or CPT_Name_6=
"SUPEROLATERAL GENICULAR NEUROTOMY" then Genicular_neurotomy=1; else
Genicular_neurotomy=0;
If CPT_Name_1= "RIGHT SAPHENOUS NERVE BLOCK" or CPT_Name_2= "RIGHT
SAPHENOUS NERVE BLOCK" or CPT_Name_3= "RIGHT SAPHENOUS NERVE BLOCK" or
CPT_Name_4= "RIGHT SAPHENOUS NERVE BLOCK" or CPT_Name_5= "RIGHT
SAPHENOUS NERVE BLOCK" or CPT_Name_6= "RIGHT SAPHENOUS NERVE BLOCK"
then Saphenous_Nerv_blk=1; else Saphenous_Nerv_blk=0;
If CPT_Name_1= "RIGHT SUPRASCAPULAR NERVE BLOCK" or CPT_Name_2= "RIGHT
SUPRASCAPULAR NERVE BLOCK" or CPT_Name_3= "RIGHT SUPRASCAPULAR NERVE
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BLOCK" or CPT_Name_4= "RIGHT SUPRASCAPULAR NERVE BLOCK" or CPT_Name_5=
"RIGHT SUPRASCAPULAR NERVE BLOCK" or CPT_Name_6= "RIGHT SUPRASCAPULAR
NERVE BLOCK" then Suprascapular_nerv_blk=1; else
Suprascapular_nerv_blk=0;
If CPT_Name_1= "SIJ RF" or CPT_Name_2= "SIJ RF" or CPT_Name_3= "SIJ RF"
or CPT_Name_4= "SIJ RF" or CPT_Name_5= "SIJ RF" or CPT_Name_6= "SIJ RF"
then SIJ_RF=1; else SIJ_RF=0;
run;
/*Freq of procedures*/
proc freq data=Bloodthinner_proc;
tables Caudal_ESI CERVICAL_ESI CERVICAL_ESI_MultTPI
GENICULAR_NERVE_BLOCK Intrarticular_Hip_Inj Intrarticular_sij_Inj
knee_inj lat_femoral_CNB LESI Lumb_Sac_MBRF Stim_trial Stim_implant
piriformis_inj Ilio_nerv_blk Sacrococc_Inj TPI Troch_Bursa_inj TFESI
Shoulder_inj Genicular_neurotomy Saphenous_Nerv_blk
Suprascapular_nerv_blk SIJ_RF;
run;
/*Office visits - blood thinners*/
proc sort data=blood_thinner out=sorted_blood_thinner;
by Patient_ID;
run;
data Num_office_bloodthin;
set sorted_blood_thinner;
by Patient_ID;
if first.Patient_ID;
Num_Officevisits=0;
if First_OfficeVisit ne . then do;
Num_Officevisits=1;
if Second_OfficeVisit ne . then Num_Officevisits+1;
if Third_OfficeVisit ne . then Num_Officevisits+1;
if Fourth_OfficeVisit ne . then Num_Officevisits+1;
if Fifth_OfficeVisit ne . then Num_Officevisits+1;
if sixth_OfficeVisit ne . then Num_Officevisits+1;
if seventh_OfficeVisit ne . then Num_Officevisits+1;
if eighth_OfficeVisit ne . then Num_Officevisits+1;
if ninth_OfficeVisit ne . then Num_Officevisits+1;
if tenth_OfficeVisit ne . then Num_Officevisits+1;
if eleventh_OfficeVisit ne . then Num_Officevisits+1;
if twelve_OfficeVisit ne . then Num_Officevisits+1;
if thirteen_OfficeVisit ne . then Num_Officevisits+1;
if fourteen_OfficeVisit ne . then Num_Officevisits+1;
if fifteen_OfficeVisit ne . then Num_Officevisits+1;
if sixteen_OfficeVisit ne . then Num_Officevisits+1;
if seventeen_OfficeVisit ne . then Num_Officevisits+1;
if eighteen_OfficeVisit ne . then Num_Officevisits+1;
if nineteen_OfficeVisit ne . then Num_Officevisits+1;
if twenty_OfficeVisit ne . then Num_Officevisits+1;
if twentyone_OfficeVisit ne . then Num_Officevisits+1;
if twentytwo_OfficeVisit ne . then Num_Officevisits+1;
if twentythree_OfficeVisit ne . then Num_Officevisits+1;
if twentyfour_OfficeVisit ne . then Num_Officevisits+1;
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if twentyfive_OfficeVisit ne . then Num_Officevisits+1;
end;
else do;
Num_Officevisits=0;
end;
run;
/*Mean median office visit - blood thinner*/
proc univariate data=Num_office_bloodthin;
var Num_Officevisits;
run;
/*Descriptive characteristics - herbal meds under current meds*/
data herbal_meds;/*45 PATIENTS*/
set Finalcohort;
Current_meds_1=upcase(Current_meds_1);
Current_meds_2=upcase(Current_meds_2);
Current_meds_3=upcase(Current_meds_3);
Current_meds_4=upcase(Current_meds_4);
Current_meds_5=upcase(Current_meds_5);
Current_meds_6=upcase(Current_meds_6);Current_meds_7=upcase(Current_med
s_7);Current_meds_8=upcase(Current_meds_8);Current_meds_9=upcase(Curren
t_meds_9);Current_meds_10=upcase(Current_meds_10);Current_meds_11=upcas
e(Current_meds_11);
Current_meds_12=upcase(Current_meds_12);Current_meds_13=upcase(Current_
meds_13);Current_meds_14=upcase(Current_meds_14);Current_meds_15=upcase
(Current_meds_15);Current_meds_16=upcase(Current_meds_16);Current_meds_
17=upcase(Current_meds_17);Current_meds_18=upcase(Current_meds_18);Curr
ent_meds_19=upcase(Current_meds_19);Current_meds_20=upcase(Current_meds
_20);Current_meds_21=upcase(Current_meds_21);Current_meds_22=upcase(Cur
rent_meds_22);
Current_meds_23=upcase(Current_meds_23);
Current_meds_24=upcase(Current_meds_24);
Current_meds_25=upcase(Current_meds_25);
Current_meds_26=upcase(Current_meds_26);
Current_meds_27=upcase(Current_meds_27);
Current_meds_28=upcase(Current_meds_28);
Current_meds_29=upcase(Current_meds_29);
Current_meds_30=upcase(Current_meds_30);
Current_meds_31=upcase(Current_meds_31);
Current_meds_32=upcase(Current_meds_32);
%let herbal_meds= "GINGER ROOT" "GINKGO BILOBA" "GARLIC-PARSLEY" "GREEN
TEA EXTRACT" "GARLIC OIL" "KOREAN GINSENG" "GREEN TEA" ;
if Current_meds_1 in (&herbal_meds) or Current_meds_2 in
(&herbal_meds)or Current_meds_3 in (&herbal_meds) or Current_meds_4 in
(&herbal_meds) or Current_meds_5 in (&herbal_meds) or Current_meds_6 in
(&herbal_meds)or Current_meds_7 in (&herbal_meds) or Current_meds_8 in
(&herbal_meds) or Current_meds_9 in (&herbal_meds) or Current_meds_10
in (&herbal_meds)or Current_meds_11 in (&herbal_meds) or
Current_meds_12 in (&herbal_meds) or Current_meds_13 in (&herbal_meds)
or Current_meds_14 in (&herbal_meds) or Current_meds_15 in
(&herbal_meds)
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or Current_meds_16 in (&herbal_meds) or Current_meds_17 in
(&herbal_meds) or Current_meds_18 in (&herbal_meds) or Current_meds_19
in (&herbal_meds) or Current_meds_20 in (&herbal_meds) or
Current_meds_21 in (&herbal_meds) or Current_meds_22 in (&herbal_meds)
or Current_meds_23 in (&herbal_meds)or Current_meds_24 in
(&herbal_meds)or Current_meds_25 in (&herbal_meds) or Current_meds_26
in (&herbal_meds) or Current_meds_27 in (&herbal_meds) or
Current_meds_28 in (&herbal_meds) or Current_meds_29 in (&herbal_meds)
or Current_meds_30 in (&herbal_meds) or Current_meds_31 in
(&herbal_meds) or Current_meds_32 in (&herbal_meds) then herbal_meds=1;
else herbal_meds=0;
if herbal_meds=1;
run;
/*Freq for herbal meds*/
proc freq data=herbal_meds order=freq;
tables race ethnicity sex smoking alcohol drug_use ;
run;
proc univariate data=herbal_meds;
var Disease_Duration__months_1 Age;
run;
/*Types of procedures performed - herbal meds cohort*/
data herbal_meds_proc;
set herbal_meds;
CPT_Name_1=upcase(CPT_Name_1); CPT_Name_2=upcase(CPT_Name_2);
CPT_Name_3=upcase(CPT_Name_3);
CPT_Name_4=upcase(CPT_Name_4);CPT_Name_5=upcase(CPT_Name_5);CPT_Name_6=
upcase(CPT_Name_6);
If CPT_Name_1= "CAUDAL ESI" or CPT_Name_2= "CAUDAL ESI" or CPT_Name_3=
"CAUDAL ESI" or CPT_Name_4= "CAUDAL ESI" or CPT_Name_5= "CAUDAL ESI" or
CPT_Name_6= "CAUDAL ESI" then Caudal_ESI=1; else Caudal_ESI=0;
If CPT_Name_1= "CERVICAL ESI" or CPT_Name_2= "CERVICAL ESI" or
CPT_Name_3= "CERVICAL ESI" or CPT_Name_4= "CERVICAL ESI" or CPT_Name_5=
"CERVICAL ESI" or CPT_Name_6= "CERVICAL ESI" then CERVICAL_ESI=1; else
CERVICAL_ESI=0;
If CPT_Name_1= "CERVICAL ESI/MULTIPLE TPI" or CPT_Name_2= "CERVICAL
ESI/MULTIPLE TPI" or CPT_Name_3= "CERVICAL ESI/MULTIPLE TPI" or
CPT_Name_4= "CERVICAL ESI/MULTIPLE TPI" or CPT_Name_5= "CERVICAL
ESI/MULTIPLE TPI" or CPT_Name_6= "CERVICAL ESI/MULTIPLE TPI" then
CERVICAL_ESI_MultTPI=1; else CERVICAL_ESI_MultTPI=0;
If CPT_Name_1= "GENICULAR NERVE BLOCK" or CPT_Name_2= "GENICULAR NERVE
BLOCK" or CPT_Name_3= "GENICULAR NERVE BLOCK" or CPT_Name_4= "GENICULAR
NERVE BLOCK" or CPT_Name_5= "GENICULAR NERVE BLOCK" or CPT_Name_6=
"GENICULAR NERVE BLOCK" then GENICULAR_NERVE_BLOCK=1; else
GENICULAR_NERVE_BLOCK=0;
If CPT_Name_1= "INTRA ARTICULAR HIP INJECTION" or CPT_Name_2= "INTRA
ARTICULAR HIP INJECTION" or CPT_Name_3= "INTRA ARTICULAR HIP INJECTION"
or CPT_Name_4= "INTRA ARTICULAR HIP INJECTION" or CPT_Name_5= "INTRA
ARTICULAR HIP INJECTION" or CPT_Name_6= "INTRA ARTICULAR HIP INJECTION"
then Intrarticular_Hip_Inj=1; else Intrarticular_Hip_Inj=0;
If CPT_Name_1= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_2= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_3= "INTRA ARTICULAR SIJ INJECTION"
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or CPT_Name_4= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_5= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_6= "INTRA ARTICULAR SIJ INJECTION"
then Intrarticular_sij_Inj=1; else Intrarticular_sij_Inj=0;
If CPT_Name_1= "KNEE INJECTION" or CPT_Name_2= "KNEE INJECTION" or
CPT_Name_3= "KNEE INJECTION" or CPT_Name_4= "KNEE INJECTION" or
CPT_Name_5= "KNEE INJECTION" or CPT_Name_6= "KNEE INJECTION" then
knee_inj=1; else knee_inj=0;
If CPT_Name_1= "LATERAL FEMORAL CUTANEOUS NERVE BLOCK" or CPT_Name_2=
"LATERAL FEMORAL CUTANEOUS NERVE BLOCK" or CPT_Name_3= "LATERAL FEMORAL
CUTANEOUS NERVE BLOCK" or CPT_Name_4= "LATERAL FEMORAL CUTANEOUS NERVE
BLOCK" or CPT_Name_5= "LATERAL FEMORAL CUTANEOUS NERVE BLOCK" or
CPT_Name_6= "LATERAL FEMORAL CUTANEOUS NERVE BLOCK" then
lat_femoral_CNB=1; else lat_femoral_CNB=0;
If CPT_Name_1= "LESI" or CPT_Name_2= "LESI" or CPT_Name_3= "LESI" or
CPT_Name_4= "LESI" or CPT_Name_5= "LESI" or CPT_Name_6= "LESI" then
LESI=1; else LESI=0;
If CPT_Name_1= "LUMBAR/SACRAL MB RF" or CPT_Name_2= "LUMBAR/SACRAL MB
RF" or CPT_Name_3= "LUMBAR/SACRAL MB RF" or CPT_Name_4= "LUMBAR/SACRAL
MB RF" or CPT_Name_5= "LUMBAR/SACRAL MB RF" or CPT_Name_6=
"LUMBAR/SACRAL MB RF" then Lumb_Sac_MBRF=1; else Lumb_Sac_MBRF=0;
If CPT_Name_1= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_2= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_3= "SPINAL CORD STIMULATION TRIAL"
or CPT_Name_4= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_5= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_6= "SPINAL CORD STIMULATION TRIAL"
then Stim_trial=1; else Stim_trial=0;
If CPT_Name_1= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_2= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_3= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_4= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_5= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_6= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" then
Stim_implant=1; else Stim_implant=0;
If CPT_Name_1= "PIRIFORMIS MUSCLE INJECTION" or CPT_Name_2= "PIRIFORMIS
MUSCLE INJECTION" or CPT_Name_3= "PIRIFORMIS MUSCLE INJECTION" or
CPT_Name_4= "PIRIFORMIS MUSCLE INJECTION" or CPT_Name_5= "PIRIFORMIS
MUSCLE INJECTION" or CPT_Name_6= "PIRIFORMIS MUSCLE INJECTION" then
piriformis_inj=1; else piriformis_inj=0;
If CPT_Name_1= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_2= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_3= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_4= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_5= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_6= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" then
Ilio_nerv_blk=1; else Ilio_nerv_blk=0;
If CPT_Name_1= "SACROCOCCYGEAL JOINT INJECTION" or CPT_Name_2=
"SACROCOCCYGEAL JOINT INJECTION" or CPT_Name_3= "SACROCOCCYGEAL JOINT
INJECTION" or CPT_Name_4= "SACROCOCCYGEAL JOINT INJECTION" or
CPT_Name_5= "SACROCOCCYGEAL JOINT INJECTION" or CPT_Name_6=
"SACROCOCCYGEAL JOINT INJECTION" then Sacrococc_Inj=1; else
Sacrococc_Inj=0;
If CPT_Name_1= "TPI" or CPT_Name_2= "TPI" or CPT_Name_3= "TPI" or
CPT_Name_4= "TPI" or CPT_Name_5= "TPI" or CPT_Name_6= "TPI" then TPI=1;
else TPI=0;
If CPT_Name_1= "TROCHANTERIC BURSA INJECTION" or CPT_Name_2=
"TROCHANTERIC BURSA INJECTION" or CPT_Name_3= "TROCHANTERIC BURSA
INJECTION" or CPT_Name_4= "TROCHANTERIC BURSA INJECTION" or CPT_Name_5=
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"TROCHANTERIC BURSA INJECTION" or CPT_Name_6= "TROCHANTERIC BURSA
INJECTION" then Troch_Bursa_inj=1; else Troch_Bursa_inj=0;
If CPT_Name_1= "RIGHT SHOULDER INJECTION" or CPT_Name_2= "RIGHT
SHOULDER INJECTION" or CPT_Name_3= "RIGHT SHOULDER INJECTION" or
CPT_Name_4= "RIGHT SHOULDER INJECTION" or CPT_Name_5= "RIGHT SHOULDER
INJECTION" or CPT_Name_6= "RIGHT SHOULDER INJECTION" then
Shoulder_inj=1; else Shoulder_inj=0;
If CPT_Name_1= "TFESI" or CPT_Name_2= "TFESI" or CPT_Name_3= "TFESI" or
CPT_Name_4= "TFESI" or CPT_Name_5= "TFESI" or CPT_Name_6= "TFESI" then
TFESI=1; else TFESI=0;
If CPT_Name_1= "SUPEROLATERAL GENICULAR NEUROTOMY" or CPT_Name_2=
"SUPEROLATERAL GENICULAR NEUROTOMY" or CPT_Name_3= "SUPEROLATERAL
GENICULAR NEUROTOMY" or CPT_Name_4= "SUPEROLATERAL GENICULAR NEUROTOMY"
or CPT_Name_5= "SUPEROLATERAL GENICULAR NEUROTOMY" or CPT_Name_6=
"SUPEROLATERAL GENICULAR NEUROTOMY" then Genicular_neurotomy=1; else
Genicular_neurotomy=0;
If CPT_Name_1= "RIGHT SAPHENOUS NERVE BLOCK" or CPT_Name_2= "RIGHT
SAPHENOUS NERVE BLOCK" or CPT_Name_3= "RIGHT SAPHENOUS NERVE BLOCK" or
CPT_Name_4= "RIGHT SAPHENOUS NERVE BLOCK" or CPT_Name_5= "RIGHT
SAPHENOUS NERVE BLOCK" or CPT_Name_6= "RIGHT SAPHENOUS NERVE BLOCK"
then Saphenous_Nerv_blk=1; else Saphenous_Nerv_blk=0;
If CPT_Name_1= "RIGHT SUPRASCAPULAR NERVE BLOCK" or CPT_Name_2= "RIGHT
SUPRASCAPULAR NERVE BLOCK" or CPT_Name_3= "RIGHT SUPRASCAPULAR NERVE
BLOCK" or CPT_Name_4= "RIGHT SUPRASCAPULAR NERVE BLOCK" or CPT_Name_5=
"RIGHT SUPRASCAPULAR NERVE BLOCK" or CPT_Name_6= "RIGHT SUPRASCAPULAR
NERVE BLOCK" then Suprascapular_nerv_blk=1; else
Suprascapular_nerv_blk=0;
If CPT_Name_1= "SIJ RF" or CPT_Name_2= "SIJ RF" or CPT_Name_3= "SIJ RF"
or CPT_Name_4= "SIJ RF" or CPT_Name_5= "SIJ RF" or CPT_Name_6= "SIJ RF"
then SIJ_RF=1; else SIJ_RF=0;
run;
/*Freq - procedures*/
proc freq data=herbal_meds_proc;
tables Caudal_ESI CERVICAL_ESI CERVICAL_ESI_MultTPI
GENICULAR_NERVE_BLOCK Intrarticular_Hip_Inj Intrarticular_sij_Inj
knee_inj lat_femoral_CNB LESI Lumb_Sac_MBRF Stim_trial Stim_implant
piriformis_inj Ilio_nerv_blk Sacrococc_Inj TPI Troch_Bursa_inj TFESI
Shoulder_inj Genicular_neurotomy Saphenous_Nerv_blk
Suprascapular_nerv_blk SIJ_RF;
run;
/*Office visits -herbal meds*/
proc sort data=herbal_meds out=sorted_herbal_meds;
by Patient_ID;
run;
data Num_office_herbalmed;
set sorted_herbal_meds;
by Patient_ID;
if first.Patient_ID;
Num_Officevisits=0;
if First_OfficeVisit ne . then do;
Num_Officevisits=1;
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if Second_OfficeVisit ne . then Num_Officevisits+1;
if Third_OfficeVisit ne . then Num_Officevisits+1;
if Fourth_OfficeVisit ne . then Num_Officevisits+1;
if Fifth_OfficeVisit ne . then Num_Officevisits+1;
if sixth_OfficeVisit ne . then Num_Officevisits+1;
if seventh_OfficeVisit ne . then Num_Officevisits+1;
if eighth_OfficeVisit ne . then Num_Officevisits+1;
if ninth_OfficeVisit ne . then Num_Officevisits+1;
if tenth_OfficeVisit ne . then Num_Officevisits+1;
if eleventh_OfficeVisit ne . then Num_Officevisits+1;
if twelve_OfficeVisit ne . then Num_Officevisits+1;
if thirteen_OfficeVisit ne . then Num_Officevisits+1;
if fourteen_OfficeVisit ne . then Num_Officevisits+1;
if fifteen_OfficeVisit ne . then Num_Officevisits+1;
if sixteen_OfficeVisit ne . then Num_Officevisits+1;
if seventeen_OfficeVisit ne . then Num_Officevisits+1;
if eighteen_OfficeVisit ne . then Num_Officevisits+1;
if nineteen_OfficeVisit ne . then Num_Officevisits+1;
if twenty_OfficeVisit ne . then Num_Officevisits+1;
if twentyone_OfficeVisit ne . then Num_Officevisits+1;
if twentytwo_OfficeVisit ne . then Num_Officevisits+1;
if twentythree_OfficeVisit ne . then Num_Officevisits+1;
if twentyfour_OfficeVisit ne . then Num_Officevisits+1;
if twentyfive_OfficeVisit ne . then Num_Officevisits+1;
end;
else do;
Num_Officevisits=0;
end;
run;
/*Mean median office visit -herbal*/
proc univariate data=Num_office_herbalmed ;
var Num_Officevisits;
run;

/*Descriptive characteristics - benzodiazepines under current meds*/
data benzo;/*67 PATIENTS*/
set Finalcohort;
Current_meds_1=upcase(Current_meds_1);
Current_meds_2=upcase(Current_meds_2);
Current_meds_3=upcase(Current_meds_3);
Current_meds_4=upcase(Current_meds_4);
Current_meds_5=upcase(Current_meds_5);
Current_meds_6=upcase(Current_meds_6);Current_meds_7=upcase(Current_med
s_7);Current_meds_8=upcase(Current_meds_8);Current_meds_9=upcase(Curren
t_meds_9);Current_meds_10=upcase(Current_meds_10);Current_meds_11=upcas
e(Current_meds_11);
Current_meds_12=upcase(Current_meds_12);Current_meds_13=upcase(Current_
meds_13);Current_meds_14=upcase(Current_meds_14);Current_meds_15=upcase
(Current_meds_15);Current_meds_16=upcase(Current_meds_16);Current_meds_
17=upcase(Current_meds_17);Current_meds_18=upcase(Current_meds_18);Curr
ent_meds_19=upcase(Current_meds_19);Current_meds_20=upcase(Current_meds
_20);Current_meds_21=upcase(Current_meds_21);Current_meds_22=upcase(Cur
rent_meds_22);
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Current_meds_23=upcase(Current_meds_23);
Current_meds_24=upcase(Current_meds_24);
Current_meds_25=upcase(Current_meds_25);
Current_meds_26=upcase(Current_meds_26);
Current_meds_27=upcase(Current_meds_27);
Current_meds_28=upcase(Current_meds_28);
Current_meds_29=upcase(Current_meds_29);
Current_meds_30=upcase(Current_meds_30);
Current_meds_31=upcase(Current_meds_31);
Current_meds_32=upcase(Current_meds_32);
%let benzo="ALPRAZOLAM" "LORAZEPAM" "CLONAZEPAM" "VALIUM" "ATIVAN"
"DIAZEPAM" "TEMAZEPAM" "XANAX" "KLONOPIN";
if Current_meds_1 in (&benzo) or Current_meds_2 in (&benzo) or
Current_meds_3 in (&benzo) or Current_meds_4 in (&benzo) or
Current_meds_5 in (&benzo) or Current_meds_6 in (&benzo)or
Current_meds_7 in (&benzo) or Current_meds_8 in (&benzo) or
Current_meds_9 in (&benzo) or Current_meds_10 in (&benzo)or
Current_meds_11 in (&benzo) or Current_meds_12 in (&benzo) or
Current_meds_13 in (&benzo) or Current_meds_14 in (&benzo) or
Current_meds_15 in (&benzo)
or Current_meds_16 in (&benzo) or Current_meds_17 in (&benzo) or
Current_meds_18 in (&benzo) or Current_meds_19 in (&benzo) or
Current_meds_20 in (&benzo) or Current_meds_21 in (&benzo) or
Current_meds_22 in (&benzo) or Current_meds_23 in (&benzo) or
Current_meds_24 in (&benzo)or Current_meds_25 in (&benzo) or
Current_meds_26 in (&benzo) or Current_meds_27 in (&benzo) or
Current_meds_28 in (&benzo) or Current_meds_29 in (&benzo)
or Current_meds_30 in (&benzo) or Current_meds_31 in (&benzo) or
Current_meds_32 in (&benzo) then benzo=1; else benzo=0;
if benzo=1;
run;
/*Demographics and clinical for benzo meds*/
proc freq data=benzo order=freq;
tables race ethnicity sex smoking alcohol drug_use ;
run;
proc univariate data=benzo ;
var Disease_Duration__months_1 Age;
run;
/*Types of procedures performed - benzo cohort*/
data benzo_proc;
set benzo;
CPT_Name_1=upcase(CPT_Name_1); CPT_Name_2=upcase(CPT_Name_2);
CPT_Name_3=upcase(CPT_Name_3);
CPT_Name_4=upcase(CPT_Name_4);CPT_Name_5=upcase(CPT_Name_5);CPT_Name_6=
upcase(CPT_Name_6);
If CPT_Name_1= "CAUDAL ESI" or CPT_Name_2= "CAUDAL ESI" or CPT_Name_3=
"CAUDAL ESI" or CPT_Name_4= "CAUDAL ESI" or CPT_Name_5= "CAUDAL ESI" or
CPT_Name_6= "CAUDAL ESI" then Caudal_ESI=1; else Caudal_ESI=0;
If CPT_Name_1= "CERVICAL ESI" or CPT_Name_2= "CERVICAL ESI" or
CPT_Name_3= "CERVICAL ESI" or CPT_Name_4= "CERVICAL ESI" or CPT_Name_5=
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"CERVICAL ESI" or CPT_Name_6= "CERVICAL ESI" then CERVICAL_ESI=1; else
CERVICAL_ESI=0;
If CPT_Name_1= "CERVICAL ESI/MULTIPLE TPI" or CPT_Name_2= "CERVICAL
ESI/MULTIPLE TPI" or CPT_Name_3= "CERVICAL ESI/MULTIPLE TPI" or
CPT_Name_4= "CERVICAL ESI/MULTIPLE TPI" or CPT_Name_5= "CERVICAL
ESI/MULTIPLE TPI" or CPT_Name_6= "CERVICAL ESI/MULTIPLE TPI" then
CERVICAL_ESI_MultTPI=1; else CERVICAL_ESI_MultTPI=0;
If CPT_Name_1= "GENICULAR NERVE BLOCK" or CPT_Name_2= "GENICULAR NERVE
BLOCK" or CPT_Name_3= "GENICULAR NERVE BLOCK" or CPT_Name_4= "GENICULAR
NERVE BLOCK" or CPT_Name_5= "GENICULAR NERVE BLOCK" or CPT_Name_6=
"GENICULAR NERVE BLOCK" then GENICULAR_NERVE_BLOCK=1; else
GENICULAR_NERVE_BLOCK=0;
If CPT_Name_1= "INTRA ARTICULAR HIP INJECTION" or CPT_Name_2= "INTRA
ARTICULAR HIP INJECTION" or CPT_Name_3= "INTRA ARTICULAR HIP INJECTION"
or CPT_Name_4= "INTRA ARTICULAR HIP INJECTION" or CPT_Name_5= "INTRA
ARTICULAR HIP INJECTION" or CPT_Name_6= "INTRA ARTICULAR HIP INJECTION"
then Intrarticular_Hip_Inj=1; else Intrarticular_Hip_Inj=0;
If CPT_Name_1= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_2= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_3= "INTRA ARTICULAR SIJ INJECTION"
or CPT_Name_4= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_5= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_6= "INTRA ARTICULAR SIJ INJECTION"
then Intrarticular_sij_Inj=1; else Intrarticular_sij_Inj=0;
If CPT_Name_1= "KNEE INJECTION" or CPT_Name_2= "KNEE INJECTION" or
CPT_Name_3= "KNEE INJECTION" or CPT_Name_4= "KNEE INJECTION" or
CPT_Name_5= "KNEE INJECTION" or CPT_Name_6= "KNEE INJECTION" then
knee_inj=1; else knee_inj=0;
If CPT_Name_1= "LATERAL FEMORAL CUTANEOUS NERVE BLOCK" or CPT_Name_2=
"LATERAL FEMORAL CUTANEOUS NERVE BLOCK" or CPT_Name_3= "LATERAL FEMORAL
CUTANEOUS NERVE BLOCK" or CPT_Name_4= "LATERAL FEMORAL CUTANEOUS NERVE
BLOCK" or CPT_Name_5= "LATERAL FEMORAL CUTANEOUS NERVE BLOCK" or
CPT_Name_6= "LATERAL FEMORAL CUTANEOUS NERVE BLOCK" then
lat_femoral_CNB=1; else lat_femoral_CNB=0;
If CPT_Name_1= "LESI" or CPT_Name_2= "LESI" or CPT_Name_3= "LESI" or
CPT_Name_4= "LESI" or CPT_Name_5= "LESI" or CPT_Name_6= "LESI" then
LESI=1; else LESI=0;
If CPT_Name_1= "LUMBAR/SACRAL MB RF" or CPT_Name_2= "LUMBAR/SACRAL MB
RF" or CPT_Name_3= "LUMBAR/SACRAL MB RF" or CPT_Name_4= "LUMBAR/SACRAL
MB RF" or CPT_Name_5= "LUMBAR/SACRAL MB RF" or CPT_Name_6=
"LUMBAR/SACRAL MB RF" then Lumb_Sac_MBRF=1; else Lumb_Sac_MBRF=0;
If CPT_Name_1= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_2= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_3= "SPINAL CORD STIMULATION TRIAL"
or CPT_Name_4= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_5= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_6= "SPINAL CORD STIMULATION TRIAL"
then Stim_trial=1; else Stim_trial=0;
If CPT_Name_1= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_2= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_3= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_4= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_5= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_6= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" then
Stim_implant=1; else Stim_implant=0;
If CPT_Name_1= "PIRIFORMIS MUSCLE INJECTION" or CPT_Name_2= "PIRIFORMIS
MUSCLE INJECTION" or CPT_Name_3= "PIRIFORMIS MUSCLE INJECTION" or
CPT_Name_4= "PIRIFORMIS MUSCLE INJECTION" or CPT_Name_5= "PIRIFORMIS
MUSCLE INJECTION" or CPT_Name_6= "PIRIFORMIS MUSCLE INJECTION" then
piriformis_inj=1; else piriformis_inj=0;
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If CPT_Name_1= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_2= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_3= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_4= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_5= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_6= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" then
Ilio_nerv_blk=1; else Ilio_nerv_blk=0;
If CPT_Name_1= "SACROCOCCYGEAL JOINT INJECTION" or CPT_Name_2=
"SACROCOCCYGEAL JOINT INJECTION" or CPT_Name_3= "SACROCOCCYGEAL JOINT
INJECTION" or CPT_Name_4= "SACROCOCCYGEAL JOINT INJECTION" or
CPT_Name_5= "SACROCOCCYGEAL JOINT INJECTION" or CPT_Name_6=
"SACROCOCCYGEAL JOINT INJECTION" then Sacrococc_Inj=1; else
Sacrococc_Inj=0;
If CPT_Name_1= "TPI" or CPT_Name_2= "TPI" or CPT_Name_3= "TPI" or
CPT_Name_4= "TPI" or CPT_Name_5= "TPI" or CPT_Name_6= "TPI" then TPI=1;
else TPI=0;
If CPT_Name_1= "TROCHANTERIC BURSA INJECTION" or CPT_Name_2=
"TROCHANTERIC BURSA INJECTION" or CPT_Name_3= "TROCHANTERIC BURSA
INJECTION" or CPT_Name_4= "TROCHANTERIC BURSA INJECTION" or CPT_Name_5=
"TROCHANTERIC BURSA INJECTION" or CPT_Name_6= "TROCHANTERIC BURSA
INJECTION" then Troch_Bursa_inj=1; else Troch_Bursa_inj=0;
If CPT_Name_1= "RIGHT SHOULDER INJECTION" or CPT_Name_2= "RIGHT
SHOULDER INJECTION" or CPT_Name_3= "RIGHT SHOULDER INJECTION" or
CPT_Name_4= "RIGHT SHOULDER INJECTION" or CPT_Name_5= "RIGHT SHOULDER
INJECTION" or CPT_Name_6= "RIGHT SHOULDER INJECTION" then
Shoulder_inj=1; else Shoulder_inj=0;
If CPT_Name_1= "TFESI" or CPT_Name_2= "TFESI" or CPT_Name_3= "TFESI" or
CPT_Name_4= "TFESI" or CPT_Name_5= "TFESI" or CPT_Name_6= "TFESI" then
TFESI=1; else TFESI=0;
If CPT_Name_1= "SUPEROLATERAL GENICULAR NEUROTOMY" or CPT_Name_2=
"SUPEROLATERAL GENICULAR NEUROTOMY" or CPT_Name_3= "SUPEROLATERAL
GENICULAR NEUROTOMY" or CPT_Name_4= "SUPEROLATERAL GENICULAR NEUROTOMY"
or CPT_Name_5= "SUPEROLATERAL GENICULAR NEUROTOMY" or CPT_Name_6=
"SUPEROLATERAL GENICULAR NEUROTOMY" then Genicular_neurotomy=1; else
Genicular_neurotomy=0;
If CPT_Name_1= "RIGHT SAPHENOUS NERVE BLOCK" or CPT_Name_2= "RIGHT
SAPHENOUS NERVE BLOCK" or CPT_Name_3= "RIGHT SAPHENOUS NERVE BLOCK" or
CPT_Name_4= "RIGHT SAPHENOUS NERVE BLOCK" or CPT_Name_5= "RIGHT
SAPHENOUS NERVE BLOCK" or CPT_Name_6= "RIGHT SAPHENOUS NERVE BLOCK"
then Saphenous_Nerv_blk=1; else Saphenous_Nerv_blk=0;
If CPT_Name_1= "RIGHT SUPRASCAPULAR NERVE BLOCK" or CPT_Name_2= "RIGHT
SUPRASCAPULAR NERVE BLOCK" or CPT_Name_3= "RIGHT SUPRASCAPULAR NERVE
BLOCK" or CPT_Name_4= "RIGHT SUPRASCAPULAR NERVE BLOCK" or CPT_Name_5=
"RIGHT SUPRASCAPULAR NERVE BLOCK" or CPT_Name_6= "RIGHT SUPRASCAPULAR
NERVE BLOCK" then Suprascapular_nerv_blk=1; else
Suprascapular_nerv_blk=0;
If CPT_Name_1= "SIJ RF" or CPT_Name_2= "SIJ RF" or CPT_Name_3= "SIJ RF"
or CPT_Name_4= "SIJ RF" or CPT_Name_5= "SIJ RF" or CPT_Name_6= "SIJ RF"
then SIJ_RF=1; else SIJ_RF=0;
run;
/*Freq- proc*/
proc freq data=benzo_proc;
tables Caudal_ESI CERVICAL_ESI CERVICAL_ESI_MultTPI
GENICULAR_NERVE_BLOCK Intrarticular_Hip_Inj Intrarticular_sij_Inj
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knee_inj lat_femoral_CNB LESI Lumb_Sac_MBRF Stim_trial Stim_implant
piriformis_inj Ilio_nerv_blk Sacrococc_Inj TPI Troch_Bursa_inj TFESI
Shoulder_inj Genicular_neurotomy Saphenous_Nerv_blk
Suprascapular_nerv_blk SIJ_RF;
run;
/*Office visits -benzo meds*/
proc sort data=benzo out=sorted_benzo;
by Patient_ID;
run;
data Num_office_benzo;
set sorted_benzo;
by Patient_ID;
if first.Patient_ID;
Num_Officevisits=0;
if First_OfficeVisit ne . then do;
Num_Officevisits=1;
if Second_OfficeVisit ne . then Num_Officevisits+1;
if Third_OfficeVisit ne . then Num_Officevisits+1;
if Fourth_OfficeVisit ne . then Num_Officevisits+1;
if Fifth_OfficeVisit ne . then Num_Officevisits+1;
if sixth_OfficeVisit ne . then Num_Officevisits+1;
if seventh_OfficeVisit ne . then Num_Officevisits+1;
if eighth_OfficeVisit ne . then Num_Officevisits+1;
if ninth_OfficeVisit ne . then Num_Officevisits+1;
if tenth_OfficeVisit ne . then Num_Officevisits+1;
if eleventh_OfficeVisit ne . then Num_Officevisits+1;
if twelve_OfficeVisit ne . then Num_Officevisits+1;
if thirteen_OfficeVisit ne . then Num_Officevisits+1;
if fourteen_OfficeVisit ne . then Num_Officevisits+1;
if fifteen_OfficeVisit ne . then Num_Officevisits+1;
if sixteen_OfficeVisit ne . then Num_Officevisits+1;
if seventeen_OfficeVisit ne . then Num_Officevisits+1;
if eighteen_OfficeVisit ne . then Num_Officevisits+1;
if nineteen_OfficeVisit ne . then Num_Officevisits+1;
if twenty_OfficeVisit ne . then Num_Officevisits+1;
if twentyone_OfficeVisit ne . then Num_Officevisits+1;
if twentytwo_OfficeVisit ne . then Num_Officevisits+1;
if twentythree_OfficeVisit ne . then Num_Officevisits+1;
if twentyfour_OfficeVisit ne . then Num_Officevisits+1;
if twentyfive_OfficeVisit ne . then Num_Officevisits+1;
end;
else do;
Num_Officevisits=0;
end;
run;
/*Mean median office visit -benzo*/
proc univariate data=Num_office_benzo ;
var Num_Officevisits;
run;
/*Descriptive characteristics - opioids under current meds*/
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data opioid;/*121 PATIENTS*/
set Finalcohort;
Current_meds_1=upcase(Current_meds_1);
Current_meds_2=upcase(Current_meds_2);
Current_meds_3=upcase(Current_meds_3);
Current_meds_4=upcase(Current_meds_4);
Current_meds_5=upcase(Current_meds_5);
Current_meds_6=upcase(Current_meds_6);Current_meds_7=upcase(Current_med
s_7);Current_meds_8=upcase(Current_meds_8);Current_meds_9=upcase(Curren
t_meds_9);Current_meds_10=upcase(Current_meds_10);Current_meds_11=upcas
e(Current_meds_11);
Current_meds_12=upcase(Current_meds_12);Current_meds_13=upcase(Current_
meds_13);Current_meds_14=upcase(Current_meds_14);Current_meds_15=upcase
(Current_meds_15);Current_meds_16=upcase(Current_meds_16);Current_meds_
17=upcase(Current_meds_17);Current_meds_18=upcase(Current_meds_18);Curr
ent_meds_19=upcase(Current_meds_19);Current_meds_20=upcase(Current_meds
_20);Current_meds_21=upcase(Current_meds_21);Current_meds_22=upcase(Cur
rent_meds_22);
Current_meds_23=upcase(Current_meds_23);
Current_meds_24=upcase(Current_meds_24);
Current_meds_25=upcase(Current_meds_25);
Current_meds_26=upcase(Current_meds_26);
Current_meds_27=upcase(Current_meds_27);
Current_meds_28=upcase(Current_meds_28);
Current_meds_29=upcase(Current_meds_29);
Current_meds_30=upcase(Current_meds_30);
Current_meds_31=upcase(Current_meds_31);
Current_meds_32=upcase(Current_meds_32);
%let opioid="HYDROCODONE-ACETAMINOPHEN" "OXYCODONE" "OXYCODONEACETAMINOPHEN" "TRAMADOL" "NORCO" "HYDROCODONE-IBUPROFEN" "HCD-APAP"
"OXYMORPHONE" "PERCOCET" "FENTANYL" "VICODIN" "MORPHINE" "XTAMPZA"
"ACETAMINOPHEN-CODEINE" "METHADONE" "ENDOCET";
if Current_meds_1 in (&opioid) or Current_meds_2 in (&opioid)or
Current_meds_3 in (&opioid) or Current_meds_4 in (&opioid) or
Current_meds_5 in (&opioid) or Current_meds_6 in (&opioid)or
Current_meds_7 in (&opioid) or Current_meds_8 in (&opioid) or
Current_meds_9 in (&opioid) or Current_meds_10 in (&opioid)or
Current_meds_11 in (&opioid) or Current_meds_12 in (&opioid) or
Current_meds_13 in (&opioid) or Current_meds_14 in (&opioid) or
Current_meds_15 in (&opioid)
or Current_meds_16 in (&opioid) or Current_meds_17 in (&opioid) or
Current_meds_18 in (&opioid) or Current_meds_19 in (&opioid) or
Current_meds_20 in (&opioid) or Current_meds_21 in (&opioid) or
Current_meds_22 in (&opioid) or Current_meds_23 in (&opioid)or
Current_meds_24 in (&opioid)or Current_meds_25 in (&opioid) or
Current_meds_26 in (&opioid) or Current_meds_27 in (&opioid) or
Current_meds_28 in (&opioid) or Current_meds_29 in (&opioid)
or Current_meds_30 in (&opioid) or Current_meds_31 in (&opioid) or
Current_meds_32 in (&opioid) then opioid=1; else opioid=0;
if opioid=1;
run;
/*Demographics and clinical for opioid meds*/
proc freq data=opioid order=freq;
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tables race ethnicity sex smoking alcohol drug_use ;
run;
proc univariate data=opioid ;
var Disease_Duration__months_1 Age;
run;
/*Types of procedures performed - opioid cohort*/
data opioid_proc;
set opioid;
CPT_Name_1=upcase(CPT_Name_1); CPT_Name_2=upcase(CPT_Name_2);
CPT_Name_3=upcase(CPT_Name_3);
CPT_Name_4=upcase(CPT_Name_4);CPT_Name_5=upcase(CPT_Name_5);CPT_Name_6=
upcase(CPT_Name_6);
If CPT_Name_1= "CAUDAL ESI" or CPT_Name_2= "CAUDAL ESI" or CPT_Name_3=
"CAUDAL ESI" or CPT_Name_4= "CAUDAL ESI" or CPT_Name_5= "CAUDAL ESI" or
CPT_Name_6= "CAUDAL ESI" then Caudal_ESI=1; else Caudal_ESI=0;
If CPT_Name_1= "CERVICAL ESI" or CPT_Name_2= "CERVICAL ESI" or
CPT_Name_3= "CERVICAL ESI" or CPT_Name_4= "CERVICAL ESI" or CPT_Name_5=
"CERVICAL ESI" or CPT_Name_6= "CERVICAL ESI" then CERVICAL_ESI=1; else
CERVICAL_ESI=0;
If CPT_Name_1= "CERVICAL ESI/MULTIPLE TPI" or CPT_Name_2= "CERVICAL
ESI/MULTIPLE TPI" or CPT_Name_3= "CERVICAL ESI/MULTIPLE TPI" or
CPT_Name_4= "CERVICAL ESI/MULTIPLE TPI" or CPT_Name_5= "CERVICAL
ESI/MULTIPLE TPI" or CPT_Name_6= "CERVICAL ESI/MULTIPLE TPI" then
CERVICAL_ESI_MultTPI=1; else CERVICAL_ESI_MultTPI=0;
If CPT_Name_1= "GENICULAR NERVE BLOCK" or CPT_Name_2= "GENICULAR NERVE
BLOCK" or CPT_Name_3= "GENICULAR NERVE BLOCK" or CPT_Name_4= "GENICULAR
NERVE BLOCK" or CPT_Name_5= "GENICULAR NERVE BLOCK" or CPT_Name_6=
"GENICULAR NERVE BLOCK" then GENICULAR_NERVE_BLOCK=1; else
GENICULAR_NERVE_BLOCK=0;
If CPT_Name_1= "INTRA ARTICULAR HIP INJECTION" or CPT_Name_2= "INTRA
ARTICULAR HIP INJECTION" or CPT_Name_3= "INTRA ARTICULAR HIP INJECTION"
or CPT_Name_4= "INTRA ARTICULAR HIP INJECTION" or CPT_Name_5= "INTRA
ARTICULAR HIP INJECTION" or CPT_Name_6= "INTRA ARTICULAR HIP INJECTION"
then Intrarticular_Hip_Inj=1; else Intrarticular_Hip_Inj=0;
If CPT_Name_1= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_2= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_3= "INTRA ARTICULAR SIJ INJECTION"
or CPT_Name_4= "INTRA ARTICULAR SIJ INJECTION" or CPT_Name_5= "INTRA
ARTICULAR SIJ INJECTION" or CPT_Name_6= "INTRA ARTICULAR SIJ INJECTION"
then Intrarticular_sij_Inj=1; else Intrarticular_sij_Inj=0;
If CPT_Name_1= "KNEE INJECTION" or CPT_Name_2= "KNEE INJECTION" or
CPT_Name_3= "KNEE INJECTION" or CPT_Name_4= "KNEE INJECTION" or
CPT_Name_5= "KNEE INJECTION" or CPT_Name_6= "KNEE INJECTION" then
knee_inj=1; else knee_inj=0;
If CPT_Name_1= "LATERAL FEMORAL CUTANEOUS NERVE BLOCK" or CPT_Name_2=
"LATERAL FEMORAL CUTANEOUS NERVE BLOCK" or CPT_Name_3= "LATERAL FEMORAL
CUTANEOUS NERVE BLOCK" or CPT_Name_4= "LATERAL FEMORAL CUTANEOUS NERVE
BLOCK" or CPT_Name_5= "LATERAL FEMORAL CUTANEOUS NERVE BLOCK" or
CPT_Name_6= "LATERAL FEMORAL CUTANEOUS NERVE BLOCK" then
lat_femoral_CNB=1; else lat_femoral_CNB=0;
If CPT_Name_1= "LESI" or CPT_Name_2= "LESI" or CPT_Name_3= "LESI" or
CPT_Name_4= "LESI" or CPT_Name_5= "LESI" or CPT_Name_6= "LESI" then
LESI=1; else LESI=0;
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If CPT_Name_1= "LUMBAR/SACRAL MB RF" or CPT_Name_2= "LUMBAR/SACRAL MB
RF" or CPT_Name_3= "LUMBAR/SACRAL MB RF" or CPT_Name_4= "LUMBAR/SACRAL
MB RF" or CPT_Name_5= "LUMBAR/SACRAL MB RF" or CPT_Name_6=
"LUMBAR/SACRAL MB RF" then Lumb_Sac_MBRF=1; else Lumb_Sac_MBRF=0;
If CPT_Name_1= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_2= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_3= "SPINAL CORD STIMULATION TRIAL"
or CPT_Name_4= "SPINAL CORD STIMULATION TRIAL" or CPT_Name_5= "SPINAL
CORD STIMULATION TRIAL" or CPT_Name_6= "SPINAL CORD STIMULATION TRIAL"
then Stim_trial=1; else Stim_trial=0;
If CPT_Name_1= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_2= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_3= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_4= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_5= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" or
CPT_Name_6= "PERMANENT SPINAL CORD STIMULATION IMPLANTATION" then
Stim_implant=1; else Stim_implant=0;
If CPT_Name_1= "PIRIFORMIS MUSCLE INJECTION" or CPT_Name_2= "PIRIFORMIS
MUSCLE INJECTION" or CPT_Name_3= "PIRIFORMIS MUSCLE INJECTION" or
CPT_Name_4= "PIRIFORMIS MUSCLE INJECTION" or CPT_Name_5= "PIRIFORMIS
MUSCLE INJECTION" or CPT_Name_6= "PIRIFORMIS MUSCLE INJECTION" then
piriformis_inj=1; else piriformis_inj=0;
If CPT_Name_1= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_2= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_3= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_4= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_5= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" or
CPT_Name_6= "RIGHT ILIOLINGUINAL/ILIOHYPOGASTRIC NERVE BLOCK" then
Ilio_nerv_blk=1; else Ilio_nerv_blk=0;
If CPT_Name_1= "SACROCOCCYGEAL JOINT INJECTION" or CPT_Name_2=
"SACROCOCCYGEAL JOINT INJECTION" or CPT_Name_3= "SACROCOCCYGEAL JOINT
INJECTION" or CPT_Name_4= "SACROCOCCYGEAL JOINT INJECTION" or
CPT_Name_5= "SACROCOCCYGEAL JOINT INJECTION" or CPT_Name_6=
"SACROCOCCYGEAL JOINT INJECTION" then Sacrococc_Inj=1; else
Sacrococc_Inj=0;
If CPT_Name_1= "TPI" or CPT_Name_2= "TPI" or CPT_Name_3= "TPI" or
CPT_Name_4= "TPI" or CPT_Name_5= "TPI" or CPT_Name_6= "TPI" then TPI=1;
else TPI=0;
If CPT_Name_1= "TROCHANTERIC BURSA INJECTION" or CPT_Name_2=
"TROCHANTERIC BURSA INJECTION" or CPT_Name_3= "TROCHANTERIC BURSA
INJECTION" or CPT_Name_4= "TROCHANTERIC BURSA INJECTION" or CPT_Name_5=
"TROCHANTERIC BURSA INJECTION" or CPT_Name_6= "TROCHANTERIC BURSA
INJECTION" then Troch_Bursa_inj=1; else Troch_Bursa_inj=0;
If CPT_Name_1= "RIGHT SHOULDER INJECTION" or CPT_Name_2= "RIGHT
SHOULDER INJECTION" or CPT_Name_3= "RIGHT SHOULDER INJECTION" or
CPT_Name_4= "RIGHT SHOULDER INJECTION" or CPT_Name_5= "RIGHT SHOULDER
INJECTION" or CPT_Name_6= "RIGHT SHOULDER INJECTION" then
Shoulder_inj=1; else Shoulder_inj=0;
If CPT_Name_1= "TFESI" or CPT_Name_2= "TFESI" or CPT_Name_3= "TFESI" or
CPT_Name_4= "TFESI" or CPT_Name_5= "TFESI" or CPT_Name_6= "TFESI" then
TFESI=1; else TFESI=0;
If CPT_Name_1= "SUPEROLATERAL GENICULAR NEUROTOMY" or CPT_Name_2=
"SUPEROLATERAL GENICULAR NEUROTOMY" or CPT_Name_3= "SUPEROLATERAL
GENICULAR NEUROTOMY" or CPT_Name_4= "SUPEROLATERAL GENICULAR NEUROTOMY"
or CPT_Name_5= "SUPEROLATERAL GENICULAR NEUROTOMY" or CPT_Name_6=
"SUPEROLATERAL GENICULAR NEUROTOMY" then Genicular_neurotomy=1; else
Genicular_neurotomy=0;
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If CPT_Name_1= "RIGHT SAPHENOUS NERVE BLOCK" or CPT_Name_2= "RIGHT
SAPHENOUS NERVE BLOCK" or CPT_Name_3= "RIGHT SAPHENOUS NERVE BLOCK" or
CPT_Name_4= "RIGHT SAPHENOUS NERVE BLOCK" or CPT_Name_5= "RIGHT
SAPHENOUS NERVE BLOCK" or CPT_Name_6= "RIGHT SAPHENOUS NERVE BLOCK"
then Saphenous_Nerv_blk=1; else Saphenous_Nerv_blk=0;
If CPT_Name_1= "RIGHT SUPRASCAPULAR NERVE BLOCK" or CPT_Name_2= "RIGHT
SUPRASCAPULAR NERVE BLOCK" or CPT_Name_3= "RIGHT SUPRASCAPULAR NERVE
BLOCK" or CPT_Name_4= "RIGHT SUPRASCAPULAR NERVE BLOCK" or CPT_Name_5=
"RIGHT SUPRASCAPULAR NERVE BLOCK" or CPT_Name_6= "RIGHT SUPRASCAPULAR
NERVE BLOCK" then Suprascapular_nerv_blk=1; else
Suprascapular_nerv_blk=0;
If CPT_Name_1= "SIJ RF" or CPT_Name_2= "SIJ RF" or CPT_Name_3= "SIJ RF"
or CPT_Name_4= "SIJ RF" or CPT_Name_5= "SIJ RF" or CPT_Name_6= "SIJ RF"
then SIJ_RF=1; else SIJ_RF=0;
run;
/*Freq- proc*/
proc freq data=opioid_proc;
tables Caudal_ESI CERVICAL_ESI CERVICAL_ESI_MultTPI
GENICULAR_NERVE_BLOCK Intrarticular_Hip_Inj Intrarticular_sij_Inj
knee_inj lat_femoral_CNB LESI Lumb_Sac_MBRF Stim_trial Stim_implant
piriformis_inj Ilio_nerv_blk Sacrococc_Inj TPI Troch_Bursa_inj TFESI
Shoulder_inj Genicular_neurotomy Saphenous_Nerv_blk
Suprascapular_nerv_blk SIJ_RF;
run;
/*Office visits -opioid meds*/
proc sort data=opioid out=sorted_opioid;
by Patient_ID;
run;
data Num_office_opioid;
set sorted_opioid;
by Patient_ID;
if first.Patient_ID;
Num_Officevisits=0;
if First_OfficeVisit ne . then do;
Num_Officevisits=1;
if Second_OfficeVisit ne . then Num_Officevisits+1;
if Third_OfficeVisit ne . then Num_Officevisits+1;
if Fourth_OfficeVisit ne . then Num_Officevisits+1;
if Fifth_OfficeVisit ne . then Num_Officevisits+1;
if sixth_OfficeVisit ne . then Num_Officevisits+1;
if seventh_OfficeVisit ne . then Num_Officevisits+1;
if eighth_OfficeVisit ne . then Num_Officevisits+1;
if ninth_OfficeVisit ne . then Num_Officevisits+1;
if tenth_OfficeVisit ne . then Num_Officevisits+1;
if eleventh_OfficeVisit ne . then Num_Officevisits+1;
if twelve_OfficeVisit ne . then Num_Officevisits+1;
if thirteen_OfficeVisit ne . then Num_Officevisits+1;
if fourteen_OfficeVisit ne . then Num_Officevisits+1;
if fifteen_OfficeVisit ne . then Num_Officevisits+1;
if sixteen_OfficeVisit ne . then Num_Officevisits+1;
if seventeen_OfficeVisit ne . then Num_Officevisits+1;
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if eighteen_OfficeVisit ne . then Num_Officevisits+1;
if nineteen_OfficeVisit ne . then Num_Officevisits+1;
if twenty_OfficeVisit ne . then Num_Officevisits+1;
if twentyone_OfficeVisit ne . then Num_Officevisits+1;
if twentytwo_OfficeVisit ne . then Num_Officevisits+1;
if twentythree_OfficeVisit ne . then Num_Officevisits+1;
if twentyfour_OfficeVisit ne . then Num_Officevisits+1;
if twentyfive_OfficeVisit ne . then Num_Officevisits+1;
end;
else do;
Num_Officevisits=0;
end;
run;
/*Mean median office visit - opioid*/
proc univariate data=Num_office_opioid ;
var Num_Officevisits;
run;
/*Prevalence of ANTINEUROPATHIC MEDS*/
data FIRSTLINE;
set FinalCohort;
Current_meds_1=upcase(Current_meds_1);
Current_meds_2=upcase(Current_meds_2);
Current_meds_3=upcase(Current_meds_3);
Current_meds_4=upcase(Current_meds_4);
Current_meds_5=upcase(Current_meds_5);
Current_meds_6=upcase(Current_meds_6);Current_meds_7=upcase(Current_med
s_7);Current_meds_8=upcase(Current_meds_8);Current_meds_9=upcase(Curren
t_meds_9);Current_meds_10=upcase(Current_meds_10);Current_meds_11=upcas
e(Current_meds_11);
Current_meds_12=upcase(Current_meds_12);Current_meds_13=upcase(Current_
meds_13);Current_meds_14=upcase(Current_meds_14);Current_meds_15=upcase
(Current_meds_15);Current_meds_16=upcase(Current_meds_16);Current_meds_
17=upcase(Current_meds_17);Current_meds_18=upcase(Current_meds_18);Curr
ent_meds_19=upcase(Current_meds_19);Current_meds_20=upcase(Current_meds
_20);Current_meds_21=upcase(Current_meds_21);Current_meds_22=upcase(Cur
rent_meds_22);
Current_meds_23=upcase(Current_meds_23);
Current_meds_24=upcase(Current_meds_24);
Current_meds_25=upcase(Current_meds_25);
Current_meds_26=upcase(Current_meds_26);
Current_meds_27=upcase(Current_meds_27);
Current_meds_28=upcase(Current_meds_28);
Current_meds_29=upcase(Current_meds_29);
Current_meds_30=upcase(Current_meds_30);
Current_meds_31=upcase(Current_meds_31);
Current_meds_32=upcase(Current_meds_32);
%let FL="NORTRIPTYLINE" "PAMELOR" "DULOXETINE" "VENLAFAXINE"
"GABAPENTIN" "PREGABALIN" "LIDOCAINE" "ASPERCREME LIDOCAINE";
if Current_meds_1 in (&FL) or Current_meds_2 in (&FL)or Current_meds_3
in (&FL) or Current_meds_4 in (&FL) or Current_meds_5 in (&FL) or
Current_meds_6 in (&FL)or Current_meds_7 in (&FL) or Current_meds_8 in
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(&FL) or Current_meds_9 in (&FL) or Current_meds_10 in (&FL)or
Current_meds_11 in (&FL) or Current_meds_12 in (&FL) or Current_meds_13
in (&FL) or Current_meds_14 in (&FL) or Current_meds_15 in (&FL)
or Current_meds_16 in (&FL) or Current_meds_17 in (&FL) or
Current_meds_18 in (&FL) or Current_meds_19 in (&FL) or Current_meds_20
in (&FL) or Current_meds_21 in (&FL) or Current_meds_22 in (&FL) or
Current_meds_23 in (&FL)or Current_meds_24 in (&FL)or Current_meds_25
in (&FL) or Current_meds_26 in (&FL) or Current_meds_27 in (&FL) or
Current_meds_28 in (&FL) or Current_meds_29 in (&FL)
or Current_meds_30 in (&FL) or Current_meds_31 in (&FL) or
Current_meds_32 in (&FL) then FL=1; else FL=0;
if FL=1;
run;
/*Second line meds are opioids - prevalence calculated in the code for
opioid medication specific cohort*/
data THIRDLINE;
set FinalCohort;
Current_meds_1=upcase(Current_meds_1);
Current_meds_2=upcase(Current_meds_2);
Current_meds_3=upcase(Current_meds_3);
Current_meds_4=upcase(Current_meds_4);
Current_meds_5=upcase(Current_meds_5);
Current_meds_6=upcase(Current_meds_6);Current_meds_7=upcase(Current_med
s_7);Current_meds_8=upcase(Current_meds_8);Current_meds_9=upcase(Curren
t_meds_9);Current_meds_10=upcase(Current_meds_10);Current_meds_11=upcas
e(Current_meds_11);
Current_meds_12=upcase(Current_meds_12);Current_meds_13=upcase(Current_
meds_13);Current_meds_14=upcase(Current_meds_14);Current_meds_15=upcase
(Current_meds_15);Current_meds_16=upcase(Current_meds_16);Current_meds_
17=upcase(Current_meds_17);Current_meds_18=upcase(Current_meds_18);Curr
ent_meds_19=upcase(Current_meds_19);Current_meds_20=upcase(Current_meds
_20);Current_meds_21=upcase(Current_meds_21);Current_meds_22=upcase(Cur
rent_meds_22);
Current_meds_23=upcase(Current_meds_23);
Current_meds_24=upcase(Current_meds_24);
Current_meds_25=upcase(Current_meds_25);
Current_meds_26=upcase(Current_meds_26);
Current_meds_27=upcase(Current_meds_27);
Current_meds_28=upcase(Current_meds_28);
Current_meds_29=upcase(Current_meds_29);
Current_meds_30=upcase(Current_meds_30);
Current_meds_31=upcase(Current_meds_31);
Current_meds_32=upcase(Current_meds_32);
%let TL="BUPROPION" "WELLBUTRIN" "CITALOPRAM" "CELEXA" "PAROXETINE"
"LAMOTRIGINE" "LAMICTAL" "TOPIRAMATE" "TOPAMAX" "ROBITUSSIN";
if Current_meds_1 in (&TL) or Current_meds_2 in (&TL)or Current_meds_3
in (&TL) or Current_meds_4 in (&TL) or Current_meds_5 in (&TL) or
Current_meds_6 in (&TL)or Current_meds_7 in (&TL) or Current_meds_8 in
(&TL) or Current_meds_9 in (&TL) or Current_meds_10 in (&TL)or
Current_meds_11 in (&TL) or Current_meds_12 in (&TL) or Current_meds_13
in (&TL) or Current_meds_14 in (&TL) or Current_meds_15 in (&TL)
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or Current_meds_16 in (&TL) or Current_meds_17 in (&TL) or
Current_meds_18 in (&TL) or Current_meds_19 in (&TL) or Current_meds_20
in (&TL) or Current_meds_21 in (&TL) or Current_meds_22 in (&TL) or
Current_meds_23 in (&TL)or Current_meds_24 in (&TL)or Current_meds_25
in (&TL) or Current_meds_26 in (&TL) or Current_meds_27 in (&TL) or
Current_meds_28 in (&TL) or Current_meds_29 in (&TL)
or Current_meds_30 in (&TL) or Current_meds_31 in (&TL) or
Current_meds_32 in (&TL) then TL=1; else TL=0;
if TL=1; ;
run;
/*code ends here*/
/*Prevalence of patients with AF, DVT, PE, CAD*/
data atrialfib_bt;
set blood_thinner;
Comorb_1=Upcase(Comorb_1); Comorb_2=Upcase(Comorb_2);
Comorb_3=Upcase(Comorb_3); Comorb_4=Upcase(Comorb_4);
Comorb_5=Upcase(Comorb_5);Comorb_6=Upcase(Comorb_6);Comorb_7=Upcase(Com
orb_7);Comorb_8=Upcase(Comorb_8);Comorb_9=Upcase(Comorb_9);Comorb_10=Up
case(Comorb_10);Comorb_11=Upcase(Comorb_11);Comorb_12=Upcase(Comorb_12)
;Comorb_13=Upcase(Comorb_13);Comorb_14=Upcase(Comorb_14);
Comorb_15=Upcase(Comorb_15);Comorb_16=Upcase(Comorb_16);Comorb_17=Upcas
e(Comorb_17);
Comorb_18=Upcase(Comorb_18);Comorb_19=Upcase(Comorb_19);Comorb_20=Upcas
e(Comorb_20);Comorb_21=Upcase(Comorb_21);Comorb_22=Upcase(Comorb_22);Co
morb_23=Upcase(Comorb_23);Comorb_24=Upcase(Comorb_24);Comorb_25=Upcase(
Comorb_25);Comorb_26=Upcase(Comorb_26);Comorb_27=Upcase(Comorb_27);Como
rb_28=Upcase(Comorb_28);Comorb_29=Upcase(Comorb_29);
%let BTComorb="ATRIAL FIBRILLATION" "DEEP VEIN THROMBOSIS" "PULMONARY
EMBOLISM" "CAD";
if Comorb_1 in (&BTComorb) or Comorb_2 in (&BTComorb) or Comorb_3 in
(&BTComorb) or Comorb_4 in (&BTComorb) or Comorb_5 in (&BTComorb) or
Comorb_6 in (&BTComorb) or Comorb_7 in (&BTComorb) or Comorb_8 in
(&BTComorb) or Comorb_9 in (&BTComorb) or Comorb_10 in (&BTComorb) or
Comorb_11 in (&BTComorb) or Comorb_12 in (&BTComorb) or Comorb_13 in
(&BTComorb) or Comorb_14 in (&BTComorb) or Comorb_15 in (&BTComorb) or
Comorb_16 in (&BTComorb) or Comorb_17 in (&BTComorb) or Comorb_18 in
(&BTComorb) or Comorb_19 in (&BTComorb) or Comorb_20 in (&BTComorb) or
Comorb_21 in (&BTComorb) or Comorb_22 in (&BTComorb) or Comorb_23 in
(&BTComorb) or Comorb_24 in (&BTComorb) or Comorb_25 in (&BTComorb) or
Comorb_26 in (&BTComorb) or Comorb_27 in (&BTComorb) or Comorb_28 in
(&BTComorb) or Comorb_29 in (&BTComorb) then output atrialfib_bt; /*40
pts*//*486 pts- pain for more than 3 months and non-cancer adult pts */
run;
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APPENDIX IV
List of current medications identified under each category
1) Blood thinners (Anti-coagulants and Anti-platelets)


Aspirin



Eliquis



Jantoven



Plavix



Ecotrin



Bayer Low Dose



Clopidogrel



Brilinta



Elmiron



Warfarin



Xarelto



Prasugrel

2) Herbal medicines with anticoagulant effects as identified in Narouze et al (2017)


Ginger Root



Ginkgo Biloba



Garlic Parsley



Green Tea Extract



Garlic oil



Korean Ginseng



Green tea
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3) Benzodiazepines


Alprazolam



Lorazepam



Clonazepam



Valium



Ativan



Diazepam



Temazepam



Xanax



Klonopin

4) Opioids


Hydrocodone Acetaminophen



Oxycodone



Oxycodone Acetaminophen



Tramadol



Norco



Hydrocodone Ibuprofen



Hydrocodone/APAP



Oxymorphone



Percocet



Fentanyl



Vicodin



Morphine



Xtampza
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Acetaminophen Codeine



Methadone



Endocet
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